AU2981101A - Cardiotrophin and uses therefor - Google Patents
Cardiotrophin and uses therefor Download PDFInfo
- Publication number
- AU2981101A AU2981101A AU29811/01A AU2981101A AU2981101A AU 2981101 A AU2981101 A AU 2981101A AU 29811/01 A AU29811/01 A AU 29811/01A AU 2981101 A AU2981101 A AU 2981101A AU 2981101 A AU2981101 A AU 2981101A
- Authority
- AU
- Australia
- Prior art keywords
- cells
- dna
- cell
- antibodies
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 299
- 238000000034 method Methods 0.000 claims description 213
- 241000282414 Homo sapiens Species 0.000 claims description 102
- 230000000694 effects Effects 0.000 claims description 71
- 238000011282 treatment Methods 0.000 claims description 50
- 239000005557 antagonist Substances 0.000 claims description 47
- 210000002569 neuron Anatomy 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 38
- 230000012010 growth Effects 0.000 claims description 37
- 241000124008 Mammalia Species 0.000 claims description 36
- 102000004127 Cytokines Human genes 0.000 claims description 32
- 108090000695 Cytokines Proteins 0.000 claims description 32
- 210000001161 mammalian embryo Anatomy 0.000 claims description 32
- 238000004519 manufacturing process Methods 0.000 claims description 28
- 241001529936 Murinae Species 0.000 claims description 23
- 241000894007 species Species 0.000 claims description 22
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 19
- 108010039445 Stem Cell Factor Proteins 0.000 claims description 16
- 238000012258 culturing Methods 0.000 claims description 16
- 230000004069 differentiation Effects 0.000 claims description 16
- 238000001727 in vivo Methods 0.000 claims description 16
- 210000003098 myoblast Anatomy 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 230000035755 proliferation Effects 0.000 claims description 16
- 210000001057 smooth muscle myoblast Anatomy 0.000 claims description 16
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 239000012528 membrane Substances 0.000 claims description 15
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 14
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 14
- 230000001886 ciliary effect Effects 0.000 claims description 14
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 14
- 210000003205 muscle Anatomy 0.000 claims description 12
- 210000004602 germ cell Anatomy 0.000 claims description 11
- 238000012546 transfer Methods 0.000 claims description 11
- 230000008859 change Effects 0.000 claims description 10
- 230000002708 enhancing effect Effects 0.000 claims description 10
- 230000000638 stimulation Effects 0.000 claims description 10
- 230000010261 cell growth Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 210000003169 central nervous system Anatomy 0.000 claims description 8
- 238000012423 maintenance Methods 0.000 claims description 8
- 230000004936 stimulating effect Effects 0.000 claims description 8
- 208000003098 Ganglion Cysts Diseases 0.000 claims description 7
- 208000005400 Synovial Cyst Diseases 0.000 claims description 7
- 230000001537 neural effect Effects 0.000 claims description 7
- 206010003246 arthritis Diseases 0.000 claims description 5
- 210000001705 ectoderm cell Anatomy 0.000 claims description 4
- 230000006576 neuronal survival Effects 0.000 claims description 4
- 241000283707 Capra Species 0.000 claims description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 230000035935 pregnancy Effects 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 2
- 102000015215 Stem Cell Factor Human genes 0.000 claims 14
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- 241000283074 Equus asinus Species 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 163
- 108090000623 proteins and genes Proteins 0.000 description 136
- 108090000765 processed proteins & peptides Proteins 0.000 description 113
- 102000004196 processed proteins & peptides Human genes 0.000 description 107
- 229920001184 polypeptide Polymers 0.000 description 105
- 238000003556 assay Methods 0.000 description 94
- 230000027455 binding Effects 0.000 description 93
- 238000009739 binding Methods 0.000 description 91
- 239000012634 fragment Substances 0.000 description 71
- 102000004169 proteins and genes Human genes 0.000 description 69
- 235000018102 proteins Nutrition 0.000 description 67
- 239000013598 vector Substances 0.000 description 61
- 150000007523 nucleic acids Chemical class 0.000 description 54
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 53
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 53
- 206010020880 Hypertrophy Diseases 0.000 description 48
- 239000000523 sample Substances 0.000 description 47
- 241000700159 Rattus Species 0.000 description 45
- 125000003275 alpha amino acid group Chemical group 0.000 description 44
- 230000014509 gene expression Effects 0.000 description 44
- 102000039446 nucleic acids Human genes 0.000 description 44
- 108020004707 nucleic acids Proteins 0.000 description 44
- 241000699666 Mus <mouse, genus> Species 0.000 description 41
- 102000004190 Enzymes Human genes 0.000 description 40
- 108090000790 Enzymes Proteins 0.000 description 40
- 241001465754 Metazoa Species 0.000 description 40
- 229940088598 enzyme Drugs 0.000 description 40
- 108091034117 Oligonucleotide Proteins 0.000 description 39
- 108060003951 Immunoglobulin Proteins 0.000 description 38
- 102000018358 immunoglobulin Human genes 0.000 description 38
- 239000002609 medium Substances 0.000 description 37
- 239000013612 plasmid Substances 0.000 description 36
- 206010019280 Heart failures Diseases 0.000 description 35
- 102000005962 receptors Human genes 0.000 description 35
- 108020003175 receptors Proteins 0.000 description 35
- 235000001014 amino acid Nutrition 0.000 description 34
- 238000000338 in vitro Methods 0.000 description 33
- 238000012360 testing method Methods 0.000 description 33
- 210000000107 myocyte Anatomy 0.000 description 32
- 150000001413 amino acids Chemical class 0.000 description 31
- 230000006870 function Effects 0.000 description 31
- 108091028043 Nucleic acid sequence Proteins 0.000 description 29
- 229940024606 amino acid Drugs 0.000 description 29
- 239000012491 analyte Substances 0.000 description 29
- 239000000427 antigen Substances 0.000 description 29
- 102000004889 Interleukin-6 Human genes 0.000 description 28
- 108090001005 Interleukin-6 Proteins 0.000 description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
- 108091007433 antigens Proteins 0.000 description 27
- 102000036639 antigens Human genes 0.000 description 27
- 230000001965 increasing effect Effects 0.000 description 27
- 230000035772 mutation Effects 0.000 description 27
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 26
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 26
- 239000001963 growth medium Substances 0.000 description 26
- -1 Jakl Proteins 0.000 description 25
- 239000002299 complementary DNA Substances 0.000 description 25
- 210000002216 heart Anatomy 0.000 description 25
- 210000002242 embryoid body Anatomy 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 24
- 210000002257 embryonic structure Anatomy 0.000 description 23
- 238000006467 substitution reaction Methods 0.000 description 22
- 230000004083 survival effect Effects 0.000 description 22
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 21
- 108010076504 Protein Sorting Signals Proteins 0.000 description 21
- 230000000747 cardiac effect Effects 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- 230000004071 biological effect Effects 0.000 description 20
- 238000004113 cell culture Methods 0.000 description 20
- 239000013604 expression vector Substances 0.000 description 19
- 230000001969 hypertrophic effect Effects 0.000 description 19
- 239000013615 primer Substances 0.000 description 19
- 239000005541 ACE inhibitor Substances 0.000 description 18
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 230000002861 ventricular Effects 0.000 description 18
- 210000004413 cardiac myocyte Anatomy 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 17
- 208000035475 disorder Diseases 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 17
- 108091008146 restriction endonucleases Proteins 0.000 description 17
- 206010007559 Cardiac failure congestive Diseases 0.000 description 16
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 16
- 230000004048 modification Effects 0.000 description 16
- 238000012986 modification Methods 0.000 description 16
- 239000002773 nucleotide Substances 0.000 description 16
- 238000013518 transcription Methods 0.000 description 16
- 230000035897 transcription Effects 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 101000916283 Homo sapiens Cardiotrophin-1 Proteins 0.000 description 15
- 125000000539 amino acid group Chemical group 0.000 description 15
- 239000003636 conditioned culture medium Substances 0.000 description 15
- 238000011161 development Methods 0.000 description 15
- 230000004927 fusion Effects 0.000 description 15
- 239000000122 growth hormone Substances 0.000 description 15
- 210000004408 hybridoma Anatomy 0.000 description 15
- 238000003780 insertion Methods 0.000 description 15
- 230000037431 insertion Effects 0.000 description 15
- 239000003446 ligand Substances 0.000 description 15
- 210000004962 mammalian cell Anatomy 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 238000001890 transfection Methods 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 230000018109 developmental process Effects 0.000 description 14
- 238000002513 implantation Methods 0.000 description 14
- 230000000508 neurotrophic effect Effects 0.000 description 14
- 238000007747 plating Methods 0.000 description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- 108091026890 Coding region Proteins 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 108010051696 Growth Hormone Proteins 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 238000012217 deletion Methods 0.000 description 13
- 230000037430 deletion Effects 0.000 description 13
- 238000009396 hybridization Methods 0.000 description 13
- 229940072221 immunoglobulins Drugs 0.000 description 13
- 230000000297 inotrophic effect Effects 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 12
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 12
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 12
- 208000006029 Cardiomegaly Diseases 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 12
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 12
- 102000004140 Oncostatin M Human genes 0.000 description 12
- 108090000630 Oncostatin M Proteins 0.000 description 12
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 238000010367 cloning Methods 0.000 description 12
- 230000029087 digestion Effects 0.000 description 12
- 239000003623 enhancer Substances 0.000 description 12
- 230000013595 glycosylation Effects 0.000 description 12
- 238000006206 glycosylation reaction Methods 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 238000002703 mutagenesis Methods 0.000 description 12
- 231100000350 mutagenesis Toxicity 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 11
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 11
- 108010025020 Nerve Growth Factor Proteins 0.000 description 11
- 108010022394 Threonine synthase Proteins 0.000 description 11
- 230000003288 anthiarrhythmic effect Effects 0.000 description 11
- 239000003416 antiarrhythmic agent Substances 0.000 description 11
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 11
- 238000004587 chromatography analysis Methods 0.000 description 11
- 102000003675 cytokine receptors Human genes 0.000 description 11
- 108010057085 cytokine receptors Proteins 0.000 description 11
- 102000004419 dihydrofolate reductase Human genes 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000010561 standard procedure Methods 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 230000009466 transformation Effects 0.000 description 11
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 10
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 10
- 101710142062 Leukemia inhibitory factor receptor Proteins 0.000 description 10
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 description 10
- 208000012902 Nervous system disease Diseases 0.000 description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 description 10
- 241000283984 Rodentia Species 0.000 description 10
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 239000012636 effector Substances 0.000 description 10
- 239000003102 growth factor Substances 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 201000000050 myeloid neoplasm Diseases 0.000 description 10
- 230000010076 replication Effects 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 9
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 9
- 101000916285 Mus musculus Cardiotrophin-1 Proteins 0.000 description 9
- 229920002684 Sepharose Polymers 0.000 description 9
- 102000004338 Transferrin Human genes 0.000 description 9
- 108090000901 Transferrin Proteins 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 210000002459 blastocyst Anatomy 0.000 description 9
- 229960000830 captopril Drugs 0.000 description 9
- 150000001720 carbohydrates Chemical group 0.000 description 9
- 239000006285 cell suspension Substances 0.000 description 9
- 230000002950 deficient Effects 0.000 description 9
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 9
- 208000033808 peripheral neuropathy Diseases 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 239000012581 transferrin Substances 0.000 description 9
- 108010039627 Aprotinin Proteins 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
- 206010061216 Infarction Diseases 0.000 description 8
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 8
- 229960004405 aprotinin Drugs 0.000 description 8
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 230000007574 infarction Effects 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 8
- 210000005240 left ventricle Anatomy 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 230000026731 phosphorylation Effects 0.000 description 8
- 238000006366 phosphorylation reaction Methods 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 101000993364 Homo sapiens Ciliary neurotrophic factor Proteins 0.000 description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000004132 cross linking Methods 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 208000025113 myeloid leukemia Diseases 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 108010000063 Ciliary Neurotrophic Factor Receptor Proteins 0.000 description 6
- 102000016989 Ciliary Neurotrophic Factor Receptor Human genes 0.000 description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 6
- 102000015336 Nerve Growth Factor Human genes 0.000 description 6
- 208000025966 Neurological disease Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 208000010125 myocardial infarction Diseases 0.000 description 6
- 229940053128 nerve growth factor Drugs 0.000 description 6
- 230000004770 neurodegeneration Effects 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 239000000700 radioactive tracer Substances 0.000 description 6
- 229960001153 serine Drugs 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 5
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 102000003815 Interleukin-11 Human genes 0.000 description 5
- 108090000177 Interleukin-11 Proteins 0.000 description 5
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 5
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- 102000007072 Nerve Growth Factors Human genes 0.000 description 5
- 108091034057 RNA (poly(A)) Proteins 0.000 description 5
- 101500027366 Rattus norvegicus Atrial natriuretic peptide Proteins 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 5
- 230000002860 competitive effect Effects 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 238000001400 expression cloning Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000010353 genetic engineering Methods 0.000 description 5
- 230000004217 heart function Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 229940074383 interleukin-11 Drugs 0.000 description 5
- 210000003292 kidney cell Anatomy 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 210000002161 motor neuron Anatomy 0.000 description 5
- 239000003900 neurotrophic factor Substances 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 208000027232 peripheral nervous system disease Diseases 0.000 description 5
- 230000036581 peripheral resistance Effects 0.000 description 5
- 238000002823 phage display Methods 0.000 description 5
- 210000002027 skeletal muscle Anatomy 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- 230000010474 transient expression Effects 0.000 description 5
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 4
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000004594 DNA Polymerase I Human genes 0.000 description 4
- 108010017826 DNA Polymerase I Proteins 0.000 description 4
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 4
- 101100390711 Escherichia coli (strain K12) fhuA gene Proteins 0.000 description 4
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 4
- 108091027305 Heteroduplex Proteins 0.000 description 4
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 241000235649 Kluyveromyces Species 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- 108010007859 Lisinopril Proteins 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 108090000157 Metallothionein Proteins 0.000 description 4
- 229930193140 Neomycin Natural products 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108090000742 Neurotrophin 3 Proteins 0.000 description 4
- 102100029268 Neurotrophin-3 Human genes 0.000 description 4
- 108090000099 Neurotrophin-4 Proteins 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 4
- 102100038803 Somatotropin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 229960003121 arginine Drugs 0.000 description 4
- 230000004872 arterial blood pressure Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000001588 bifunctional effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000012875 competitive assay Methods 0.000 description 4
- 230000001143 conditioned effect Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003205 diastolic effect Effects 0.000 description 4
- 239000002934 diuretic Substances 0.000 description 4
- 229940030606 diuretics Drugs 0.000 description 4
- 210000005064 dopaminergic neuron Anatomy 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 210000000609 ganglia Anatomy 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
- 102000046645 human LIF Human genes 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000016784 immunoglobulin production Effects 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 238000005470 impregnation Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 4
- 229960003646 lysine Drugs 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 229960004927 neomycin Drugs 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 201000001119 neuropathy Diseases 0.000 description 4
- 230000007823 neuropathy Effects 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000001742 protein purification Methods 0.000 description 4
- 210000001147 pulmonary artery Anatomy 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000002889 sympathetic effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 3
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 3
- 230000004544 DNA amplification Effects 0.000 description 3
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 3
- 102100022624 Glucoamylase Human genes 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 3
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 3
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- 102000003792 Metallothionein Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101000942966 Mus musculus Leukemia inhibitory factor Proteins 0.000 description 3
- 208000021642 Muscular disease Diseases 0.000 description 3
- 201000009623 Myopathy Diseases 0.000 description 3
- 101100407828 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) ptr-3 gene Proteins 0.000 description 3
- 230000004989 O-glycosylation Effects 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 3
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 108010046334 Urease Proteins 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 3
- 230000002763 arrhythmic effect Effects 0.000 description 3
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000005547 deoxyribonucleotide Substances 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 230000013020 embryo development Effects 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004720 fertilization Effects 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 230000036513 peripheral conductance Effects 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 229960002898 threonine Drugs 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 235000011178 triphosphate Nutrition 0.000 description 3
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 2
- VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 238000011265 2D-echocardiography Methods 0.000 description 2
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 2
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 2
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 2
- 102000013563 Acid Phosphatase Human genes 0.000 description 2
- 108010051457 Acid Phosphatase Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 241000304886 Bacilli Species 0.000 description 2
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 241000701822 Bovine papillomavirus Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102100028892 Cardiotrophin-1 Human genes 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 108010068426 Contractile Proteins Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 101150074155 DHFR gene Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 108010061435 Enalapril Proteins 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 2
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 2
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000992170 Homo sapiens Oncostatin-M Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 2
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102100020880 Kit ligand Human genes 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 2
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 2
- 102000003683 Neurotrophin-4 Human genes 0.000 description 2
- 102100033857 Neurotrophin-4 Human genes 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 241000607720 Serratia Species 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 2
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 2
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 208000024340 acute graft versus host disease Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000004931 aggregating effect Effects 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 238000012867 alanine scanning Methods 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000012911 assay medium Substances 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 230000001746 atrial effect Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229940097633 capoten Drugs 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 210000001054 cardiac fibroblast Anatomy 0.000 description 2
- 230000031768 cardiac muscle hypertrophy Effects 0.000 description 2
- 238000012219 cassette mutagenesis Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000011098 chromatofocusing Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000022811 deglycosylation Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000002592 echocardiography Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 229960000873 enalapril Drugs 0.000 description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000002064 heart cell Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000005734 heterodimerization reaction Methods 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 102000043703 human OSM Human genes 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 150000002463 imidates Chemical class 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229960002394 lisinopril Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 210000000472 morula Anatomy 0.000 description 2
- 229960000951 mycophenolic acid Drugs 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 229940032018 neurotrophin 3 Drugs 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000011330 nucleic acid test Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 2
- OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 230000004983 pleiotropic effect Effects 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 229960003581 pyridoxal Drugs 0.000 description 2
- 235000008164 pyridoxal Nutrition 0.000 description 2
- 239000011674 pyridoxal Substances 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000011867 re-evaluation Methods 0.000 description 2
- 238000001525 receptor binding assay Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000004873 systolic arterial blood pressure Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- 101150108727 trpl gene Proteins 0.000 description 2
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000004340 zona pellucida Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- FXYPGCIGRDZWNR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)CCC1=O FXYPGCIGRDZWNR-UHFFFAOYSA-N 0.000 description 1
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 1
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- KYBXNPIASYUWLN-WUCPZUCCSA-N (2s)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- RMBMWXHVTXYPQN-UHFFFAOYSA-N 1-[3-[(1-hydroxy-2,5-dioxopyrrolidin-3-yl)methyl]phenyl]pyrrole-2,5-dione Chemical compound O=C1N(O)C(=O)CC1CC1=CC=CC(N2C(C=CC2=O)=O)=C1 RMBMWXHVTXYPQN-UHFFFAOYSA-N 0.000 description 1
- PQMRRAQXKWFYQN-UHFFFAOYSA-N 1-phenyl-2-sulfanylideneimidazolidin-4-one Chemical compound S=C1NC(=O)CN1C1=CC=CC=C1 PQMRRAQXKWFYQN-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 1
- KGLPWQKSKUVKMJ-UHFFFAOYSA-N 2,3-dihydrophthalazine-1,4-dione Chemical class C1=CC=C2C(=O)NNC(=O)C2=C1 KGLPWQKSKUVKMJ-UHFFFAOYSA-N 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- BHANCCMWYDZQOR-UHFFFAOYSA-N 2-(methyldisulfanyl)pyridine Chemical compound CSSC1=CC=CC=N1 BHANCCMWYDZQOR-UHFFFAOYSA-N 0.000 description 1
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 1
- FKJSFKCZZIXQIP-UHFFFAOYSA-N 2-bromo-1-(4-bromophenyl)ethanone Chemical compound BrCC(=O)C1=CC=C(Br)C=C1 FKJSFKCZZIXQIP-UHFFFAOYSA-N 0.000 description 1
- JQPFYXFVUKHERX-UHFFFAOYSA-N 2-hydroxy-2-cyclohexen-1-one Natural products OC1=CCCCC1=O JQPFYXFVUKHERX-UHFFFAOYSA-N 0.000 description 1
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 1
- VJINKBZUJYGZGP-UHFFFAOYSA-N 3-(1-aminopropylideneamino)propyl-trimethylazanium Chemical compound CCC(N)=NCCC[N+](C)(C)C VJINKBZUJYGZGP-UHFFFAOYSA-N 0.000 description 1
- ONZQYZKCUHFORE-UHFFFAOYSA-N 3-bromo-1,1,1-trifluoropropan-2-one Chemical compound FC(F)(F)C(=O)CBr ONZQYZKCUHFORE-UHFFFAOYSA-N 0.000 description 1
- QHSXWDVVFHXHHB-UHFFFAOYSA-N 3-nitro-2-[(3-nitropyridin-2-yl)disulfanyl]pyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1SSC1=NC=CC=C1[N+]([O-])=O QHSXWDVVFHXHHB-UHFFFAOYSA-N 0.000 description 1
- HJBUBXIDMQBSQW-UHFFFAOYSA-N 4-(4-diazoniophenyl)benzenediazonium Chemical compound C1=CC([N+]#N)=CC=C1C1=CC=C([N+]#N)C=C1 HJBUBXIDMQBSQW-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- NLPWSMKACWGINL-UHFFFAOYSA-N 4-azido-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(N=[N+]=[N-])C=C1O NLPWSMKACWGINL-UHFFFAOYSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 102100036664 Adenosine deaminase Human genes 0.000 description 1
- 241000256118 Aedes aegypti Species 0.000 description 1
- 241000256173 Aedes albopictus Species 0.000 description 1
- OBVSBEYOMDWLRJ-BFHQHQDPSA-N Ala-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N OBVSBEYOMDWLRJ-BFHQHQDPSA-N 0.000 description 1
- 101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 1
- 101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- UFBURHXMKFQVLM-CIUDSAMLSA-N Arg-Glu-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O UFBURHXMKFQVLM-CIUDSAMLSA-N 0.000 description 1
- WYBVBIHNJWOLCJ-IUCAKERBSA-N Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N WYBVBIHNJWOLCJ-IUCAKERBSA-N 0.000 description 1
- ZDOQDYFZNGASEY-BIIVOSGPSA-N Asn-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N)C(=O)O ZDOQDYFZNGASEY-BIIVOSGPSA-N 0.000 description 1
- HXWUJJADFMXNKA-BQBZGAKWSA-N Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O HXWUJJADFMXNKA-BQBZGAKWSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 101710192393 Attachment protein G3P Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- 208000035905 Autosomal recessive malignant osteopetrosis Diseases 0.000 description 1
- 241000713842 Avian sarcoma virus Species 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 101150071434 BAR1 gene Proteins 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108700003860 Bacterial Genes Proteins 0.000 description 1
- 108090000363 Bacterial Luciferases Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241000409811 Bombyx mori nucleopolyhedrovirus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000015280 CCAAT-Enhancer-Binding Protein-beta Human genes 0.000 description 1
- 108010064535 CCAAT-Enhancer-Binding Protein-beta Proteins 0.000 description 1
- 108010041884 CD4 Immunoadhesins Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710169873 Capsid protein G8P Proteins 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- 201000006868 Charcot-Marie-Tooth disease type 3 Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 108090000746 Chymosin Proteins 0.000 description 1
- OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000005754 Cytokine Receptor gp130 Human genes 0.000 description 1
- 108010006197 Cytokine Receptor gp130 Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000031972 Dejerine-Sottas syndrome Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108010066671 Enalaprilat Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000702224 Enterobacteria phage M13 Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001522878 Escherichia coli B Species 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 108010015133 Galactose oxidase Proteins 0.000 description 1
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700023863 Gene Components Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101100508941 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) ppa gene Proteins 0.000 description 1
- 102000014702 Haptoglobin Human genes 0.000 description 1
- 108050005077 Haptoglobin Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000006411 Hereditary Sensory and Motor Neuropathy Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 101500027325 Homo sapiens Atrial natriuretic peptide Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
- 101000939500 Homo sapiens UBX domain-containing protein 11 Proteins 0.000 description 1
- 101000854879 Homo sapiens V-type proton ATPase 116 kDa subunit a 2 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical group O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- JWBXCSQZLLIOCI-GUBZILKMSA-N Ile-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C JWBXCSQZLLIOCI-GUBZILKMSA-N 0.000 description 1
- UWBDLNOCIDGPQE-GUBZILKMSA-N Ile-Lys Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN UWBDLNOCIDGPQE-GUBZILKMSA-N 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 208000032578 Inherited retinal disease Diseases 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 101150009057 JAK2 gene Proteins 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 208000028226 Krabbe disease Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241000481961 Lachancea thermotolerans Species 0.000 description 1
- 241000235651 Lachancea waltii Species 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 1
- 244000043158 Lens esculenta Species 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 101710156564 Major tail protein Gp23 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 1
- 101000942958 Mus musculus Leukemia inhibitory factor receptor Proteins 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 101100178822 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) htrA1 gene Proteins 0.000 description 1
- 102100026925 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Human genes 0.000 description 1
- 101710105127 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Proteins 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- WYBVBIHNJWOLCJ-UHFFFAOYSA-N N-L-arginyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCCN=C(N)N WYBVBIHNJWOLCJ-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 108091008604 NGF receptors Proteins 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 241000221961 Neurospora crassa Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000003987 Oncostatin M Receptors Human genes 0.000 description 1
- 108010082522 Oncostatin M Receptors Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101100378536 Ovis aries ADRB1 gene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 240000007377 Petunia x hybrida Species 0.000 description 1
- OZILORBBPKKGRI-RYUDHWBXSA-N Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 OZILORBBPKKGRI-RYUDHWBXSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 208000010366 Postpoliomyelitis syndrome Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108010011939 Pyruvate Decarboxylase Proteins 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 102000004879 Racemases and epimerases Human genes 0.000 description 1
- 108090001066 Racemases and epimerases Proteins 0.000 description 1
- 101000916279 Rattus norvegicus Cardiotrophin-1 Proteins 0.000 description 1
- 101000993333 Rattus norvegicus Ciliary neurotrophic factor Proteins 0.000 description 1
- 208000005587 Refsum Disease Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 208000032430 Retinal dystrophy Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 101100277437 Rhizobium meliloti (strain 1021) degP1 gene Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 241000311088 Schwanniomyces Species 0.000 description 1
- 241001123650 Schwanniomyces occidentalis Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
- PLQWGQUNUPMNOD-KKUMJFAQSA-N Ser-Tyr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O PLQWGQUNUPMNOD-KKUMJFAQSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 241000269319 Squalius cephalus Species 0.000 description 1
- 108700034501 Staphylococcus aureus auR Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 206010049447 Tachyarrhythmia Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000001163 Tangier disease Diseases 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 241000223258 Thermomyces lanuginosus Species 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 208000030193 Tinel sign Diseases 0.000 description 1
- 241001149964 Tolypocladium Species 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- BMPPMAOOKQJYIP-WMZOPIPTSA-N Tyr-Trp Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C([O-])=O)C1=CC=C(O)C=C1 BMPPMAOOKQJYIP-WMZOPIPTSA-N 0.000 description 1
- 102100029645 UBX domain-containing protein 11 Human genes 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 102100020745 V-type proton ATPase 116 kDa subunit a 2 Human genes 0.000 description 1
- 244000000188 Vaccinium ovalifolium Species 0.000 description 1
- 208000009982 Ventricular Dysfunction Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 208000004622 abetalipoproteinemia Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229940077422 accupril Drugs 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 208000030597 adult Refsum disease Diseases 0.000 description 1
- MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229940077927 altace Drugs 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 208000025213 autosomal recessive osteopetrosis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 230000001756 cardiomyopathic effect Effects 0.000 description 1
- 108010041776 cardiotrophin 1 Proteins 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000027902 cell growth involved in cardiac muscle cell development Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- VIMWCINSBRXAQH-UHFFFAOYSA-M chloro-(2-hydroxy-5-nitrophenyl)mercury Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[Hg]Cl VIMWCINSBRXAQH-UHFFFAOYSA-M 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 229940080701 chymosin Drugs 0.000 description 1
- 108010086192 chymostatin Proteins 0.000 description 1
- 108090001092 clostripain Proteins 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000002594 corticospinal effect Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- OILAIQUEIWYQPH-UHFFFAOYSA-N cyclohexane-1,2-dione Chemical compound O=C1CCCCC1=O OILAIQUEIWYQPH-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 101150018266 degP gene Proteins 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Chemical group OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 101150015424 dmd gene Proteins 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000000327 embryotrophic effect Effects 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 239000003532 endogenous pyrogen Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 239000004060 excitotoxin Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002169 extracardiac Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000002458 fetal heart Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 201000006321 fundus dystrophy Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000007045 gastrulation Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 230000009067 heart development Effects 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 108010067006 heat stable toxin (E coli) Proteins 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000056021 human CTF1 Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 101150020087 ilvG gene Proteins 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000007925 in vitro drug release testing Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000017532 inherited retinal dystrophy Diseases 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 108010052620 leukocyte endogenous mediator Proteins 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 230000008752 local inflammatory process Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940080268 lotensin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- YCXSYMVGMXQYNT-UHFFFAOYSA-N methyl 3-[(4-azidophenyl)disulfanyl]propanimidate Chemical compound COC(=N)CCSSC1=CC=C(N=[N+]=[N-])C=C1 YCXSYMVGMXQYNT-UHFFFAOYSA-N 0.000 description 1
- DFTAZNAEBRBBKP-UHFFFAOYSA-N methyl 4-sulfanylbutanimidate Chemical compound COC(=N)CCCS DFTAZNAEBRBBKP-UHFFFAOYSA-N 0.000 description 1
- RMAHPRNLQIRHIJ-UHFFFAOYSA-N methyl carbamimidate Chemical compound COC(N)=N RMAHPRNLQIRHIJ-UHFFFAOYSA-N 0.000 description 1
- NEGQCMNHXHSFGU-UHFFFAOYSA-N methyl pyridine-2-carboximidate Chemical compound COC(=N)C1=CC=CC=N1 NEGQCMNHXHSFGU-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 108010029942 microperoxidase Proteins 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 229940118178 monopril Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000018364 negative regulation of epithelial cell proliferation Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000008271 nervous system development Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108010058731 nopaline synthase Proteins 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 210000003540 papillary muscle Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 108010018625 phenylalanylarginine Proteins 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- 229940117953 phenylisothiocyanate Drugs 0.000 description 1
- 101150009573 phoA gene Proteins 0.000 description 1
- HMFAQQIORZDPJG-UHFFFAOYSA-N phosphono 2-chloroacetate Chemical compound OP(O)(=O)OC(=O)CCl HMFAQQIORZDPJG-UHFFFAOYSA-N 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 229940088953 prinivil Drugs 0.000 description 1
- 210000001176 projection neuron Anatomy 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- IBBLRJGOOANPTQ-JKVLGAQCSA-N quinapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 IBBLRJGOOANPTQ-JKVLGAQCSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 238000007347 radical substitution reaction Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 230000025175 skeletal muscle hypertrophy Effects 0.000 description 1
- 230000022379 skeletal muscle tissue development Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000002483 superagonistic effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Chemical group ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229940099270 vasotec Drugs 0.000 description 1
- 230000006815 ventricular dysfunction Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229940072252 zestril Drugs 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Description
AUSTRALIA
Patents Act 1990 COMPLETE SPECIFICATION STANDARD PATENT Applicant(s): GENENTECH, INC.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Invention Title: CARDIOTROPHIN AND USES THEREFOR IP Austrea i Documents receit\,ed on 2 2 MAR 2001 Batch No: The following statement is a full description of this invention, including the best method of performing it known to me/us: CARDIOTROPHIN AND USES THEREFOR TECHNICAL FIELD This application relates to a cardiac hypertrophy factor (also known as CT-1) for modulating cardiac function in the treatment of heart failure, for modulating neural function in the treatment of neurological disorders, and for treatment of a variety of other disorders related to a CT-1 receptor, particularly the LIFRP.
BACKGROUND
All references, including any patents or patent applications, cited in this specification are hereby incorporated by reference. No admission is made that any reference constitutes prior art. The discussion of the references states what their authors assert, and the applicants reserve the right to challenge the accuracy and pertinency of the cited documents. It will be clearly understood that, although a number of prior art publications are referred to herein, this reference does not constitute an admission that any of these documents forms part of the common general knowledge in the art, in Australia or in any other country.
o* o *e 1A Heart failure affects approximately three million Americans, developing in about 400,000 each year.
It is currently one of the leading admission diagnoses in the U.S. Recent advances in the management of acute cardiac diseases, including acute myocardial infarction, are resulting in an expanding patient population that will eventually develop chronic heart failure.
Current therapy for heart failure is primarily directed to using angiotensin-converting enzyme (ACE) inhibitors and diuretics.. While prolonging survival in the setting of heart failure, ACE inhibitors appear to slow the progression towards end-stage heart failure, and substantial numbers of patients on ACE inhibitors have functional class III heart failure. Moreover, ACE inhibitors consistently appear unable to relieve symptoms in more than 60% of heart failure patients and reduce mortality of heart failure only by approximately 15-20%.
Heart transplantation is limited by the availability of donor hearts. Further, with the exception of digoxin, the chronic administration of positive inotropic agents has not resulted in a useful drug without accompanying adverse side effects, such as increased arrhythmogenesis, sudden death, or other deleterious side effects related to survival. These deficiencies in current therapy suggest the need for additional therapeutic approaches.
"A wide body of data suggests that pathological hypertrophy of cardiac muscle in the setting of heart 15 failure can be deleterious, characterized by dilation of the ventricular chamber, an increase in wall tension/stress, an increase in the length vs. width of cardiac muscle cells, and an accompanying decrease in cardiac performance and function. Studies have shown that the activation of physiological or compensatory hypertrophy can be beneficial in the setting of heart failure. In fact, the effects of ACE inhibitors have been purported not only to unload the heart, but also to inhibit the pathological hypertrophic response that has been presumed to be linked 20 to the localized renin-angiotensin system within the myocardium.
Cardiac muscle hypertrophy is an important adaptive response of the heart to injury or to an increased demand for cardiac output. This hypertrophic response is characterized by the reactivation of genes normally oexpressed during fetal heart development and by the accumulation of sarcomeric proteins in the absence of DNA replication or cell division (Rockman et al., Circulation, 87:VII14-VII21 (1993); Chien, FASEB 5:3037- 25 3046 (1991); Shubeita et al., J. Biol. Chem., 265:20555-20562 (1990)).
On a molecular biology level, the heart functions as a syncytium of myocytes and surrounding support cells, called non-myocytes. While non-myocytes are primarily fibroblast/mesenchymal cells, they also include endothelial and smooth muscle cells. Indeed, although myocytes make up most of the adult myocardial mass, they represent only about 30% of the total cell numbers present in heart. Because of their close relationship with cardiac myocytes in vivo, non-myocytes are capable of influencing myocyte growth and/or development. This interaction may be mediated directly through cell-cell contact or indirectly via production of a paracrine factor.
Such association in vivo is important since both non-myocyte numbers and the extracellular matrix with which 1B v they interact are increased in myocardial hypertrophy and in response to injury and infarction. These changes are associated with abnormal myocardial function.
Cardiac myocytes are unable to divide shortly after birth. Further growth occurs through hypertrophy of the individual cells. Cell culture models ofmyocyte hypertrophy have been developed to understand better the mechanisms for cardiac myocyte hypertrophy. Simpson et al., Circ. Res., 51:787-801 (1982); Chien et al., FASEB 5:3037-3046 (1991). Most studies of heart myocytes in culture are designed to minimize contamination by non-myocytes. See, for example, Simpson et al., Cir. Cres., 50:101-116 (1982); Libby, J. Mol.
Cell. Cardiol., 16:803-811 (1984); Iwaki et al., J. Biol. Chem., 265:13809-13817 (1990).
Shubaita et al., J. Biol. Chem., 265:20555-20562 (1990) documented the utility of a culture model to identify peptide-derived growth factors such as endothelin-1 that can activate a hypertrophic response. Long et al., Cell Regulation, 2:1081-1095 (1991) investigated the effect of the cardiac non-myocytes on cardiac myocyte growth in culture. Myocyte hypertrophic growth was stimulated in high-density cultures with increased numbers of non-myocytes and in co-cultures with increased numbers of non-myocytes. This effect of non-myocytes on myocyte size could be reproduced by serum-free medium conditioned by non-myocyte cultures. The major myocyte growth-promoting activity in the cultures was heparin binding. The properties of this growth factor were compared to various growth factors known to be present in myocardium, including fibroblast growth factor (FGF), platelet derived growth factor (PDGF), tumor necrosis factor-alpha (TNF-a), and transforming growth factor-betal (TGF-P The growth factor of Long et al. was found to be larger than these other known growth factors and to have a different heparin-Sepharose elution profile from that of all these growth factors except 20 PDGF. Further, it was not neutralized by a PDGF-specific antibody. The authors proposed that it defines a paracrine relationship important for cardiac muscle cell growth and development.
Not only is there a need for an improvement in the therapy of heart failure such as congestive heart failure, but there is also a need to offer effective treatment for neurological disorders. Neurotrophic factors such as insulin-like growth factors, nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3, and and ciliary neurotrophic factor have been proposed as potential means for enhancing neuronal survival, for example, as a treatment for neurodegenerative diseases such as amyotrophic lateral sclerosis, Alzheimer's disease, stroke, epilepsy, Huntington's disease, Parkinson's disease, and peripheral neuropathy. It would be desirable to provide an additional therapy for this purpose.
In addition, there is a need for identification of and improvement in the therapy of diseases for which 30 cytokines, their antagonists or agonists play a role. The IL-6 family of cytokines (IL-6/LIF/CNTF/OSM/IL- 11) S. has a wide range of growth and differentiation activities on many cell types including those from the blood, liver, and nervous system (Akira et al., Adv. Immunol., 54:1-78 (1993); Kishimoto et al., Science, 258:593-597 (1992)). The biological effects induced by IL-6 and related proteins are mediated by a family of structurally similar cell surface receptors, the cytokine receptor family, that includes the receptors for growth hormone and prolactin as well as for many cytokines (Cosman et al., Trends Biochem. Sci., 15:265-270 (1990); Miyajima et al., Ann. Rev. Immunol., 10:295-331 (1992); Taga etal., FASEB J, 6:3387-3396 (1992); Bazan, Immunol. Today, 11:350-354 (1990)). The IL-6 receptor subfamily is composed ofmulti-subunit complexes that share a common signaling subunit, gpl30 (Davis et al., Curr. Opin. Cell Biol., 5:281-285 (1993); Stahl et al., Cell, 74:587-590 (1993); Kishimoto et al., Cell, 76:253-262 (1994)). Some members of the IL-6 cytokine family (IL-6 and IL-11) induce the homodimerization ofgpl30 (Murakami et al., Science, 260:1808-1810 (1993); Hilton et al., EMBO 13:4765-4775 (1994)), while others (LIF, OSM and CNTF) induce gpl30 heterodimer formation with the 190 kDa LIF receptor (Davis et al., Science, 260:1805-1808 (1993)). Following dimerization of the signaling S components, these receptors induce a number of intracellular signaling events including activation of the transcription factor, NF-IL6, probably via the ras-MAP kinase cascade (Kishimoto et al., Cell, 76:253-262 (1994)), and activation of the Jak/STAT signaling pathway (Darnell et Science, 264:1415-1421 (1994)). The latter pathway includes the tyrosine phosphorylation and activation of the intracellular tyrosine kinases, Jakl, Jak2, and Tyk2 (Lltticken et al., Science, 263:89-92 (1994); Stahl et al., Science, 263:92-95 (1994); Yin et al., Exp. Hematol., 22:467-472 (1994); Narazaki et al., Proc. Natl. Acad. USA, 91:2285-2289 (1994)) and of the transcription factors, STATI and STAT3 (Lotticken et al., Science, 263:89-92 (1994); Zh6ng et al., Science, 264:95-98 (1994); Akira et al., Cell, 77:63-71 (1994)).
Accordingly, it is an object of the present invention to provide an improved therapy for the prevention and/or treatment of heart failure such as congestive heart failure, particularly the promotion of physiological forms of hypertrophy or inhibition of pathological forms of hypertrophy, for the prevention and/or treatment of neurological disorders such as peripheral neuropathy, and for the prevention and treatment of disorders in which cytokines, particularly the IL-6/LIF/CNTF/OSM/IL- 11 cytokine family, their antagonists, their agonists, or their receptors play a role.
These and other objects of the invention will be apparent to the ordinarily skilled artisan upon consideration of the specification as a whole.
20 SUMMARY OF THE INVENTION An in vitro neonatal rat heart hypertrophy assay has been developed that allows for expression cloning and protein purification of the cardiac hypertrophy factor (referred to as CHF, more preferably cardiotrophin-1 or CT-1) disclosed herein. The assay capacity of 1000 single samples a week coupled with the small sample *size requirement of 100 pL or less has enabled expression cloning and protein purification that would have been impossible using the currently published methods. Hence, in one embodiment, the invention provides a method for assaying a test sample for hypertrophic activity comprising: plating 96-well plates with a suspension of myocytes at a cell density of about 7.5 x 104 cells per mL in Dulbecco's modified Eagle's medium (D-MEM)/F-12 medium comprising insulin, transferrin, and aprotinin; 30 culturing the cells; adding the test sample (such as one suspected of containing a CT-1) to the cultured cells; culturing the cells with the test sample; and determining if the test sample has hypertrophic activity.
Besides the assay, the invention provides isolated CT-I polypeptide. This CT-I polypeptide is preferably substantially homogeneous, may be glycosylated or unglycosylated, and may be selected from the group consisting of the native sequence polypeptide, a fragment polypeptide, a variant polypeptide, and a chimeric polypeptide. Additionally, the CT-I polypeptide may be selected from the group consisting of the polypeptide that is isolated from a mammal, the polypeptide that is made by recombinant means, and the whether hybridization has occurred, or comprising hybridizing the CT-1 nucleic acid molecule to a test sample nucleic acid and determining the presence of CT-1 nucleic acid.
In still another aspect, the invention provides a method of amplifying a nucleic acid test sample comprising priming a nucleic acid polymerase chain reaction in the test sample with the CT-I nucleic acid molecule.
In a still further aspect, the invention provides a CT-1 antagonist and a method of identifying such antagonist comprising using cell supernatants as the test sample in the hypertrophy assay as described above and screening for molecules that antagonize the hypertrophic activity of a CT-I demonstrated in such assay.
In a still further aspect, the invention provides a method for treating a mammal having or at risk for heart failure, an inotropic disorder, or an arrhythmic disorder comprising administering to a mammal in need of such treatment a therapeutically effective amount of a pharmaceutical composition comprising the CT-1 or a CTantagonist in a pharmaceutically acceptable carrier.
The invention also provides a method for treating a mammal having or at risk for a neurological disorder comprising administering to a mammal in need of such treatment a therapeutically effective amount of a pharmaceutical composition comprising the CT-i in a pharmaceutically acceptable carrier.
The invention also provides a method for treating a mammal having or at risk for a disorder in which cytokines, particularly the IL-6/LIF/CNTF/OSM/IL-I 1 cytokine family, more preferably LIF and OSM, more preferably LIF, their antagonists or their agonists, and most preferably a LIF-Receptor P subunit that interacts with gpl30, play a role. The methods comprise administering to a mammal in need of such treatment a 20 therapeutically effective amount of a pharmaceutical composition comprising CT-1, its antagonist, or its agonist, in a pharmaceutically acceptable carrier. In a most preferred embodiment the disorders involve a pathway regulated or induced by the activation of LIFR3 by CT-1 binding and subsequent interaction with In a still further aspect, the invention provides a CT-1 antagonist and a method of identifying such antagonist comprising using cell supematants or purified or synthetic compounds as the test sample in an assay in which CT-1 has a demonstrated biological activity, receptor binding activity, or signaling pathway induction activity, preferably in a microassay, and screening for molecules that antagonize the activity of a CT-1 "demonstrated in such an assay.
In additional embodiments, the invention supplies a method of identifying a receptor for CT-I comprising using labeled CT-1, preferably radiolabeled CT-1, in a cellular receptor assay, allowing the CT-1 30 to bind to cells, or using the labeled CT-1 to pan for cells that contain the receptor.
BRIEF DESCRIPTION OF THE DRAWINGS Figures 1A and IB depict the nucleotide sequence (sense and anti-sense strands) (SEQ ID NOS: 1 and 2) and deduced amino acid sequence (SEQ ID NO: 3) of a mouse CT-1 DNA clone. The underlined complementary nucleotides at position 27 show the start of another mouse CT-I clone used to obtain the fulllength clone.
Figure 2 aligns the translated amino acid sequence of the mouse CT-I clone (chf.781) (SEQ ID NO: 3) with the amino acid sequence of human ciliary neurotrophic factor (humcntf) (SEQ ID NO: 4) to show the extent of sequence identity.
Figure 3 shows a graph of atrial natriuretic peptide (ANP) release for phenylephrine (standard curve) and transfections into 293 cells in a neonatal cardiac hypertrophy assay.
Figure 4 shows a graph of survival of live ciliary ganglion neurons (measured by cell count) as a function of either the ciliary neutrotrophic factor (CNTF) standard (in ng/mL) or the transfected 293 conditioned medium (in fraction of assay volume), using a CNTF standard (circles), medium from a CT-1 DNA transfection of 293 cells (triangles), and medium from a control DNA transfection of 293 cells (squares).
Figures 5A and 5B depict the nucleotide sequence (sense and anti-sense strands) (SEQ ID NOS: 6 and 7) and deduced amino acid sequence (SEQ ID NO: 8) of a human CT-I DNA clone.
Figure 6 aligns the translated amino acid sequence of the human CT-1 clone (humctl) (SEQ ID NO: 8) with the translated amino acid sequence of the mouse CT-1 clone (chf.781) (SEQ ID NO: 3) to show the extent of sequence identity.
Figures 7A and 7B depict activity of CT-1 in hematopoietic cell assays. The induction by the human or mouse cytokines was performed as described in the Example VI, Materials and Methods. Figure 7A shows stimulation of 3 H-thymidine incorporation in the mouse hybridoma cell line, B9, with an EC 5 0 [IL-6] 0.13 0.03) nM. Figure 7B shows inhibition of 3H-thymidine incorporation in the mouse myeloid leukemia cell line, MI, with an EC 5 0 [CT-1] 0.0076 0.0006) nM, EC 50 [LIF] 0.048 0.004) nM.
Figures 8A, 8B, and 8C depict activity of CT-1 in neuronal cell assays. The induction by mouse (m) or rat cytokines was performed as described in Example VI, Materials and Methods. Figure 8A shows the switch in transmitter phenotype of rat sympathetic neurons. Tyrosine hydroxylase (TH) and choline 20 acetyltransferase (ChAT) activities were determined in duplicate. Figure 8B shows survival of at dopaminergic neurons. Plotted are the average and standard deviation of triplicate determinations. Figure 8C shows survival of chick ciliary neurons with an EC 50 [CT-1] 10 (k 8.2) nM and EC 5 0 [CNTF] 0.0074 0.0049) nM.
Figure 9 depicts activity of CT-I in embryonic stem cells development. Mouse embryonic stem cells were cultured in the presence of the mouse cytokines as described in Example VI, Materials and Methods.
25 Figures 10A, 10B, 10C and 10D depict binding and cross-competition of CT-I and LIF to mouse M1 cells. Assays contained 0.047 nM 12 5 1-mouse CT-1 (125I-mCT-1) and unlabeled mouse CT-I, Figure or unlabeled LIF, Figure 10B; or 0.042 nM 12 5 I-mouse LIF (125I-mLIF) and unlabeled CT-1, Figure 10C, or LIF, Figure 10D. Shown are competition and Scatchard (insert) plots of the data. For the labeled CT-1 binding, Kd 0.61 0.11) nM, 1500 220) sites/cell; Kd [LIF]= 0.19 0.05) nM, 1800 150) sites/cell.
For labeled LIF binding, Kd [CT-1] 0.83 0.13) nM, 1300 80) sites/cell; Kd [LIF] 0.26 0.10) nM, 1200 300) sites/cell.
Figure 11 depicts cross-linking of CT-I and LIF to MI Cells. 12 5I-mouse CT-1 (125I-mCT-I) or 125mouse LIF (1 2 5 I-mLIF) were bound and cross-linked to M1 cells in the absence (None) or presence of a 100 fold excess of the indicated mouse cytokine, and the reaction products analyzed by SDS gel electrophoresis. The mobility of molecular weight standards is indicated.
Figures 12A depicts inhibition of CT-1 binding to MI cells by an anti-gpl30 monoclonal antibody.
Assays contained 0.12 nM 12 5 I-mouse CT-1 and antibodies as indicated. For the anti-gpl30 antibody, EC 5 0 44 8) nM. Figure 12B depicts electrophoretic mobility shift of the DNA element SIE induced by CT-I binding to MI cells. MI cells were incubated without or with 5 nM mouse CT-1 or LIF, lysed, and -6the cell extract assayed for binding to the DNA element SIE as described in the Materials and Methods. Binding specificity was determined by the addition of unlabeled SIE DNA (Cold Oligo). The specific DNA complex is indicated (arrow).
Figure 13A and 13B depict binding and cross-competition of CT-I and LIF to rat primary cardiac myocytes. Duplicate assays contained either 0.047 nM 1 2 5 I-mouse CT-I (125I-mCT-1) or 0.042 nM 125Imouse LIF (125I-mLIF) and unlabeled mouse CT-1 or LIF as indicated.
Figures 14A, 14B, 14C and 14D depict binding of CT-I to purified, soluble LIF receptor and Figures 14A-C show per cent binding of 1 2 5 1-mouse CT-1 (0.089 nM) to soluble mouse LIF receptor (smLIFR) and soluble mouse gpl30 (smgpl30) in the absence or presence of 164 nM unlabeled mouse CT-I (mCT- Figure 14A depicts binding to increasing concentrations soluble LIF receptor alone; FIgure 14B depicts binding to increasing concentrations of soluble gpl30 alone; Figure 14C depicts binding at bne soluble LIF receptor concentration with increasing concentrations of soluble gp130. Plotted is the average and half the difference of duplicate determinations. The results for 0.84 nM soluble LIF receptor are shown twice for clarity.
Figure 14D depicts competition binding of 12 5 I-mouse CT-1 (0.089 nM) to the soluble LIF receptor (2.8 nM) with increasing concentrations of unlabeled CT-I. Kd [CT-1] 1.9 0.2) nM.
Figures 15A and 15B depict similarity of IL-6 family ligands and subunit structure of their receptors.
Figure 15A shows per cent amino acid identity of the mature form of the IL-6 family ligands mouse, (h) human, chicken. The bottom row gives the per cent identity of the cytokine to its human homologue. Shown S* in bold are the percentages greater than 40 Figure 15B is a diagram of the IL-6 family receptors. The subunit 20 stoichiometry of the various complexes is not known in most cases, although recent work has led to a conclusion that the IL-6 receptor complex is a hexamer containing two IL-6 molecules, two IL-6 receptors, and two gp130 signaling subunits. Ward et al., J. Biol. Chem., 269:23286-23289 (1994).
S Figure 16 depicts alignment of the protein sequence of human CT-I, LIF and CNTF. Encoded amino acid sequence of human CT-1 (hCT-1) aligned with that of human LIF (hLIF) and human CNTF (hCNTF).
25 Overlining indicates the location of four amphipathic helices based on their proposed locations in CNTF (Bazan, Neuron, 7:197-208 (1991)).
Figures 17A and 17B depict the competition for the binding of human LIF to mouse M or human Hela cell. For Figure 17A 1251-human LIF was bound in duplicate to M1 (5 million cells per reaction) in the presence of the indicated competitors. For Figure 17B 1251-human LIF was bound in duplicate to Hela cells (2.5 million per reaction) in the presence of the indicated competitors. CM is conditioned medium from 293 cells transfected with human CT-I.
Figure 18 depicts the binding of mouse CT-1 to human Hela cells. Duplicate assays containing 0.23 nM 1251-mouse-CT-I and 9 million cells were performed as described in the Examples. The insert is a Scatchard plot of the data. Kd=0.75 nM, 860(+/-130 sites per cell).
Figure 19 depicts the competition for the binding of human OSM to human WI-26 cells. 1251-human OSM was bound in duplicate to WI-26 VA4 cells (2.4 million cells per reaction) in the presence of the indicated competitors as described in the Examples.
Figure 20 depicts expression of CT-I in human tissues, Northern blots containing polyA+RNA from the indicated tissues were hybridized with a human CT-I cDNA probe as described in the Examples.
Figure 21 is a schematic depicting several biological activities of CT-1.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS I. Definitions In general, the following words or phrases have the indicated definition when used in the description, examples, and claims: "CHF" (or "cardiac hypertrophy factor" or "cardiotrophin" or "cardiotrophin-l" or is defined herein to be any polypeptide sequence that possesses at least one biological property (as defined below) of a naturally occurring polypeptide comprising the polypeptide sequence of Fig. 1 or the human equivalent thereof shown in Fig. 5. It does not include the rat homolog of CT-1, CT-I from the rat species. This definition encompasses not only the polypeptide isolated from a native CT-I source such as mu'rine embryoid bodies described herein or from another source, such as another animal species except rat, includingthumans, but also the polypeptide prepared by recombinant or synthetic methods. It also includes variant forms including functional derivatives, alleles, isoforms and analogues thereof.
A "CT-I fragment" is a portion of a naturally occurring mature full-length CT-I sequence having one or more amino acid residues or carbohydrate units deleted. The deleted amino acid residue(s) may occur anywhere in the polypeptide, including at either the N-terminal or C-terminal end or internally. The fragment will share at least one biological property in common with CT-1. CT-I fragments typically will have a consecutive sequence of at least 10, 15, 20, 25, 30, or 40 amino acid residues that are identical to the sequences of the CT-1 isolated from a mammal including the CT-I isolated from murine embryoid bodies or the human CT- 20 1.
"CT-I variants" or "CT-1 sequence variants" as defined herein mean biologically active CT-is as defined below having less than 100% sequence identity with the CT-1 isolated from recombinant cell culture or from murine embryoid bodies having the deduced sequence described in Fig. 1, or with the human equivalent described in Fig. 5. Ordinarily, a biologically active CT-I variant will have an amino acid sequence having at 25 least about 70% amino acid sequence identity with the CT-1 isolated from murine embryoid bodies or the mature human CT-1 (see Figs. 1 and preferably at least about 75%, more preferably at least about 80%, still more preferably at least about 85%, even more preferably at least about 90%, and most preferably at least about A "chimeric CT-I" is a polypeptide comprising full-length CT-1 or one or more fragments thereof fused or bonded to a second protein or one or more fragments thereof. The chimera will share at least one biological property in common with CT-1. The second protein will typically be a cytokine, growth factor, or hormone such as growth hormone, IGF-I, or a neurotrophic factor such as CNTF, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 neurotrophin-4 neurotrophin-5 NT-6, or the like.
"Isolated CT-I", "highly purified CT-I" and "substantially homogeneous CT-I" are used interchangeably and mean a CT-I that has been purified from a CT-1 source or has been prepared by recombinant or synthetic methods and is sufficiently free of other peptides or proteins to obtain at least and preferably 20 amino acid residues of the N-terminal or of an internal amino acid sequence by using a spinning cup sequenator or the best commercially available amino acid sequenator marketed or as modified by published methods as of the filing date of this application, or to homogeneity by SDS-PAGE under nonreducing or reducing conditions using Coomassie blue or, preferably, silver stain. Homogeneity here means less than about 5% contamination with other source proteins.
"Biological property" when used in conjunction with either "CT-1" or "isolated CT-i" means having myocardiotrophic, inotropic, anti-arrhythmic, or neurotrophic activity or having an in vivo effector or antigenic function or activity that is directly or indirectly caused or performed by a CT-1 (whether in its native or denatured conformation) or a fragment thereof. Effector functions include receptor binding and any carrier binding activity, agonism or antagonism of CT-1, especially transduction of a proliferative signal including replication, DNA regulatory function, modulation of the biological activity of other growth factors, receptor activation, deactivation, up- or down-regulation, cell growth or differentiation, and the like. However, effector functions do not include possession of an epitope or antigenic site that is capable of cross-reacting with antibodies raised against native CT-1.
An "antigenic function" means possession of an epitope or antigenic site that is capable of cross-reacting with antibodies raised against the native CT-1 whose sequence is shown in Fig. 1 or another mammalian native CT-1, including the human homolog whose sequence is shown in Fig. 5. The principal antigenic function of a CT-1 polypeptide is that it binds with an affinity of at least about 10 6 L/mole to an antibody raised against CT-1 isolated from mouse embryoid bodies or a human homolog thereof. Ordinarily, the polypeptide binds with an affinity of at least about 10 7 L/mole. Most preferably, the antigenically active CT-1 polypeptide'is a polypeptide that binds to an antibody raised against CT-1 having one of the above-described effector functions. The antibodies used to define "biologically activity" are rabbit polyclonal antibodies raised by formulating the CT-1 20 isolated from recombinant cell culture or embryoid bodies in Freund's complete adjuvant, subcutaneously injecting the formulation, and boosting the immune response by intraperitoneal injection of the formulation until the titer of the anti-CT-1 antibody plateaus.
*"Biologically active" when used in conjunction with either "CT-I" or "isolated CT-I" mean a CT-1 polypeptide that exhibits hypertrophic, inotropic, anti-arrhythmic, or neurotrophic activity or shares an effector function of CT-1 isolated from murine embryoid bodies or produced in recombinant cell culture described herein, and that may (but need not) in addition possess an antigenic function. One principal effector function of CT-1 or CT-1 polypeptide herein is influencing cardiac growth or hypertrophy activity, as measured, by atrial natriuretic peptide (ANP) release or by the myocyte hypertrophy assay described herein using-a specific plating medium and plating density, and preferably using crystal violet stain for readout. The desired function of a CT-1 (or CT-1 antagonist) is to increase physiological (beneficial) forms of hypertrophy and decrease pathological hypertrophy. In addition, the CT-I herein is expected to display anti-arrhythmic function by promoting a more normal electrophysiological phenotype. Another principal effector function of CT-I or CT-1 polypeptide herein is stimulating the proliferation of chick ciliary ganglion neurons in an assay for CNTF activity.
Antigenically active CT-1 is defined as a polypeptide that possesses an antigenic function of CT-I and that may (but need not) in addition possess an effector function.
In preferred embodiments, antigenically active CT-1 is a polypeptide that binds with an affinity of at least about 106 L/mole to an antibody capable of binding CT-1. Ordinarily, the polypeptide binds with an affinity of at least about 10 7 LUmole. Isolated antibody capable of binding CT-1 is an antibody that is identified and separated from a component of the natural environment in which it may be present. Most preferably, the antigenically active CT-1 is a polypeptide that binds to an antibody capable of binding CT-I in its native conformation. CT-1 in its native conformation is CT-1 as found in nature that has not been denatured by chaotropic agents, heat, or other treatment that substantially modifies the three-dimensional structure of CT-1 as determined, for example, by migration on non-reducing, non-denaturing sizing gels. Antibody used in this determination is rabbit polyclonal antibody raised by formulating native CT-I from a non-rabbit species in Freund's complete adjuvant, subcutaneously injecting the formulation, and boosting the immune response by intraperitoneal injection of the formulation until the titer ofanti-CT-1 antibody plateaus.
"Percent amino acid sequence identity" with respect to the CT-I sequence is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the residues in the CT-1 sequence isolated from murine embryoid bodies having the deduced amino acid sequence described in Fig. 1 or the deduced human CT-1 amino acid sequence described in Fig. 5, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. None of N-terminal, C-terminal, or internal extensions, deletions, or insertions into the CT-1 sequence shall be construed as affecting sequence identity or homology. Thus, exemplary biologically active CT-1 polypeptides considered to have identical sequences include prepro-CT-1, pro-CT-1, and mature CT-I.
"CT-1 microsequencing" may be accomplished by any appropriate standard procedure provided the procedure is sensitive enough. In one such method, highly purified polypeptide obtained from SDS gels or from a final HPLC step is sequenced directly by automated Edman (phenyl isothiocyanate) degradation using a model 20 470A Applied Biosystems gas-phase sequencer equipped with a 120A phenylthiohydantoin (PTH) amino acid analyzer. Additionally, CT-1 fragments prepared by chemical CNBr, hydroxylamine, or thiocyanobenzoate) or enzymatic trypsin, clostripain, or staphylococcal protease) digestion followed by fragment purification HPLC) may be similarly sequenced. PTH amino acids are analyzed using the ChromPerfectTM data system (Justice Innovations, Palo Alto, CA). Sequence interpretation is performed on a 25 VAX 11/785 Digital Equipment Co. computer as described by Henzel et al., J. Chromatography, 404:41-52 (1987). Optionally, aliquots of HPLC fractions may be electrophoresed on 5-20% SDS-PAGE, electrotransferred to a PVDF membrane (ProBlott, AIB, Foster City, CA) and stained with Coomassie Brilliant Blue. Matsurdiara, J. Biol. Chem., 262:10035-10038 (1987). A specific protein identified by the stain is excised from the blot and N-terminal sequencing is carried out with the gas-phase sequenator described above. For internal protein sequences, HPLC fractions are dried under vacuum (SpeedVac), resuspended in appropriate buffers, and digested with cyanogen bromide, the Lys-specific enzyme Lys-C (Wako Chemicals, Richmond, VA), or Asp-N (Boehringer Mannheim, Indianapolis, IN). After digestion, the resultant peptides are sequenced as a mixture or after HPLC resolution on a C4 column developed with a propanol gradient in 0.1% trifluoroacetic acid (TFA) prior to gas-phase sequencing.
"Isolated CT-1 nucleic acid" is RNA or DNA containing greater than 16 and preferably 20 or more sequential nucleotide bases that encodes biologically active CT-I or a fragment thereof, is complementary to the RNA or DNA, or hybridizes to the RNA or DNA and remains stably bound under moderate to stringent conditions. This RNA or DNA is free from at least one contaminating source nucleic acid with which it is normally associated in the natural source and preferably substantially free of any other mammalian RNA or DNA. The phrase "free from at least one contaminating source nucleic acid with which it is normally associated" includes the case where the nucleic acid is present in the source or natural cell but is in a different chromosomal location or is otherwise flanked by nucleic acid sequences not normally found in the source cell. An example of isolated CT-i nucleic acid is RNA or DNA that encodes a biologically active CT-i sharing at least 75%, more preferably at least 80%, still more preferably at least 85%, even more preferably 90%, and most preferably sequence identity with the murine CT-1 or with the human CT-I.
"Control sequences" when referring to expression means DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, a ribosome binding site, and possibly, other as yet poorly understood sequences. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.
"Operably linked" when referring to nucleic acids means that the nucleic acids are placed in a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked'are contiguous and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the 20 synthetic oligonucleotide adaptors or linkers are used in accord with conventional practice.
"Exogenous" when referring to an element means a nucleic acid sequence that is foreign to the cell, or homologous to the cell but in a position within the host cell nucleic acid in which the element is ordinarily not found.
"Cell," "cell line," and "cell culture" are used interchangeably herein and such designations include all 25 progeny of a cell or cell line. Thus, for example, terms like "transformants" and "transformed cells" include the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant progeny that have the same function or biological activity as screened for in the originally transformed cell are included. Where distinct designations are intended, it will be clear from the context.
"Plasmids" are autonomously replicating circular DNA molecules possessing independent origins of replication and are designated herein by a lower case preceded and/or followed by capital letters and/or numbers. The starting plasmids herein either are commercially available, are publicly available on an unrestricted basis, or can be constructed from such available plasmids in accordance with published procedures.
In addition, other equivalent plasmids are known in the art and will be apparent to the ordinary artisan.
"Restriction enzyme digestion" when referring to DNA means catalytic cleavage of internal phosphodiester bonds of DNA with an enzyme that acts only at certain locations or sites in the DNA sequence.
Such enzymes are called "restriction endonucleases." Each restriction endonuclease recognizes a specific DNA sequence called a "restriction site" that exhibits two-fold symmetry. The various restriction enzymes used herein are commercially available and their reaction conditions, cofactors, and other requirements as established by the -11enzyme suppliers are used. Restriction enzymes commonly are designated by abbreviations composed of a capital letter followed by other letters representing the microorganism from which each restriction enzyme originally was obtained and then a number designating the particular enzyme. In general, about 1 pg of plasmid or DNA fragment is used with about 1-2 units of enzyme in about 20 plL of buffer solution. Appropriate buffers and substrate amounts for particular restriction enzymes are specified by the manufacturer. Incubation for about 1 hour at 37°C is ordinarily used, but may vary in accordance with the supplier's instructions. After incubation, protein or polypeptide is removed by extraction with phenol and chloroform, and the digested nucleic acid is recovered from the aqueous fraction by precipitation with ethanol. Digestion with a restriction enzyme may be followed with bacterial alkaline phosphatase hydrolysis of the terminal 5' phosphates to prevent the two restriction-cleaved ends of a DNA fragment from "circularizing" or forming a closed Idop that would impede insertion of another DNA fragment at the restriction site. Unless otherwise stated, digestion pfplasmids is not followed by 5' terminal dephosphorylation. Procedures and reagents for dephosphorylation are conventional as described in sections 1.56-1.61 of Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989).
"Recovery" or "isolation" of a given fragment of DNA from a restriction digest means separation of the digest on polyacrylamide or agarose gel by electrophoresis, identification of the fragment of interest by comparison of its mobility versus that of marker DNA fragments of known molecular weight, remnoval of the gel section containing the desired fragment, and separation of the gel from DNA. This procedure is known generally.
For example, see Lawn et al., Nucleic Acids Res., 9:6103-6114 (1981) and Goeddel et al., Nucleic Acids Res., 20 8:4057 (1980).
"Southern analysis" or "Southern blotting" is a method by which the presence of DNA sequences in a :restriction endonuclease digest of DNA or a DNA-containing composition is confirmed by hybridization to a known, labeled oligonucleotide or DNA fragment. Southern analysis typically involves electrophoretic separation of DNA digests on agarose gels, denaturation of the DNA after electrophoretic separation, and transfer 25 of the DNA to nitrocellulose, nylon, or another suitable membrane support for analysis with a radiolabeled, biotinylated, or enzyme-labeled probe as described in sections 9.37-9.52 of Sambrook et al., supra.
"Northern analysis" or "Northern blotting" is a method used to identify RNA sequences that hybridize to a known probe such as an oligonucleotide, DNA fragment, cDNA or fragment thereof, or RNA fragment. The probe is labeled with a radioisotope such as 3 2 p, or by biotinylation, or with an enzyme. The RNA to be analyzed is usually electrophoretically separated on an agarose or polyacrylamide gel, transferred to nitrocellulose, nylon, or other suitable membrane, and hybridized with the probe, using standard techniques well known in the art such as those described in sections 7.39-7.52 of Sambrook et al., supra.
"Ligation" is the process of forming phosphodiester bonds between two nucleic acid fragments. For ligation of the two fragments, the ends of the fragments must be compatible with each other. In some cases, the ends will be directly compatible after endonuclease digestion. However, it may be necessary first to convert the staggered ends commonly produced after endonuclease digestion to blunt ends to make them compatible for ligation. For blunting the ends, the DNA is treated in a suitable buffer for at least 15 minutes at 15* C with about units of the Klenow fragment of DNA polymerase I or T4 DNA polymerase in the presence of the four deoxyribonucleotide triphosphates. The DNA is then purified by phenol-chloroform extraction and ethanol -12precipitation. The DNA fragments that are to be ligated together are put in solution in about equimolar amounts.
The solution will also contain ATP, ligase buffer, and a ligase such as T4 DNA ligase at about 10 units per gg of DNA. If the DNA is to be ligated into a vector, the vector is first linearized by digestion with the appropriate restriction endonuclease(s). The linearized fragment is then treated with bacterial alkaline phosphatase or calf intestinal phosphatase to prevent self-ligation during the ligation step.
"Preparation" of DNA from cells means isolating the plasmid DNA from a culture of the host cells.
Commonly used methods for DNA preparation are the large- and small-scale plasmid preparations described in sections 1.25-1.33 of Sambrook etal., supra. After preparation of the DNA, it can be purified by methods well known in the art such as that described in section 1.40 of Sambrook et al., supra.
"Oligonucleotides" are short-length, single- or double-stranded polydeoxynucleotides that are chemically synthesized by known methods such as phosphotriester, phosphite, or phosphoramidite chemistry, using solid-phase techniques such as described in EP 266,032 published 4 May 1988, or via deoxynucleoside H-phosphonate intermediates as described by Froehler et al., Nucl. Acids Res., 14:5399-5407 (1986). Further methods include the polymerase chain reaction defined below and other autoprimer methods and oligonucleotide syntheses on solid supports. All of these methods are described in Engels et al., Agnew. Chem. Int. Ed. Engl., 28:716-734 (1989). These methods are used if the entire nucleic acid sequence of the gene is known, or the sequence of the nucleic acid complementary to the coding strand is available. Alternatively, if the target amino acid sequence is known, one may infer potential nucleic acid sequences using known and preferred coding residues for each amino acid residue. The oligonucleotides are then purified on polyacrylamide gels.
20 "Polymerase chain reaction" or "PCR" refers to a procedure or technique in which minute amounts of a specific piece of nucleic acid, RNA and/or DNA, are amplified as described in U.S. Patent.No. 4,683,195 issued 28 July 1987. Generally, sequence information from the ends of the region of interest or beyond needs to be available, such that oligonucleotide primers can be designed; these primers will be identical or similar in sequence to opposite strands of the template to be amplified. The 5' terminal nucleotides of the two primers may 25 coincide with the ends of the amplified material. PCR can be used to amplify specific RNA sequences, specific DNA sequences from total genomic DNA, and cDNA transcribed from total cellular RNA, bacteriophage or plasmid sequences, etc. See generally Mullis et al., Cold Spring Harbor Symp. Quant. Biol., 51:263 (1987); Erlich, ed., PCR Technology, (Stockton Press, NY, 1989). As used herein, PCR is considered to be one, but not the only, example of a nucleic acid polymerase reaction method for amplifying a nucleic acid test sample comprising the use of a known nucleic acid as a primer and a nucleic acid polymerase to amplify or generate a specific piece of nucleic acid.
"Stringent conditions" are those that (Chien etal., Annu. Rev. Physiol., 55:77-95 (1993)) employ low ionic strength and high temperature for washing, for example, 0.015 M NaCI/0.0015 M sodium citrate/0.1% NaDodSO 4 (SDS) at 500C, or employ during hybridization a denaturing agent such as formamide, for example, 50% (vol/vol) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% mM sodium phosphate buffer at pH 6.5 with 750 mM NaCI, 75 mM sodium citrate at 42* C. Another example is use of 50% formamide, 5 x SSC (0.75 M NaCI, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 ug/mL), 0.1% SDS, and dextran sulfate at 420 C, with washes at 42°C in 0.2 x SSC and 0.1% SDS.
-13- "Moderately stringent conditions" are described in Sambrook et al., supra, and include the use of a washing solution and hybridization conditions temperature, ionic strength, and %SDS) less stringent than described above. An example of moderately stringent conditions is a condition such as overnight incubation at 37*C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCI, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/mL denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50*C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc., as necessary to accommodate factors such as probe length and the like.
"Antibodies" (Abs) and "immunoglobulins" (Igs) are glycoproteins having the same structural characteristics. While antibodies exhibit binding specificity to a specific antigen, immunoglobulins include both antibodies and other antibody-like molecules which lack antigen specificity. Polypeptides of the latter kind are, for example, produced at low levels by the lymph system and at increased levels by myelomas. "Native antibodies and immunoglobulins" are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light chains and two identical heavy chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number ofdisulfide linkages varies between the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain (VH) followed by a number of constant domains.
Each light chain has a variable domain at one end (VL) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable S, 20 domain is aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light- and heavy-chain variable domains (Clothia et al., J. Mol. Biol., 186:651-663 (1985); Novotny et al, Proc. Natl. Acad. Sci. USA, 82:4592-4596 (1985)).
The term "variable" refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its 25 particular antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called complementarity-determining regions (CDRs) or hypervariable regions both in the light-chain and the heavy-chain variable domains. The more highly conserved portions of variable domains are called the framework The variable domains of native heavy and light chains each comprise four FR regions, largely adopting a p-sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the P-sheet structure. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, National Institute of Health, Bethesda, MD (1991)). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity.
Papain digestion of antibodies produces two identical antigen- binding fragments, called "Fab" fragments, each with a single antigen-binding site, and a residual "Fc" fragment, whose name reflects its ability to crystallize readily. Pepsin treatment yields an F(ab') 2 fragment that has two antigen-combining sites and is still capable of cross-linking antigen.
-14- "Fv" is the minimum antibody fragment which contains a complete antigen-recognition and -binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigenbinding site on the surface of the VH-VL dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
The Fab fragment also contains the constant domain of the light chain and the first constant domain (CH of the heavy chain. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CHI domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constaht domains bear a free thiol group. F(ab') 2 antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
The "light chains" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda based on the amino acid sequences of their constant domains.
Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), IgG-1, IgG-2, IgG-3, IgG-4, 20 IgA-1, and IgA-2. The heavy-chain constant domains that correspond to the different classes of immunoglobulins are called a, 6, E, y, and p, respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.
The term "antibody" is used in the broadest sense and specifically covers single monoclonal antibodies (including agonist and antagonist antibodies) and antibody compositions with polyepitopic specificity.
The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hybridoma culture, uncontaminated by other immunoglobulins.
The monoclonal antibodies herein include hybrid and recombinant antibodies produced by splicing a variable (including hypervariable) domain of an anti-CT-I antibody with a constant domain "humanized" antibodies), or a light chain with a heavy chain, or a chain from one species with a chain from another species, or fusions with heterologous proteins, regardless of species of origin or immunoglobulin class or subclass designation, as well as antibody fragments Fab, F(ab') 2 and Fv), so long as they exhibit the desired biological activity. (See, e.g. Cabilly, et al., U.S. Pat. No. 4,816,567; Mage et al., Monoclonal Antibody Production Techniques and Applications, pp.79-97 (Marcel Dekker, Inc., New York, 1987).) Thus, the modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al., Nature, 256:495 (1975), or may be made by recombinant DNA methods (Cabilly etal., supra). The monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (Cabilly et al., supra; Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)).
"Humanized" forms of non-human murine) antibodies are specific chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab') 2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary-determining region (CDR) of the recipient are replaced by residues from a CDR of a nonhuman species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity.
In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non- "human residues. Furthermore, humanized antibodies may comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and optimize antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region typically that of a human immunoglobulin. For further o* details see: Jones et al., Nature, 321:522-525 (1986); Reichmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992).
"Non-immunogenic in a human" means that upon contacting the polypeptide in a pharmaceutically acceptable carrier and in a therapeutically effective amount with the appropriate tissue of a human, no state of sensitivity or resistance to the polypeptide is demonstratable upon the second administration of the polypeptide after an appropriate latent period 8 to 14 days).
"Neurological disorder" refers to a disorder of neurons, including both peripheral neurons and neurons from the central nervous system. Examples of such disorders include all neurodegenerative diseases, such as peripheral neuropathies (motor and sensory), amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, stroke, Huntington's disease, epilepsy, and ophthalmologic diseases such as those involving the retina, diabetic retinopathy, retinal dystrophy, and retinal degeneration caused by infantile malignant osteopetrosis, ceroid-lipofuscosis, or cholestasis, or caused by photodegeneration, trauma, axotomy, neurotoxicexcitatory degeneration, or ischemic neuronal degeneration.
-16- "Peripheral neuropathy" refers to a disorder affecting the peripheral nervous system, most often manifested as one or a combination of motor, sensory, sensorimotor, or autonomic neural dysfunction. The wide variety of morphologies exhibited by peripheral neuropathies can each be attributed uniquely to an equally wide number of causes. For example, peripheral neuropathies can be genetically acquired, can result from a systemic disease, or can be induced by a toxic agent. Examples include but are not limited to distal sensorimotor neuropathy, or autonomic neuropathies such as reduced motility of the gastrointestinal tract or atony of the urinary bladder. Examples of neuropathies associated with systemic disease include post-polio syndrome; examples of hereditary neuropathies include Charcot-Marie-Tooth disease, Refsum's disease, Abetalipoproteinemia, Tangier disease, Krabbe's disease, Metachromatic leukodystrophy, Fabry's disease, and Dejerine-Sottas syndrome; and examples of neuropathies caused by a toxic agent include those caused by treatment with a chemotherapeutic agent such as vincristine.
"Heart failure' refers to an abnormality of cardiac function where the heart does not pump blood at the rate needed for the requirements of metabolizing tissues. Heart failure includes a wide range of disease states such as congestive heart failure, myocardial infarction, and tachyarrhythmia.
"Treatment" refers to both therapeutic treatment and prophylactic or preventative measures. Those in S•need of treatment include those already with the disorder as well as those prone to have the disorder or those in which the disorder is to be prevented.
"Mammal" for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, etc. Preferably, the mammal herein is human.
As used herein, "ACE inhibitor" refers to angiotensin-converting enzyme inhibiting drugs which prevent the conversion ofangiotensin I to angiotensin II. The ACE inhibitors may be beneficial in congestive heart failure by reducing systemic vascular resistance and relieving circulatory congestion. The ACE inhibitors include but are not limited to those designated by the trademarks Accupril® (quinapril), Altace® (ramipril), Capoten® (captopril), Lotensin® (benazepril), Monopril® (fosinopril), Prinivil® (lisinopril), Vasotec® (enalapril), and Zestril® (lisinopril). One example of an ACE inhibitor is that sold under the trademark Capoten®. Generically referred to as captopril, this ACE inhibitor is designated chemically as 1-[(2S)-3-mercapto-2-methylpropionyl]-Lproline.
_e o•* -17- For the purposes of this specification it will be clearly understood that the word "comprising" means "including but not limited to", and that the word "comprises" has a corresponding meaning.
II. Modes for Practicing the Invention 1. CT-1 Polypeptides Preferred polypeptides of this invention are substantially homogenous CT-1 polypeptides(s), having the biological properties of being myocyte hypertrophic and of stimulating the development of chick ciliary neurons in a CNTF assay. More preferred CT-Is are isolated mammalian protein(s) having hypertrophic, anti-arrhythmic, inotropic, and neurological activity. Most preferred polypeptides of this invention are mouse and human CT- s, including fragments thereof having hypertrophic, anti-arrhythmic, inotropic, and neurological activity. Optionally these murine and human CT-is lack glycosylation.
15 W09529237, which published November, 02, 1995, and which is incorporated herein by reference, discloses CT-1 nucleic acid and protein sequences and certain uses of CT-1.
*i *go o*o 17A- Optional preferred polypeptides of this invention are biologically active CT-1 variant(s) with an amino acid sequence having at least 70% amino acid sequence identity with the murine CT-I of Fig. 1, preferably at least 75%, more preferably at least 80%, still more preferably at least 85%, even more preferably at least and most preferably at least 95% 70-100%, 75-100%, 80-100%, 85-100%, 90-100%, and 95-100% sequence identity, respectively). Alternatively, the preferred biologically active CT-I variant(s) have an amino acid sequence having at least 70%, preferably at least 75%, more preferably at least 80%, still more preferably at least 85%, even more preferably at least 90%, and most preferably at least 95% amino acid sequence identity with the human CT-1 sequence of Fig. 5 70-100%, 75-100%, 80-100%, 85-100%, 90-100%, and 95-100% sequence identity, respectively).
The CT-I cloned from murine embryoid bodies has the following characteristics: It has a molecular weight of about 21-23 kD as measured by reducing SDS-PAGE; It shows positive activity in the CNTF chick ciliary neuron assay and in the myocyte hypertrophy and ANP-release hypertrophy assays.
More preferred CT-1 polypeptides are those encoded by genomic DNA or cDNA and having the ami"n acid sequence of murine CT-I described in Fig. 1 or the amino acid sequence of human CT-I described in Fig.
S Other preferred naturally occurring biologically active CT-I polypeptides of this invention include prepro-CT-1, pro-CT-1, pre-CT-1, mature CT-1, and glycosylation variants thereof.
Still other preferred polypeptides of this invention include CT-I sequence variants and chimeric CT- s.
S* 20 Ordinarily, preferred CT-I sequence variants are biologically active CT-I variants that have an amino acid sequence having at least 70% amino acid sequence identity with the human or murine CT-1, preferably at least more preferably at least 80%, still more preferably at least 85%, even more preferably at least 90%, andmost preferably at least 95%. An exemplary preferred CT-i variant is a C-terminal domain CT-i variant in which one or more of the basic or dibasic amino acid residue(s) R or K) is substituted with a non-basic 25 amino acid residue(s) hydrophobic, neutral, acidic, aromatic, gly, pro and the like).
Another exemplary preferred CT-1 sequence variant is a "domain chimera" that consists of the Nterminal residues substituted with one or more, but not all, of the human CNTF residues approximately aligned as shown in Fig. 2. In this embodiment, the CT-I chimera would have individual or blocks of residues from the *human CNTF sequence added to or substituted into the CT-1 sequence at positions corresponding to the alignment shown in Fig. 2. For example, one or more of those segments of CNTF that are not homologous could be substituted into the corresponding segments of CT-1. It is contemplated that this "CT-1-CNTF domain chimera" will have mixed hypertrophic/anti-arrhythmic/inotropic/neurotrophic biological activity.
Other preferred polypeptides of this invention include CT-I fragments having a consecutive sequence of at least 10, 15, 20, 25, 30, or 40 amino acid residues, preferably about 10-150 residues, that is identical to the sequence of the CT-1 isolated from murine embryoid bodies or to that of the corresponding human CT-1. Other preferred CT-I fragments include those produced as a result of chemical or enzymatic hydrolysis or digestion of the purified CT-1.
Another aspect of the invention is a method for purifying CT- molecules comprising contacting a CTsource containing the CT-1 molecules to be purified with an immobilized receptor or antibody polypeptide, under -18conditions whereby the CT-I molecules to be purified are selectively adsorbed onto the immobilized receptor or antibody polypeptide, washing the immobilized support to remove non-adsorbed material, and eluting the molecules to be purified from the immobilized receptor or antibody polypeptide to which they are adsorbed with an elution buffer. The source containing the CT-1 may be a cell suspension of embryoid bodies.
Alternatively, the source containing the CT-1 is recombinant cell culture where the concentration of CT- 1 in either the culture medium or in cell lysates is generally higher than in plasma or other natural sources. In this case the above-described immunoaffinity method, while still useful, is usually not necessary and more traditional protein purification methods known in the art may be applied. Briefly, the preferred purification method to provide substantially homogeneous CT-1 comprises: removing particulate debris by, for example, centrifugation or ultrafiltration; optionally concentrating the protein pool with a commercially available protein concentration filter; and thereafter purifying the CT-I from contaminant soluble proteins and polypeptides, with the following procedures being exemplary of suitable purification procedures: by fractionation on immunoaffinity or ion-exchange columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cationexchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; Toyopearl and MONO-Q or MONO-S chromatography; gel filtration using, for example, Sephadex G-75; chromatography on columns that bind the CT-I, and protein A Sepharose columns to remove contaminants such as IgG. One preferred purification scheme for both native and recombinant CT-1 uses a Butyl Toyopearl column followed by a MONO-Q column and a reverse-phase C4 column as described further below.
In another preferred embodiment, this invention provides an isolated antibody capable of binding to the 20 CT-I. A preferred isolated anti-CT-1 antibody is monoclonal (Kohler et al., Nature, 256:495-497 (1975); Campbell, Laboratory Techniques in Biochemistry and Molecular Biology, Burdon et al., Eds, Volume 13, Elsevier Science Publishers, Amsterdam (1985); and Huse et al., Science, 246:1275-1281 (1989)). Preferred isolated anti-CT-I antibody is one that binds to CT-1 with an affinity of at least about 10 6 L/mole. More preferably, the antibody binds with an affinity of at least about 107 L/mole. Most preferably, the antibody is 25 raised against a CT-1 having one of the above-described effector functions. The isolated antibody capable of S binding to the CT-1 may optionally be fused to a second polypeptide and the antibody or fusion thereof may be used to isolate and purify CT-I from a source as described above for immobilized CT-I polypeptide. In a further preferred aspect of this embodiment, the invention provides a method for detecting the CT- 1 in vitro or in vivo comprising contacting the antibody with a sample, especially a serum sample, suspected of containing the CT-1 and detecting if binding has occurred.
The invention also provides an isolated nucleic acid molecule encoding the CT-1 or fragments thereof, which nucleic acid molecule may be labeled or unlabeled with a detectable moiety, and a nucleic acid molecule having a sequence that is complementary to, or hybridizes under stringent or moderately stringent conditions with, a nucleic acid molecule having a sequence encoding a CT-1. A preferred CT-I nucleic acid is RNA or DNA that encodes a biologically active CT-1 sharing at least 75%, more preferably at least 80%, still more preferably at least 85%, even more preferably 90%, and most preferably 95%, sequence identity with the murine or human CT-I. More preferred isolated nucleic acid molecules are DNA sequences encoding biologically active CT-1, selected from: DNA based on the coding region of a mammalian CT-1 gene DNA comprising the nucleotide sequence provided in Fig. 1 or Fig. 5, or fragments thereof); DNA capable of hybridizing to -19a DNA of(a) under at least moderately stringent conditions; and DNA that is degenerate to a DNA defined in or which results from degeneracy of the genetic code. It is contemplated that the novel CT-Is described herein may be members of a family of ligands having suitable sequence identity that their DNA may hybridize with the DNA of Fig. 1 or Fig. 5 (or fragments thereof) under low to moderate stringency conditions. Thus, a further aspect of this invention includes DNA that hybridizes under low to moderate stringency conditions with DNA encoding the CT-1 polypeptides.
Preferably, the nucleic acid molecule is cDNA encoding the CT-I and further comprises a replicable vector in which the cDNA is operably linked to control sequences recognized by a host transformed with the vector. This aspect further includes host cells transformed with the vector and a method of using the cDNA to effect production of CT-1, comprising expressing the cDNA encoding the CT-1 in a culture of the transformed host cells and recovering the CT-I from the host cell culture. The CT-I prepared in this manner is preferably substantially homogeneous murine or human CT-1.
The invention further includes a preferred method for treating a mammal having heart failure, or an arrhythmic, inotropic, or neurological disorder, comprising administering a therapeutically effective amount of a CT-1 to the mammal. Optionally, the CT-I is administered in combination with an ACE inhibitor, such as captopril, in the case of congestive heart failure, or with another myocardiotrophic, anti-arrhythmic, or inotropic factor in the case of other types of heart failure or cardiac disorder, or with a neurotrophic molecule such as, e.g., S" IGF-I, CNTF, NGF, NT-3, BDNF, NT-4, NT-5, etc. in the case of a neurological disorder.
2. Preparation of Natural-Sequence CT-i and Variants Most of the discussion below pertains to production of CT-I by culturing cells transformed with a vector containing CT-1 nucleic acid and recovering the polypeptide from the cell culture. It is further envisioned that the CT-1 of this invention may be produced by homologous recombination, as provided for in WO 91/06667 published 16 May 1991. Briefly, this method involves transforming primary mammalian cells containing endogenous CT-1 gene human cells if the desired CT-1 is human) with a construct vector) comprising 25 an amplifiable gene (such as dihydrofolate reductase [DHFR] or others discussed below) and at least one flanking region of a length of at least about 150 bp that is homologous with a DNA sequence at the locus of the coding S. region of the CT-1 gene to provide amplification of the CT-I gene. The amplifiable gene must be at a site that S does not interfere with expression of the CT-I gene. The transformation is conducted such that the construct becomes homologously integrated into the genome of the primary cells to define an amplifiable region.
Primary cells comprising the construct are then selected for by means of the amplifiable gene or other marker present in the construct. The presence of the marker gene establishes the presence and integration of the construct into the host genome. No further selection of the primary cells need be made, since selection will be made in the second host. If desired, the occurrence of the homologous recombination event can be determined by employing PCR and either sequencing the resulting amplified DNA sequences or determining the appropriate length of the PCR fragment when DNA from correct homologous integrants is present and expanding only those cells containing such fragments. Also if desired, the selected cells may be amplified at this point by stressing the cells with the appropriate amplifying agent (such as methotrexate if the amplifiable gene is DHFR), so that multiple copies of the target gene are obtained. Preferably, however, the amplification step is not conducted until after the second transformation described below.
After the selection step, DNA portions of the genome, sufficiently large to include the entire amplifiable region, are isolated from the selected primary cells. Secondary mammalian expression host cells are then transformed with these genomic DNA portions and cloned, and clones are selected that contain the amplifiable region. The amplifiable region is then amplified by means of an amplifying agent, if not already amplified in the primary cells. Finally, the secondary expression host cells now comprising multiple copies of the amplifiable region containing CT-I are grown so as to express the gene and produce the protein.
A. Isolation of DNA Encoding CT-I The DNA encoding CT-I may be obtained from any cDNA library prepared from tissue believed to possess the CT-I mRNA and to express it at a detectable level. The mRNA is suitably prepared, for example, from seven-day differentiated embryoid bodies. The CT-I gene may also be obtained from a genomic library or by in vitro oligonucleotide synthesis as defined above assuming the complete nucleotide or amino acid sequence is known.
Libraries are screened with probes designed to identify the gene of interest or the protein encoded by it. For cDNA expression libraries, suitable probes include, monoclonal or polyclonal antibodies that recognize and specifically bind to the CT-I; oligonucleotides of about 20-80 bases in length that encode known or suspected portions of the CT-I cDNA from the same or different species; and/or complementary or homologous cDNAs or fragments thereof that encode the same or a similar gene. Appropriate probes for screening genomic DNA libraries include, but are not limited to, oligonucleotides, cDNAs, or fragments thereof S. that encode the same or a similar gene, and/or homologous genomic DNAs or fragments thereof. Screening the S. 20 cDNA or genomic library with the selected probe may be conducted using standard procedures as described in chapters 10-12 of Sambrook et al.. supra.
.I *An alternative means to isolate the gene encoding CT-I is to use PCR methodology as described in section 14 of Sambrook et al., supra. This method requires the use of oligonucleotide probes that will hybridize to the CT-1. Strategies for selection of oligonucleotides are described below.
A preferred method of practicing this invention is to use carefully selected oligonucleotide sequences to screen cDNA libraries from various tissues, preferably mammalian differentiated embryoid bodies and placental, cardiac, and brain cell lines. More preferably, human embryoid, placental, cardiac, and brain cDNA libraries are screened with the oligonucleotide probes.
The oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized. The actual nucleotide sequence(s) is usually based on conserved or highly homologous nucleotide sequences. The oligonucleotides may be degenerate at one or more positions.
The use of degenerate oligonucleotides may be of particular importance where a library is screened from a species in which preferential codon usage is not known.
The oligonucleotide must be labeled such that it can be detected upon hybridization to DNA in the library being screened. The preferred method of labeling is to use 3 2 P-labeled ATP with polynucleotide kinase, as is well known in the art, to radiolabel the oligonucleotide. However, other methods may be used to label the oligonucleotide, including, but not limited to, biotinylation or enzyme labeling.
Of particular interest is the CT-I nucleic acid that encodes a full-length polypeptide. In some preferred embodiments, the nucleic acid sequence includes the native CT-1 signal sequence. Nucleic acid having all the -21protein coding sequence is obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequence disclosed herein for the first time, and, if necessary, using conventional primer extension procedures as described in section 7.79 of Sambrook et al., supra, to detect precursors and processing intermediates ofmRNA that may not have been reverse-transcribed into cDNA.
B. Amino Acid Seauence Variants of Native CT-1 Amino acid sequence variants of native CT-i are prepared by introducing appropriate nucleotide changes into the native CT-i DNA, or by in vitro synthesis of the desired CT-I polypeptide. Such variants include, for example, deletions from, or insertions or substitutions of, residues within the amino acid sequence shown for murine CT-I in Figure 1 and for human CT-I in Figure 5. Any combination of deletion, insertion, and substitution is made to arrive at the final construct, provided that the final construct possesses the desired characteristics. Excluded from the scope of this invention are CT-I variants or polypeptide sequences that are the rat homolog of CT-1. The amino acid changes also may alter post-translational processes of the native CT-I, such as changing the number or position of glycosylation sites.
For the design of amino acid sequence variants of native CT-I, the location of the mutation site and the nature of the mutation will depend on the CT-1 characteristic(s) to be modified. For example, candidate CT-1 antagonists or super agonists will be initially selected by locating sites that are identical or highly conserved among CT-1 and other ligands binding to members of the growth hormone (GH)/cytokine receptor family, especially CNTF and leukemia inhibitory factor (LIF). The sites for mutation can be modified individually or in series, by substituting first with conservative amino acid choices and then with more radical selections depending upon the results achieved, deleting the target residue, or inserting residues of the same or a different class adjacent to the located site, or combinations of options 1-3.
o* o A useful method for identification of certain residues or regions of the native CT-I polypeptide that are preferred locations for mutagenesis is called "alanine scanning mutagenesis," as described by Cunningham et 0 0 al., Science, 244:1081-1085 (1989). Here, a residue or group of target residues are identified charged 25 residues such as arg, asp, his, lys, and glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine) to affect the interaction of the amino acids with the surrounding aqueous environment in or outside the cell. Those domains demonstrating functional sensitivity to the substitutions then S* o are refined by introducing further or other variants at or for the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined. For example, to optimize the performance of a mutation at a given site, alanine scanning or random mutagenesis is conducted at the target codon or region and the CT-I variants produced are screened for the optimal combination of desired activity.
There are two principal variables in the construction of amino acid sequence variants: the location of the mutation site and the nature of the mutation. These are variants from the Fig. 1 or Fig. 5 sequence, and may represent naturally occurring alleles (which will not require manipulation of the native CT-I DNA) or predetermined mutant forms made by mutating the DNA, either to arrive at an allele or a variant not found in nature. In general, the location and nature of the mutation chosen will depend upon the CT-I characteristic to be modified.
-22- Amino acid sequence deletions generally range from about 1 to 30 residues, more preferably about 1 to 10 residues, and typically are contiguous. Contiguous deletions ordinarily are made in even numbers of residues, but single or odd numbers of deletions are within the scope hereof. Deletions may be introduced into regions of low homology among CT-1 and other ligands binding to the GH/cytokine receptor family which share the most sequence identity to the human CT-I amino acid sequence to modify the activity of CT-1. Deletions from CT-I in areas of substantial homology with one of the receptor binding sites of other ligands that bind to the GH/cytokine receptor family will be more likely to modify the biological activity of CT-1 more significantly.
The number of consecutive deletions will be selected so as to preserve the tertiary structure of CT-I in the affected domain, beta-pleated sheet or alpha helix.
Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Intrasequence insertions insertions within the mature CT-1 sequence) may range generally from about 1 to 10 residues, more preferably 1 to 5, most preferably 1 to 3. Insertions are preferably made in even numbers of residues, but this is not required. Examples of terminal insertions include mature CT-1 with an N-terminal methionyl residue, an artifact of the direct production of mature CT-1 in Srecombinant cell culture, and fusion of a heterologous N-terminal signal sequence to the N-terminus of the mature CT-1 molecule to facilitate the secretion of mature CT-1 from recombinant hosts. Such signal sequences generally will be obtained from, and thus homologous to, the intended host cell species. Suitable sequences include STII or Ipp for E. coli, alpha factor for yeast, and viral signals such as herpes gD for mammalian cells.
Other insertional variants of the native CT-1 molecule include the fusion to the N- or C-terminus of native CT-1 of immunogenic polypeptides, bacterial polypeptides such as beta-lactamase or an enzyme encoded by the S"E. coli trp locus, or yeast protein, and C-terminal fusions with proteins having a long half-life such as immunoglobulin constant regions (or other immunoglobulin regions), albumin, or ferritin, as described in WO 89/02922 published 6 April 1989.
A third group of variants are amino acid substitution variants. These variants have at least one amino acid residue in the native CT-1 molecule removed and a different residue inserted in its place. The sites of S. greatest interest for substitutional mutagenesis include sites identified as the active site(s) of native CT-1 and sites where the amino acids found in the known analogues are substantially different in terms of side-chain bulk, charge, or hydrophobicity, but where there is also a high degree of sequence identity at the selected site within various animal CT-1 species, or where the amino acids found in known ligands that bind to members of the GH/cytokine receptor family and novel CT-1 are substantially different in terms of side-chain bulk, charge, or hydrophobicity, but where there also is a high degree of sequence identity at the selected site within various animal analogues of such ligands among all the animal CNTF molecules). This analysis will highlight residues that may be involved in the differentiation of activity of the cardiac hypertrophic, anti-arrhythmic, inotropic, and neurotrophic factors, and therefore, variations at these sites may affect such activities.
Other sites of interest are those in which particular residues of the CT-I obtained from various species are identical among all animal species of CT-1 and other ligands binding to GH/cytokine receptor family molecules, this degree of conformation suggesting importance in achieving biological activity common to these enzymes. These sites, especially those falling within a sequence of at least three other identically conserved sites, -23are substituted in a relatively conservative manner. Such conservative substitutions are shown in Table 1 under the heading of preferred substitutions. If such substitutions result in a change in biological activity, then more substantial changes, denominated exemplary substitutions in Table 1, or as further described below in reference to amino acid classes, are introduced and the products screened.
Table 1 Original Residue Exemplary Substitutions Preferred Substitutions Ala (A) Arg (R) Asn (N) Asp (D) Cys (C) Gin (Q) Glu (E) Gly (G) His (H) Ile (I)
S
0 56 6f a S* S .a S 4@ val; leu; ile lys; gin; asn gin; his; lys; arg glu ser asn asp pro asn; gin; lys; arg leu; val; met; ala; phe; norleucine norleucine; ile; val; met; ala; phe arg; gin; asn leu; phe; ile leu; val; ile; ala gly thr ser tyr Leu (L) Lys (K) Met (M) Phe (F) Pro (P) 25 Ser (S) Thr (T) Trp (W) 0S 05 .er
S
S. 5* @5 S
SO
S.
Tyr trp; phe; thr; ser phe Val ile; leu; met; phe; 30 ala; norleucine leu Substantial modifications in function or immunological identity of the native CT-I are accomplished by selecting substitutions that differ significantly in their effect on maintaining the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, the charge or hydrophobicity of the molecule at the target site, or the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain properties: hydrophobic: norleucine, met, ala, val, leu, ile; neutral hydrophilic: cys, ser, thr, acidic: asp, glu; basic: asn, gin, his, lys, arg; residues that influence chain orientation: gly, pro; and -24aromatic: trp, tyr, phe.
Non-conservative substitutions will entail exchanging a member of one of these classes for another.
Such substituted residues also may be introduced into the conservative substitution sites or, more preferably, into the remaining (non-conserved) sites.
In one embodiment of the invention, it is desirable to inactivate one or more protease cleavage sites that are present in the molecule. These sites are identified by inspection of the encoded amino acid sequence, in the case of trypsin, for an arginyl or lysinyl residue. When protease cleavage sites are identified, they are rendered inactive to proteolytic cleavage by substituting the targeted residue with another residue, preferably a basic residue such as glutamine or a hydrophobic residue such as serine; by deleting the residue; or by inserting a prolyl residue immediately after the residue.
In another embodiment, any methionyl residues other than the starting methionyl residue of the signal sequence, or any residue located within about three residues N- or C-terminal to each such methionyl residue, is substituted by another residue (preferably in accord with Table 1) or deleted. Alternatively, about 1-3 residues are inserted adjacent to such sites.
Any cysteine residues not involved in maintaining the proper conformation of native CT-1 also may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking.
Nucleic acid molecules encoding amino acid sequence variants of native CT-1 are prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in 0. 20 the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or sitedirected) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of native CT-I.
Oligonucleotide-mediated mutagenesis is a preferred method for preparing substitution, deletion, and insertion variants of native CT-1 DNA. This technique is well known in the art as described by Adelman et al., 25 DNA, 2:183 (1983). Briefly, native CT-I DNA is altered by hybridizing an oligonucleotide encoding the desired mutation to a DNA template, where the template is the single-stranded form of a plasmid or bacteriophage containing the unaltered or native DNA sequence of CT-1. After hybridization, a DNA polymerase is used to synthesize an entire second complementary strand of the template that will thus incorporate the oligonucleotide primer, and will code for the selected alteration in the native CT-I DNA.
Generally, oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonucleotide will have 12 to 15 nucleotides that are completely complementary to the template on either side of the nucleotide(s) coding for the mutation. This ensures that the oligonucleotide will hybridize properly to the single-stranded DNA template molecule. The oligonucleotides are readily synthesized using techniques known in the art such as that described by Crea et al., Proc. Natl. Acad. Sci. USA, 75:5765 (1978).
The DNA template can be generated by those vectors that are either derived from bacteriophage M 13 vectors (the commercially available Ml3mpl8 and Ml3mpl9 vectors are suitable), or those vectors that contain a single-stranded phage origin of replication as described by Viera et al., Meth. Enzymol., 153:3 (1987). Thus, the DNA that is to be mutated may be inserted into one of these vectors to generate single-stranded template.
Production of the single-stranded template is described in Sections 4.21-4.41 of Sambrook et al., supra.
Alternatively, single-stranded DNA template may be generated by denaturing double-stranded plasmid (or other) DNA using standard techniques.
For alteration of the native DNA sequence (to generate amino acid sequence variants, for example), the oligonucleotide is hybridized to the single-stranded template under suitable hybridization conditions. A DNA polymerizing enzyme, usually the Klenow fragment of DNA polymerase I, is then added to synthesize the complementary strand of the template using the oligonucleotide as a primer for synthesis. A heteroduplex molecule is thus formed such that one strand of DNA encodes the mutated form of native CT-1, and the other strand (the original template) encodes the native, unaltered sequence of CT-1. This heteroduplex molecule is then transformed into a suitable host cell, usually a prokaryote such as E. coli JM101. After the cells are grown, they are plated onto agarose plates and screened using the oligonucleotide primer radiolabeled with 32P to identify the bacterial colonies that contain the mutated DNA. The mutated region is then reknbved and placed in an appropriate vector for protein production, generally an expression vector of the type typically employed for transformation of an appropriate host.
The method described immediately above may be modified such that a homoduplex molecule is created wherein both strands of the plasmid contain the mutation(s). The modifications are as follows: The single-stranded oligonucleotide is annealed to the single-stranded template as described above. A mixture of three deoxyribonucleotides, deoxyriboadenosine (dATP), deoxyriboguanosine (dGTP), and deokyribothymidine (dTTP), is combined with a modified thio-deoxyribocytosine called dCTP-(aS) (which can be obtained from the Amersham Corporation). This mixture is added to the template-oligonucleotide complex. Upon addition of 20 DNA polymerase to this mixture, a strand of DNA identical to the template except for the mutated bases is generated. In addition, this new strand of DNA will contain dCTP-(aS) instead ofdCTP, which serves to protect it from restriction endonuclease digestion.
After the template strand of the double-stranded heteroduplex is nicked with an appropriate restriction enzyme, the template strand can be digested with ErollI nuclease or another appropriate nuclease past the region that contains the site(s) to be mutagenized. The reaction is then stopped to leave a molecule that is only partially single-stranded. A complete double-stranded DNA homoduplex is then formed using DNA polymerase in the presence of all four deoxyribonucleotide triphosphates, ATP, and DNA ligase. This homoduplex molecule can then be transformed into a suitable host cell such as E. coli JMI01, as described above.
DNA encoding mutants of native CT-I with more than one amino acid to be substituted may be 30 generated in one of several ways. If the amino acids are located close together in the polypeptide chain, they may be mutated simultaneously using one oligonucleotide that codes for all of the desired amino acid substitutions.
If, however, the amino acids are located some distance from each other (separated by more than about ten amino acids), it is more difficult to generate a single oligonucleotide that encodes all of the desired changes. Instead, one of two alternative methods may be employed.
In the first method, a separate oligonucleotide is generated for each amino acid to be substituted. The oligonucleotides are then annealed to the single-stranded template DNA simultaneously, and the second strand of DNA that is synthesized from the template will encode all of the desired amino acid substitutions.
The alternative method involves two or more rounds ofmutagenesis to produce the desired mutant. The first round is as described for the single mutants: wild-type DNA is used for the template, an oligonucleotide -26encoding the first desired amino acid substitution(s) is annealed to this template, and the heteroduplex DNA molecule is then generated. The second round ofmutagenesis utilizes the mutated DNA produced in the first round of mutagenesis as the template. Thus, this template already contains one or more mutations. The oligonucleotide encoding the additional desired amino acid substitution(s) is then annealed to this template, and the resulting strand of DNA now encodes mutations from both the first and second rounds of mutagenesis. This resultant DNA can be used as a template in a third round of mutagenesis, and so on.
PCR mutagenesis is also suitable for making amino acid variants of native CT-1. While the following discussion refers to DNA, it is understood that the technique also finds application with RNA. The PCR technique generally refers to the following procedure (see Erlich, supra, the chapter by R. Higuchi, p. 61-70): When small amounts of template DNA are used as starting material in a PCR, primers that differ slightly in sequence from the corresponding region in a template DNA can be used to generate relatively large quantities of a specific DNA fragment that differs from the template sequence only at the positions where the primers differ from the template. For introduction of a mutation into a plasmid DNA, one of the primers is designed to overlap the position of the mutation and to contain the mutation; the sequence of the other primer must be identical to a stretch of sequence of the opposite strand of the plasmid, but this sequence can be located anywhere along the plasmid DNA. It is preferred, however, that the sequence of the second primer is located within 200 nucleotides from that of the first, such that in the end the entire amplified region of DNA bounded by the primers can be easily sequenced. PCR amplification using a primer pair like the one just described results in a population of DNA fragments that differ at the position of the mutation specified by the primer, and possibly at other positions, o 20 as template copying is somewhat error-prone.
If the ratio of template to product material is extremely low, the vast majority of product DNA fragments incorporate the desired mutation(s). This product material is used to replace the corresponding region in the plasmid that served as PCR template using standard DNA technology. Mutations at separate positions can be introduced simultaneously by either using a mutant second primer, or performing a second PCR with different 25 mutant primers and ligating the two resulting PCR fragments simultaneously to the vector fragment in a three (or more)-part ligation.
In a specific example of PCR mutagenesis, template plasmid DNA (1 pg) is linearized by digestion with a restriction endonuclease that has a unique recognition site in the plasmid DNA outside of the region to be amplified. Of this material, 100 ng is added to a PCR mixture containing PCR buffer, which contains the four deoxynucleotide triphosphates and is included in the GeneAmp® kits (obtained from Perkin-Elmer Cetus, Norwalk, CT and Emeryville, CA), and 25 pmole of each oligonucleotide primer, to a final volume of 50 pL.
The reaction mixture is overlayed with 35 pL mineral oil. The reaction mixture is denatured for five minutes at 100*C, placed briefly on ice, and then 1 pL Thermus aquaticus (Taq) DNA polymerase (5 units/pL, purchased from Perkin-Elmer Cetus) is added below the mineral oil layer. The reaction mixture is then inserted into a DNA Thermal Cycler (purchased from Perkin-Elmer Cetus) programmed as follows: 2 min. sec. 72* C, then 19 cycles of the following: sec. 94 C sec. 55C, and -27sec. 72*C.
At the end of the program, the reaction vial is removed from the thermal cycler and the aqueous phase transferred to a new vial, extracted with phenol/chloroform (50:50 vol), and ethanol precipitated, and the DNA is recovered by standard procedures. This material is subsequently subjected to the appropriate treatments for insertion into a vector.
Another method for preparing variants, cassette mutagenesis, is based on the technique described by Wells et al., Gene, 34:315 (1985). The starting material is the plasmid (or other vector) comprising the native CT-1 DNA to be mutated. The codon(s) in the native CT-1 DNA to be mutated are identified. There must be a unique restriction endonuclease site on each side of the identified mutation site(s). If no such restriction sites exist, they may be generated using the above-described oligonucleotide-mediated mutagenesis method to introduce them at appropriate locations in the native CT-I DNA. After the restriction sites have been introduced into the plasmid, the plasmid is cut at these sites to linearize it. A double-stranded oligonucleotide encoding the sequence of the DNA between the restriction sites but containing the desired mutation(s) is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques. This double-stranded oligonucleotide is referred to as the cassette. This cassette is designed to have 3' and 5' ends that are compatible with the ends of the linearized plasmid, such that it can be directly ligated to the plasmid. This plasmid now contains the CT-1 DNA sequence mutated from native CT-1.
C. Insertion of Nucleic Acid into Replicable Vector The nucleic acid cDNA or genomic DNA) encoding CT-1 is inserted into a replicable vector for 20 further cloning (amplification of the DNA) or for expression. Many vectors are available, and selection of the appropriate vector will depend on 1) whether it is to be used for DNA amplification or for DNA expression, 2) the size of the nucleic acid to be inserted into the vector, and 3) the host cell to be transformed with the vector.
Each vector contains various components depending on its function (amplification of DNA or expression of DNA) and the host cell with which it is compatible. The vector components generally include, but are not limited 25 to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence.
Signal Seauence Component The CT-is of this invention may be produced not only directly, but also as a fusion with a heterologous polypeptide, preferably a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of the CT-1 DNA that is inserted into the vector. The heterologous signal sequence selected should be one that is recognized and processed cleaved by a signal peptidase) by the host cell. For prokaryotic host cells that do not recognize and process the native CT-I signal sequence, the signal sequence is substituted by a prokaryotic signal sequence selected, for example, from the group consisting of the alkaline phosphatase, penicillinase, Ipp, or heat-stable enterotoxin II leaders. For yeast secretion the native signal sequence may be substituted by, the yeast invertase leader, yeast alpha factor leader (including Saccharomyces and Kluyveromyces a-factor leaders, the latter described in U.S. Patent No. 5,010,182 issued 23 April 1991), yeast acid phosphatase leader, mouse salivary amylase leader, carboxypeptidase leader, yeast BAR1 leader, Humicola lanuginosa lipase leader, the C. albicans glucoamylase leader (EP 362,179 published 4 April 1990), or the signal -28described in WO 90/13646 published 15 November 1990. In mammalian cell expression the native human signal sequence the CT-1 presequence that normally directs secretion of native CT-1 from human cells in vivo) is satisfactory, although other mammalian signal sequences may be suitable, such as signal sequences from other animal CT-ls, signal sequences from a ligand binding to another GH/cytokine receptor family member, and signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders, for example, the herpes simplex gD signal.
The DNA for such precursor region is ligated in reading frame to DNA encoding the mature CT-I.
(ii) Origin of Replication Component Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Generally, in cloning vectors this sequence is one thai enables the vector to replicate independently of the host chromosomal DNA, and includes origins of replication.or autonomously replicating sequences. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2p plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV, or BPV) are useful for cloning vectors in mammalian cells. Generally, the origin of replication component is not needed for mammalian expression vectors (the SV40 origin may typically be used only because it contains the early promoter).
Most expression vectors are "shuttle" vectors, they are capable of replication in at least one class S of organisms but can be transfected into another organism for expression. For example, a vector is cloned in E.
coli and then the same vector is transfected into yeast or mammalian cells for expression even though it is not S 20 capable of replicating independently of the host cell chromosome.
DNA may also be amplified by insertion into the host genome. This is readily accomplished using Bacillus species as hosts, for example, by including in the vector a DNA sequence that is complementary to a sequence found in Bacillus genomic DNA. Transfection of Bacillus with this vector results in homologous recombination with the genome and insertion of CT-1 DNA. However, the recovery ofgenomic DNA encoding CT-1 is more complex than that of an exogenously replicated vector because restriction enzyme digestion is required to excise the CT-I DNA.
(iii) Selection Gene Component 0 Expression and cloning vectors should contain a selection gene, also termed a selectable marker. This gene encodes a protein necessary for the survival or growth of transformed host cells grown in a selective culture 30 medium. Host cells not transformed with the vector containing the selection gene will not survive in the culture medium. Typical selection genes encode proteins that confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, complement auxotrophic deficiencies, or supply critical nutrients not available from complex media, the gene encoding D-alanine racemase for Bacilli.
One example of a selection scheme utilizes a drug to arrest growth of a host cell. Those cells that are successfully transformed with a heterologous gene produce a protein conferring drug resistance and thus survive the selection regimen. Examples of such dominant selection use the drugs neomycin (Southern et al., J. Molec.
Appl. Genet., 1:327 (1982)), mycophenolic acid (Mulligan et al., Science, 209:1422 (1980)), or hygromycin (Sugden et al., Mol. Cell. Biol., 5:410-413 (1985)). The three examples given above employ bacterial genes -29under eukaryotic control to convey resistance to the appropriate drug G418 or neomycin (geneticin), xgpt (mycophenolic acid), or hygromycin, respectively.
Another example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the CT-I nucleic acid, such as DHFR or thymidine kinase. The mammalian cell transformants are placed under selectio Tpressure that only the transformants are uniquely adapted to survive by virtue of having taken up the marker. Selection pressure is imposed by culturing the transformants under conditions in which the concentration of selection agent in the medium is successively changed, thereby leading to amplification of both the selection gene and the DNA that encodes CT-I.
Amplification is the process by which genes in greater demand for the production of a protein critical for growth are reiterated in tandem within the chromosomes of successive generations of recombinant cells. Increased quantities of CT-1 are synthesized from the amplified DNA. Other examples of amplifiable genes include metallothionein-I and -II, preferably primate metallothionein genes, adenosine deaminase, omithine decarboxylase, etc.
For example, cells transformed with the DHFR selection gene are first identified by culturing all of the transformants in a culture medium that contains methotrexate (Mtx), a competitive antagonist of DHFR. An appropriate host cell when wild-type DHFR is employed is the Chinese hamster ovary (CHO) cell line deficient o* in DHFR activity, prepared and propagated as described by Urlaub et al., Proc. Natl. Acad. Scl USA, 77:4216 (1980). The transformed cells are then exposed to increased levels of methotrexate. This leads to the synthesis of multiple copies of the DHFR gene, and, concomitantly, multiple copies of other DNA comprising the expression vectors, such as the DNA encoding CT-1. This amplification technique can be used with any otherwise suitable host, ATCC No. CCL61 CHO-Kl, notwithstanding the presence of endogenous DHFR if, for example, a mutant DHFR gene that is highly resistant to Mtx is employed (EP 117,060).
SAlternatively, host cells (particularly wild-type hosts that contain endogenous DHFR) transformed or co-transformed with DNA sequences encoding CT-1, wild-type DHFR protein, and another selectable marker such as aminoglycoside 3-phosphotransferase (APH) can be selected by cell growth in medium containing a selection agent for the selectable marker such as an aminoglycosidic antibiotic, kanamycin, neomycin, or G418. See U.S. Patent No. 4,965,199.
S. A suitable selection gene for use in yeast is the trpl gene present in the yeast plasmid YRp7 (Stinchcomb et al., Nature, 282:39 (1979); Kingsman et al., Gene, 7:141 (1979); or Tschemper et al., Gene, 10:157 (1980)). The trpl gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 (Jones, Genetics, 85:12 (1977)). The presence of the t1i lesion in the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan. Similarly, Leu2-deficient yeast strains (ATCC 20,622 or 38,626) are complemented by known plasmids bearing the Leu2 gene.
In addition, vectors derived from the 1.6 pm circular plasmid pKDI can be used for transformation of Kluyveromyces yeasts. Bianchi et al., Curr. Genet. 12: 185 (1987). More recently, an expression system for large-scale production of recombinant calf chymosin was reported for K lactis. Van den Berg, Bio/Technology, 8: 135 (1990). Stable multi-copy expression vectors for se&etion of mature recombinant human serum albumin by industrial strains of Kluyveromyces have also been disclosed. Fleer et al., Bio/Technology. 2: 968-975 (1991).
(iv) Promoter Component Expression and cloning vectors usually contain a promoter that is recognized by the host organism and is operably linked to the CT-1 nucleic acid. Promoters are untranslated sequences located upstream to the start codon of a structural gene (generally within about 100 to 1000 bp) that control the transcription and translation of particular nucleic acid sequence, such as the CT-I nucleic acid sequence, to which they are operably linked. Such promoters typically fall into two classes, inducible and constitutive. Inducible promoters are promoters that initiate increased levels of transcription from DNA under their control in response to some change in culture conditions, the presence or absence of a nutrient or a change in temperature. At this time a large number of promoters recognized by a variety of potential host cells are well known.'These promoters are operably linked to CT-I-encoding DNA by removing the promoter from the source DNA by restriction enzyme digestion and inserting the isolated promoter sequence into the vector. Both the native CT-1 promoter sequence and many heterologous promoters may be used to direct amplification and/or expression of the CT-1 DNA. However, heterologous promoters are preferred, as they generally permit greater transcription and higher yields ofrecombinantly produced CT-1 as compared to the native CT-1 promoter.
C
Promoters suitable for use with prokaryotic hosts include the p-lactamase and lactose promoter systems (Chang et al., Nature, 25: 615 (1978); and Goeddel etal., Nature, 281: 544 (1979)), alkaline phosphatase, a tryptophan (trp) promoter system (Goeddel, Nucleic Acids Res., 8: 4057 (1980) and EP 36,776), and hybrid 20 promoters such as the tac promoter (deBoer et al., Proc. Natl. Acad. Sci. USA, 8: 21-25 (1983)). However, other known bacterial promoters are suitable. Their nucleotide sequences have been published, thereby enabling a skilled worker operably to ligate them to DNA encoding CT-1 (Siebenlist et al., Cell, 20: 269 (1980)) using Slinkers or adaptors to supply any required restriction sites. Promoters for use in bacterial systems also will contain a Shine-Dalgamo sequence operably linked to the DNA encoding CT-1.
25 Promoter sequences are known for eukaryotes. Virtually all eukaryotic genes have an AT-rich region located approximately 25 to 30 bases upstream from the site where transcription is initiated. Another sequence found 70 to 80 bases upstream from the start of transcription of many genes is a CXCAAT region where X may be any nucleotide. At the 3' end of most eukaryotic genes is an AATAAA sequence that may be the signal for addition of the poly A tail to the 3' end of the coding sequence. All of these sequences are suitably inserted into eukaryotic expression vectors.
Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3phosphoglycerate kinase (Hitzeman et al., J. Biol. Chem.. 25: 2073 (1980)) or other glycolytic enzymes (Hess et al., J. Adv. Enzyme Re.. 1: 149 (1968); and Holland, Biochemistry. 1: 4900 (1978)), such as enolase, .glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose- 6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.
Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phos- -31phate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in Hitzeman et al., EP 73,657. Yeast enhancers also are advantageously used with yeast promoters.
CT-1 transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and most preferably Simian Virus 40 (SV40), from heterologous mammalian promoters, the actin promoter or an immunoglobulin promoter, from heat-shock promoters, and from the promoter normally associated with the CT-I sequence, provided such promoters are compatible with the host cell systems.
The early and late promoters of the SV40 virus are conveniently obtained as an SV40 restriction fragment that also contains the SV40 viral origin of replication. Fiers et al., Nature, 273:113 (1978); Mulligan and Berg, Science, 209: 1422-1427 (1980); Pavlakisetal., Proc. Natl. Acad. Sci. USA, 78: 7398-7402 (1981).
The immediate early promoter of the human cytomegalovirus is conveniently obtained as a HindIII E restriction fragment. Greenaway et al., Gene, 8: 355-360 (1982). A system for expressing DNA in mammalian hosts using i the bovine papilloma virus as a vector is disclosed in U.S. Patent No. 4,419,446. A modification of this system is described in U.S. Patent No. 4,601,978. See also Gray et al., Nature 295: 503-508 (1982) on expressing cDNA encoding immune interferon in monkey cells; Reyes et al., Nature, 222: 598-601 (1982) on expression of human p-interferon cDNA in mouse cells under the control of a thymidine kinase promoter from herpes 20 simplex virus; Canaani and Berg, Proc. Natl. Acad. Sci. USA, 72: 5166-5170 (1982) on expression of the human interferon 0 1 gene in cultured mouse and rabbit cells; and Gorman et al., Proc. Natl. Acad. Sci. USA, 22: 6777- 6781 (1982) on expression of bacterial CAT sequences in CV-1 monkey kidney cells, chicken embryo fibroblasts, Chinese hamster ovary cells, HeLa cells, and mouse NIH-3T3 cells using the Rous sarcoma virus long terminal repeat as a promoter.
25 Enhancer Element Component Transcription of a DNA encoding the CT-I of this invention by higher eukaryotes is often increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Enhancers are relatively orientation and position independent, having been found 5' (Laimins et al., Proc. Natl. Acad. Sci. USA. 28: 993 (1981)) and 3' (Lusky et al., Mol. Cell Bio.. 1108 (1983)) to the transcription unit, within an intron (Banerji et al., Cell, 32: 729 (1983)), as well as within the coding sequence itself (Osbore et al., Mol. Cell Bio., 4: 1293 (1984)). Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, a-fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. See also Yaniv, Nature 292:17-18 (1982) on enhancing elements for activation of eukaryotic promoters. The enhancer may be spliced into the vector at a position 5' or 3' to the CT-I-encoding sequence, but is preferably located at a site from the promoter.
-32- (vi) Transcription Termination Component Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding CT-1.
(vii) Construction and Analysis of Vectors Construction of suitable vectors containing one or more of the above listed components employs standard ligation techniques. Isolated plasmids or DNA fragments are cleaved, tailored, and religated in the form desired to generate the plasmids required.
For analysis to confirm correct sequences in plasmids constructed, the ligation mixtures are used to transform E. coli K12 strain 294 (ATCC 31,446) and successful transformants selected by ampicillin or tetracycline resistance where appropriate. Plasmids from the transformants are prepared, analyzed by restriction endonuclease digestion, and/or sequenced by the method of Messing et al., Nucleic Acids Res., 2: 309 (1981) or by the method of Maxam et al., Methods in Enzvmolovg, 6: 499 (1980).
(viii) Transient Expression Vectors SParticularly useful in the practice of this invention are expression vectors that provide for the transient expression in mammalian cells of DNA encoding CT-1. In general, transient expression involves the use of an expression vector that is able to replicate efficiently in a host cell, such that the host cell accumulates many copies of the expression vector and, in turn, synthesizes high levels of a desired polypeptide encoded by the expression vector. Sambrook et al., supra, pp. 16.17 16.22. Transient expression systems, comprising a suitable expression vector and a host cell, allow for the convenient positive identification of polypeptides encoded by cloned DNAs, as well as for the rapid screening of such polypeptides for desired biological or physiological properties. Thus, transient expression systems are particularly useful in the invention for purposes 25 of identifying analogs and variants of native CT-I that are biologically active CT-1.
(ix) Suitable Exemplary Vertebrate Cell Vectors Other methods, vectors, and host cells suitable for adaptation to the synthesis of CT-1 in recombinant vertebrate cell culture are described in Gething et al., Nature, 293: 620-625 (1981); Mantei et al., Nature, 281: 40-46 (1979); EP 117,060; and EP 117,058. A particularly useful plasmid for mammalian cell culture production of CT-I is pRK5 (EP 307,247) or pSVI6B (WO 91/08291 published 13 June 1991). The derivative pRKSB (Holmes et al., Science 252: 1278-1280 (1991)) is particularly suitable herein for such expression.
D. Selection and Transformation of Host Cells Suitable host cells for cloning or expressing the vectors herein are the prokaryote, yeast, or higher eukaryote cells described above. Suitable prokaryotes for this purpose include eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as Escherichia, E. coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, Salmonella typhimurium, Serratia, Serratia marcescans, and Shigella, as well as Bacilli such as B. subtilis and B. licheniformis B. licheniformis 41P disclosed in DD 266,710 published 12 April 1989), Pseudomonas such as P. aeruginosa, and Streptomyces. One preferred -33- E. coli cloning host is E. coli 294 (ATCC 31,446), although other strains such as E. coli B, E. coli X1776 (ATCC 31,537), E. coli DH5a, and E. coli W3110 (ATCC 27,325) are suitable. These examples are illustrative rather than limiting. Strain W3110 is one particularly preferred host or parent host because it is a common host strain for recombinant DNA product fermentations. Preferably, the host cell secretes minimal amounts of proteolytic enzymes. For example, strain W3110 may be modified to effect a genetic mutation in the genes encoding proteins endogenous to the host, with examples of such hosts including E. coli W3110 strain 1A2, which has the complete genotype tonA A; E. coli W3110 strain 9E4, which has the complete genotype tonA A ptr3;.E. coli W3110 strain 27C7 (ATCC 55,244), which has the complete genotype tonA ptr3 phoA AE1S A(argF-lac)169 AdegP AompT kanr; E. coli W3110 strain 37D6, which has the complete genotype tonA ptr3 A(argF-lac)169 AdegP AompT Arbs7 ilvG kan'; E. coli W3110 strain 40B4, which is strain 37D6 with a nonkanamycin resistant degP deletion mutation; and an E. coli strain having mutant periplasmic protease disclosed in U.S. Patent No. 4,946,783 issued 7 August 1990. Alternatively, in vitro methods of cloning, PCR or other nucleic acid polymerase reactions, are suitable.
In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for CT-1-encoding vectors. Saccharomyces cerevisiae, or common baker's yeast, is the most commonly used among lower eukaryotic host microorganisms. However, a number of other genera, species, and strains are commonly available and useful herein, such as Schizosaccharomyces pombe (Beach and Nurse, Nature, 290: 140 (1981); EP 139,383 published 2 May 1985); Kluyveromyces hosts Patent No. 4,943,529; Fleer et al., supra) such as, K lactis (MW98-8C, CBS683, CBS4574; Louvencourt et al., J. Bacteriol., 737 20 (1983)), K. fragilis (ATCC 12,424), K. bulgaricus (ATCC 16,045), K. wickeramii (ATCC 24,178), K. waltii (ATCC 56,500), K drosophilarum (ATCC 36,906; Van den Berg et al., supra), K. thermotolerans, and K.
marxianus; yarrowia (EP 402,226); Pichia pastoris (EP 183,070; Sreekrishna et al., J. Basic Microbiol., 28: 265-278 (1988)); Candida; Trichoderma reesia (EP 244,234); Neurospora crassa (Case et al., Proc. Natl. Acad.
Sci. USA, 76: 5259-5263 (1979)); Schwanniomyces such as Schwanniomyces occidentalis (EP 394,538 25 published 31 October 1990); and filamentous fungi such as, Neurospora, Penicillium, Tolypocladium (WO 91/00357 published 10 January 1991), and Aspergillus hosts such as A. nidulans (Ballance et al., Biochem.
Biophvs. Res. Commun., 112: 284-289 (1983); Tilburn et al., Gene, 2: 205-221 (1983); Yelton et al., Proc.
Natl. Acad. Sci. USA. S1: 1470-1474 (1984)) and A. niger (Kelly and Hynes, MBO 4: 475-479 (1985)).
Suitable host cells for the production of CT-I are derived from multicellular organisms. Such host cells are capable of complex processing and glycosylation activities. In principle, any higher eukaryotic cell culture is workable, whether from vertebrate or invertebrate culture. Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as Spodopterafrugiperda (caterpillar), Aedes aegypti (mosquito), Aedes albopictus (mosquito), Drosophila melanogaster (fruitfly), and Bombyx mori have been identified. See, Luckow et al., Bio/Technologv, 6: 47-55 (1988); Miller et al., in Genetic Engineering, Setlow, J.K. et al., eds., Vol. 8 (Plenum Publishing, 1986), pp. 277-279; and Maeda et al., Nature 31: 592-594 (1985). A variety of viral strains for transfection are publicly available, the L-1 variant ofAutographa californica NPV and the Bm-5 strain of Bombyx mori NPV, and such viruses may be used as the virus herein according to the present invention, particularly for transfection of Spodopterafrugiperda cells.
-34- Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco can be utilized as hosts.
Typically, plant cells are transfected by incubation with certain strains of the bacterium Agrobacterium tumefaciens, which has been previously manipulated to contain the CT-1 DNA. During incubation of the plant cell culture with A. tumefaciens, the DNA encoding the CT-1 is transferred to the plant cell host such that it is transfected, and will, under appropriate conditions, express the CT-1 DNA. In addition, regulatory and signal sequences compatible with plant cells are available, such as the nopaline synthase promoter and polyadenylation signal sequences. Depicker etal., J. Mol. Appl. Gen. 1: 561 (1982). In addition, DNA segments isolated from the upstream region of the T-DNA 780 gene are capable of activating or increasing transcription levels of plantexpressible genes in recombinant DNA-containing plant tissue. EP 321,196 published 21 June 1989.
However, interest has been greatest in vertebrate cells, and propagation of vertebrate cells in culture (tissue culture) has become a routine procedure in recent years (Tissue Culture, Academic'Press, Kruse and Patterson, editors (1973)). Examples of useful mammalian host cell lines are a monkey kidney CVl cell line transformed by SV40 (COS-7, ATCC CRL 1651); a human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Viro., 6: 59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 772:4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod.. 2: 243-251 (1980)); monkey kidney cells (CVL ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); 20 mouse mammary tumor cells (MMT 060562, ATCC CCL5 TRI cells (Mather et al., Annals N.Y. Acad. Sci., 383: 44-68 (1982)); MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2).
Host cells are transfected and preferably transformed with the above-described expression or cloning vectors of this invention and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.
25 Transfection refers to the taking up of an expression vector by a host cell whether or not any coding sequences are in fact expressed. Numerous methods oftransfection are known to the ordinarily skilled artisan, for example, CaPO 4 and electroporation. Successful transfection is generally recognized when any indication of the operation of this vector occurs within the host cell.
Transformation means introducing DNA into an organism so that the DNA is replicable, either as an extrachromosomal element or by chromosomal integrant. Depending on the host cell used, transformation is done using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in section 1.82 of Sambrook et al., supra, or electroporation is generally used for prokaryotes or other cells that contain substantial cell-wall barriers. Infection with Agrobacterium tumefaciens is used for transformation of certain plant cells, as described by Shaw et al., Gene. 23: 315 (1983) and WO 89/05859 published 29 June 1989. In addition, plants may be transfected using ultrasound treatment as described in WO 91/00358 published 10 January 1991. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, YViro1gy, 52: 456-457 (1978) is preferred. General aspects of mammalian cell host system transformations have been described by Axel in U.S. Patent No. 4,399,216 issued 16 August 1983. Transformations into yeast are typically carried out according to the method of Van Solingen et al., J. Bact., 130: 946 (1977) and Hsiao et Proc. Natl. Acad. Sci. (USA), 6: 3829 (1979). However, other methods for introducing DNA into cells, such as by nuclear microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, polybrene, polyornithine, etc., may also be used. For various techniques for transforming mammalian cells, see Keown et al., Methods in Enzvmologv, 185: 527-537 (1990) and Mansour et al., Natur 326: 348-352 (1988).
E. Culturing the Host Cells Prokaryotic cells used to produce the CT-1 polypeptide of this invention are cultured in suitable media as described generally in Sambrook et al., supra.
The mammalian host cells used to produce the CT-1 of this invention may be cultured in a variety of media. Commercially available media such as Ham's F-10 (Sigma), F-12 (Sigma), Minimal Essential Medium Sigma), RPMI-1640 (Sigma), Dulbecco's Modified Eagle's Medium Sigma), and D- MEM/F-12 (Gibco BRL) are suitable for culturing the host cells. In addition, any of the media described, for example, in Ham and Wallace, Methods in Enzymology, 58: 44 (1979); Barnes and Sato, Anal. Biochem., 102: 255 (1980); U.S. Patent Nos. 4,767,704; 4,657,866; 4,927,762; 5,122,469; or 4,560,655; U.S. Patent Re. No.
30,985; WO 90/03430; or WO 87/00195 may be used as culture media for the host cells. Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, aprotinin, and/or epidermal growth factor salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleosides (such as adenosine and thymidine), antibiotics (such as GentamycinTM drug), trace elements (defmed as inorganic compounds usually present at final concentrations in 20 the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art. The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
In general, principles, protocols, and practical techniques for maximizing the productivity of in vitro 25 mammalian cell cultures can be found in Mammalian Cell Biotechnology: a Practical Approach, M. Butler, ed.
(IRL Press, 1991).
The host cells referred to in this disclosure encompass cells in in vitro culture as well as cells that are within a host animal.
S. F. Detecting Gene Amplification/Expression Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, northern blotting to quantitate the transcription of mRNA (Thomas, Proc. Natl.
Acad. Sci. USA 22: 5201-5205 (1980)), dot blotting (DNA analysis), or in situ hybridization, using an appropriately labeled probe, based on the sequences provided herein. Various labels may be employed, most commonly radioisotopes, particularly 3 2 P. However, other techniques may also be employed, such as using biotin-modified nucleotides for introduction into a polynucleotide. The biotin then serves as the site for binding to avidin or antibodies, which may be labeled with a wide variety of labels, such as radionuclides, fluorescers, enzymes, or the like. Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in -36turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.
Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. With immunohistochemical staining techniques, a cell sample is prepared, typically by dehydration and fixation, followed by reaction with labeled antibodies specific for the gene product coupled, where the labels are usually visually detectable, such as enzymatic labels, fluorescent, labels, luminescent labels, and the like. A particularly sensitive staining technique suitable for use in the present invention is described by Hsu et al., Am. J. Clin. Path. 75: 734-738 (1980).
Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native CT-I polypeptide or against a synthetic peptide based on the DNA sequences provided herein as described further in Section 4 below.
G. Purification of CT-1 Polvpeptide CT-I preferably is recovered from the culture medium as a secreted polypeptide, although it also may be recovered from host cell lysates when directly produced without a secretory signal. When CT-1 is produced in a recombinant cell other than one of human origin, the CT-I is completely free of proteins or polypeptides of human origin. However, it is necessary to purify CT-1 from cell proteins or polypeptides to obtain preparations that are substantially homogeneous as to CT-1. As a first step, the particulate debris, either 20 host cells or lysed fragments, is removed, for example, by centrifugation or ultrafiltration; optionally, the protein may be concentrated with a commercially available protein concentration filter, followed by separating the CT-1 from other impurities by one or more steps selected from immunoaffmity chromatography, ion-exchange column fractionation on DEAE or matrices containing carboxymethyl or sulfopropyl groups), chromatography on Blue-Sepharose, CM Blue-Sepharose, MONO-Q, MONO-S, lentil lectin-Sepharose, WGA-Sepharose, Con A- 25 Sepharose, Ether Toyopearl, Butyl Toyopearl, Phenyl Toyopearl, or protein A Sepharose, SDS-PAGE chromatography, silica chromatography, chromatofocusing, reverse phase HPLC silica gel with appended aliphatic groups), gel filtration using, Sephadex molecular sieve or size-exclusion chromatography, chromatography on columns that selectively bind the CT-I, and ethanol or ammonium sulfate precipitation. A protease inhibitor may be included in any of the foregoing steps to inhibit proteolysis. Examples of suitable protease inhibitors include phenylmethylsulfonyl fluoride (PMSF), leupeptin, pepstatin, aprotinin, 4-(2aminoethyl)-benzenesulfonyl fluoride hydrochloride-bestatin, chymostatin, and benzamidine.
A preferred purification scheme involves adjusting the culture medium conditioned by cells transfected with the relevant clone to 1.5 M NaCI and applying to a Butyl Toyopearl T M column. The column is washed with Tris[hydroxymethyl]aminomethane hydrochloride (TRIS-HCI), pH 7.5, containing NaCI, and the activity eluted with TRIS-HCI, pH 7.5, containing 10 mM ZwittergentTM 3-10 surfactant. The peak of activity is adjusted to 150 mM NaCI, pH 8.0, and applied to a MONO-Q Fast Flow column. This column is washed with TRIS-HCI, pH 8.0, containing NaCI and octyl glucoside. Activity is found in the flow-through fraction. The active material is then applied to a reverse phase C4 column in 0.1% TFA, 10% acetonitrile, and eluted with a gradient of 0.1% -37- TFA up to 80%. The activity fractionates at about 15-30 kDa on gel filtration columns. It is expected that a chaotrope such as guanidine-HCI is required for resolution and recovery.
CT-I variants in which residues have been deleted, inserted, or substituted are recovered in the same fashion as native CT-I, taking account of any substantial changes in properties occasioned by the variation. For example, preparation of a CT-1 fusion with another protein or polypeptide, a bacterial or viral antigen, facilitates purification; an immunoaffmity column containing antibody to the antigen can be used to adsorb the fusion polypeptide. Immunoaffinity columns such as a rabbit polyclonal anti-CT-1 column can be employed to absorb the CT-1 variant by binding it to at least one remaining immune epitope. A protease inhibitor such as those defined above also may be useful to inhibit proteolytic degradation during purification, and antibiotics may be included to prevent the growth of adventitious contaminants. One skilled in the art will appreciate that purification methods suitable for native CT-1 may require modification to account for changes in the character of CT-1 or its variants upon production in recombinant cell culture.
H. Covalent Modifications of CT-1 Polvpeptides Covalent modifications of CT-I polypeptides are included within the scope of this invention. Both native CT-1 and amino acid sequence variants of native CT-I may be covalently modified. One type of covalent modification included within the scope of this invention is the preparation of a variant CT-I fragment. Variant CT- 1 fragments having up to about 40 amino acid residues may be conveniently prepared by chemical synthesis or by enzymatic or chemical cleavage of the full-length or variant CT-1 polypeptide. Other types of covalent modifications of the CT-1 or fragments thereof are introduced into the molecule by reacting targeted amino acid 20 residues of the CT-I or fragments thereof with an organic derivatizing agent that is capable of reacting with 4 selected side chains or the N- or C-terminal residues.
Cysteinyl residues most commonly are reacted with ca-haloacetates (and corresponding amines), such as chloroacetic acid or chloroacetamide, to give carboxymethyl or carboxyamidomethyl derivatives. Cysteinyl residues also are derivatized by reaction with bromotrifluoroacetone, a-bromo- P-(5-imidozoyl)propionic acid, chloroacetyl phosphate, N-alkylmaleimides, 3-nitro-2-pyridyl disulfide, methyl 2-pyridyl disulfide, pchloromercuribenzoate, 2-chloromercuri-4-nitrophenol, or chloro-7-nitrobenzo-2-oxa-1,3-diazole.
Histidyl residues are derivatized by reaction with diethylpyrocarbonate at pH 5.5-7.0 because this agent S. is relatively specific for the histidyl side chain. Para-bromophenacyl bromide also is useful; the reaction is preferably performed in 0.1 M sodium cacodylate at pH Lysinyl and amino-terminal residues are reacted with succinic or other carboxylic acid anhydrides.
Derivatization with these agents has the effect of reversing the charge of the lysinyl residues. Other suitable reagents for derivatizing a-amino-containing residues include imidoesters such as methyl picolinimidate, pyridoxal phosphate, pyridoxal, chloroborohydride, trinitrobenzenesulfonic acid, O-methylisourea, 2,4pentanedione, and transaminase-catalyzed reaction with glyoxylate.
Arginyl residues are modified by reaction with one or several conventional reagents, among them phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin. Derivatization of arginine residues requires that the reaction be performed in alkaline conditions because of the high pKa of the guanidine functional group. Furthermore, these reagents may react with the groups oflysine as well as the arginine epsilon-amino group.
-38- The specific modification of tyrosyl residues may be made, with particular interest in introducing spectral labels into tyrosyl residues by reaction with aromatic diazonium compounds or tetranitromethane. Most commonly, N-acetylimidizole and tetranitromethane are used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively. Tyrosyl residues are iodinated using 1251 or 1311 to prepare labeled proteins for use in radioimmunoassay, the chloramine T method described above being suitable.
Carboxyl side groups (aspartyl or glutamyl) are selectively modified by reaction with carbodiimides (Rwhere R and R' are different alkyl groups, such as l-cyclohexyl-3-(2-morpholinyl-4-ethyl) carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore, aspartyl and glutamyl residues are converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.
Derivatization with bifunctional agents is useful for crosslinking CT-I to a water-insoluble support matrix or surface for use in the method for purifying anti-CT-1 antibodies, and vice-versa. ,Commonly used crosslinking agents include, 1,l-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), and bifunctional maleimides such as bis-N-maleimido-1,8octane. Derivatizing agents such as methyl-3-[(p-azidophenyl)dithio]propioimidate yield photoactivatable intermediates that are capable of forming crosslinks in the presence of light. Alternatively, reactive waterinsoluble matrices such as cyanogen bromide-activated carbohydrates and the reactive substrates described in *9 U.S. Patent Nos. 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; and 4,330,440 are employed for protein immobilization.
20 Glutaminyl and asparaginyl residues are frequently deamidated to the corresponding glutamyl and aspartyl residues, respectively. These residues are deamidated under neutral or basic conditions. The deamidated form of these residues falls within the scope of this invention.
Other modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the a-amino groups of lysine, arginine, and histidine side chains 25 Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman Co., San Francisco, pp. 79-86 S.(1983)), acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.
Another type of covalent modification of the CT-1 polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. By altering is meant deleting one or more carbohydrate moieties found in native CT-I, and/or adding one or more glycosylation sites that are not present in the native CT-1.
Glycosylation of polypeptides is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-Xserine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-aceylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.
Addition of glycosylation sites to the CT-I polypeptide is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tripeptide sequences (for N-linked -39glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the native CT-1 sequence (for O-linked glycosylation sites). For ease, the native CT-1 amino acid sequence is preferably altered through changes at the DNA level, particularly by mutating the DNA encoding the native CT-1 polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids. The DNA mutation(s) may be made using methods described above under Section 2B.
Another means of increasing the number of carbohydrate moieties on the CT-1 polypeptide is by chemical or enzymatic coupling ofglycosides to the polypeptide. These procedures are advantageous in that they do not require production of the polypeptide in a host cell that has glycosylation capabilities for N- or O-linked glycosylation. Depending on the coupling mode used, the sugar(s) may be attached to arginine and histidine, free carboxyl groups, free sulfhydryl groups such as those of cysteine, free hydroxyl groups such as those of serine, threonine, or hydroxyproline, aromatic residues such as those of phenylalanine, tyrosine, or tryptophan, or the amide group of glutamine. These methods are described in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem.. pp. 259-306 (1981).
Removal of any carbohydrate moieties present on the CT-1 polypeptide may be accomplished chemically or enzymatically. Chemical deglycosylation requires exposure of the polypeptide to the compound trifluoromethanesulfonic acid, or an equivalent compound. This treatment results in the cleavage of most or all sugars except the linking sugar (N-acetylglucosamine or N-acetylgalactosamine), while leaving the polypeptide :t i intact. Chemical deglycosylation is described by Hakimuddin, et al., Arch. Biochem. Biophvs., 25: 52 (1987) and by Edge et al., Anal. Biochem., 118: 131 (1981). Enzymatic cleavage of carbohydrate moieties on S: 20 polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura o et al., Meth. Enzvmol., 138: 350 (1987).
Glycosylation at potential glycosylation sites may be prevented by the use of the compound tunicamycin as described by Duskin et al., J. Biol. Chem., 257: 3105 (1982). Tunicamycin blocks the formation of protein-No••o glycoside linkages.
Another type of covalent modification of CT-I comprises linking the CT-1 polypeptide to one of a variety of nonproteinaceous polymers, polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.
CT-I also may be entrapped in microcapsules prepared, for example, by cbacervation techniques or by interfacial polymerization (for example, hydroxymethylcellulose or gelatin-microcapsules and poly- 30 [methylmethacylate] microcapsules, respectively), in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules), or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Oslo, Ed., (1980).
CT-I preparations are also useful in generating antibodies, as standards in assays for CT-1 by labeling CT-1 for use as a standard in a radioimmunoassay, enzyme-linked immunoassay, or radioreceptor assay), in affinity purification techniques, and in competitive-type receptor binding assays when labeled with radioiodine, enzymes, fluorophores, spin labels, and the like.
Since it is often difficult to predict in advance the characteristics of a variant CT-1, it will be appreciated that some screening of the recovered variant will be needed to select the optimal variant. One can screen for enhanced cardiac hypertrophic, anti-arrhythmic, inotropic, or neurotrophic activity, possession of CT-1 antagonist activity, increased expression levels, oxidative stability, ability to be secreted in elevated yields, and the like. For example, a change in the immunological character of the CT-I molecule, such as affinity for a given antibody, is measured by a competitive-type immunoassay. The variant is assayed for changes in the suppression or enhancement of its hypertrophic, anti-arrhythmic, inotropic, and neurotrophic activities by comparison to the respective activities observed for native CT-I in the same assay (using, for example, the hypertrophy and neurotrophic assays described in the examples below.) Other potential modifications of protein or polypeptide properties such as redox or thermal stability, hydrophobicity, susceptibility to proteolytic degradation, or the tendency to aggregate with carriers or into multimers are assayed by methods well known in the art.
I. Antagonists of CT-I Antagonists to CT-1 can be prepared by using the predicted family of receptors for CT-1 (the GH/cytokine receptor family, including the CNTF, LIF, and oncostatin M receptor subfamily, most preferably the LIFRP or a LIFRP/gpl30 complex). Thus, the receptor can be expression cloned; then a soluble form of the receptor is made by identifying the extracellular domain and excising the transmembrane domain therefrom.
The soluble form of the receptor can then be used as an antagonist, or the receptor can be used to screen for small molecules that would antagonize CT-1 activity. Transfected cells expressing recombinant receptor find use in screening molecules both for receptor binding and receptor activation agonism or antagonism.
Alternatively, using the murine sequence shown in Figure 1 or the human sequence shown in Figure variants of native CT-1 are made that act as antagonists. Since the GH/cytokine receptor family is known to have two binding sites on the ligand, the receptor binding sites of CT-1 can be determined by binding studies and one 20 of them eliminated by standard techniques (deletion or radical substitution) so that the molecule acts as an antagonist. For example, as discussed herein, Figure 16 indicate regions that can act as antagonists.
Antagonist activity can be determined by several means, including the hypertrophy assay, the neurotrophic assay, and the other CT-I assays presented herein.
J. Hypertrophy Assay 25 A miniatured assay is preferably used to assay for hypertrophic activity. In this assay the medium used allows the cells to survive at a low plating density without serum. By plating directly into this medium, washing steps are eliminated so that fewer cells are removed. The plating density is important: many fewer cells and the survival is reduced; many more cells and the myocytes begin to self-induce hypertrophy.
The steps involved are: plating 96-well plates with a suspension of myocytes at a cell density of about 7.5 x 104 cells per mL in D-MEM/F-12 medium supplemented with at least insulin, transferrin, and aprotinin; culturing the cells; adding a substance to be assayed (such as one suspected of containing a CT-1); culturing the cells with the substance; and measuring for hypertrophy.
The medium can be supplemented with additional elements such as EGF that ensure a longer viability of the cells, but such supplements are not essential. D-MEM/F-12 medium is available from Gibco BRL, Gaithersburg, MD, and consists of one of the following media (Table 2): TABLE 2 -41- Corn- 11320 11321 11330 11331 12400 12500 ponent x I. I j.I. Powder Powder Liquid Liquid Liquid Liqauid (mg/L) (rngfL) m L
AMINO
ACIDS: L-Ala-nine 4.45 4.45 4.45 4.45 4.45 4.45 L-Arg- 147.50 147.50 147.50 147.50 147.50 147.50 inine L-Asp-ara- 7.50 7.50 7.50 7.50 7.50 7.50 gine L-Asp- 6.65 6.65 6.65 6.65 6.65 6.65 artic L-Cys- 17.56 17.56 17.56 17.56 17.56 17.56 teine -HCI 0 L-Cys-tine 31.29 31.29 31.29 31.29 31.29 31.29 L-Glu- 7.35 7.35 7.35 7.35 7.35 7.35, tamnic L-Glu- 365.00 365.00 365.00 365.00 365.00 365.00 Gly-cine 18.75 18.75 18.75 18.75 18.75 18.75 L-His- 31.48 31.48 31.48 31.48 31.48 31.48 tidine
*HCI
L-Iso-Ieu- 54.47 54.47 54.47 54.47 54.47 54.47 cine L-Leu-cine 59.0.5 59.05 59.05 59.05 59.05 59.05 L-Lys-ine 91.25 91.25 91.25 91.25 91.25 91.25 -HC1 L-Metb- 17.24 17.24 17.24 17.24 17.24 17.24 ionine L-Phen- 35.48 35.48 35.48 35.48 35.48 35.48 L-Pro-Iine 17.25 17.25 17.25 17.25 17.25 17.25 L-Ser-ine 26.25 26.25 26.25 26.25 26.25 26.25 L-Thre- 53.45 53.45 53.45 53.45 53.45 53.45 on ne -42- L-Tryp- 9.02 9.02 9.02 9.02 9.02 9.02 tophan L-Tyro- 55.79 55.79 55.79 55.79 55.79 55.79 sine -2Na L-Val-ine 52.85 52.85 52.85 52.85 52.85 52.85
INOR-
GANIC
CaCI 2 116.60 116.60 116.60 116.60 116.60 116.60 CuSO 4 0.00B,~ 0.0013 0.0013 0.0013 0.0013 0.0013 Fe 0.05 0.05 0.05 0.05 0.05 0.05
(NO
3 3 ~9H,O FeSO 4 0.417 0.417 0.417 0.417 0.417 0.417 -7H,O KCI 311.80 311.80 311.80 311.80 311.80 311.80 MgC., 28.64 28.64 28.64 28.64 28.64 28.64 MgS04 48.84 48.84 48.84 48.84 48.84 48.84 NaCI 6999.50 6999.50 6999.50 6999.50 6999.50 6999.50 NaHC03 2438.00 2438.00 2438.00 2438.00 NaH 2
PO
4 62.50 62.50 62.50 62.50 62.50 Na,HPOA 71.02 71.02 71.02 Z- 71.02 71.02 ZnSO 4 0.432 0.432 0.432 0.432 0.432 0.432 -7H,O
OTHER
COMPO-
NENTS:____ D-Glu- 3151.00 3151.00 3151.00 3151.00 3151.00 3151.00 cose HEPES 3574.50 3574.50 3574.50 Na 2.39 2.39 2.39 2.39 2.39 2.39 hypo-xanthine Lino-leic 0.042 0.042 0.042 0.042 0.042 0.042 Lipoic 0.105 0.105 0.105 0.105 0.105 0.105 acid Phenol red 8.10 8.10 8.10 8.10 8.10 8.10 -43- 0 0 0 1.
Pu- 0.081 0.081 0.081 0.081 0.081 0.081 trescine -2H,O Sodium 55.00 55.00 55.00 55.00 55.00 55.00 pyru-vate
VITA-
MINS: Biotin 0.0035 0.0035 0.0035 0.0035 0.0035 0.0035 D-Ca. 2.24 2.24 2.24 2.24 2.24 2.24 panto- Cho-line 8.98 8.98 8.98 8.98 8.98 8.98 chior-ide Folic acid 2.65 2.65 2.65 2.65 2.65 2.65 i-Ino-sitol 12.60 12.60 12.60 12.60 12.60 12.60 Nia-cin- 2.02 2.02 2.02 2.02 2.02 2.02 amide Pyrid-oxal 2.00 2.00 2.00 2.00
-HCI
Pyrid- 0.031 2.031 0.031 2.031 0.031 0.031' oxine -HCl Ribo- 0.219 0.219 0.219 0.219 0.219 0.219 flavin Thi- 2.17 2.17 2.17 2.17 2.17 2.17 amine *HCI Thy- 0.365 0.365 0.365 0.365 0.365 0.365 midine Vi- 0.68 0.68 0.68 0.68 0.68 0.68 taminB, The preferred hypertrophy assay comprises: precoating the wells of 96-well tissue culture plates with a medium containing calf serum, preferably D-MEM/F- 12. medium containing 4% fetal calf serum, wherein preferably the wells are incubated with the medium for about eight hours at about 370 C; removing the medium; plating a suspension of myocytes in the inner 60 wells at 7.5 x 104~ cells per mL in D-MEMIF- 12 medium supplemented with insulin, transferrin, and aprotinin; culturing the myocytes for at least 24 hours; adding the test substance; -44culturing the cells with the test substance (preferably for about 24-72 hours, more preferably for about 48 hours); and measuring for hypertrophy, preferably with crystal violet stain.
Preferably the medium used in step is a serum-free medium also containing penicillin/streptomycin (pen/strep) and glutamine. Most preferably, the medium contains 100 mL D-MEM/F-12, 100 pL transferrin mg/mL), 20 pL insulin (5 mg/mL), 50 pL aprotinin (2 mg/mL), 1 mL pen/strep (JRH Biosciences No. 59602- 77P), and 1 mL L-glutamine (200 mM).
The assay capacity of 1000 single samples a week coupled with the small sample size requirement of 100 pL or less has enabled an expression cloning and protein purification that would have been impossible to accomplish using the current methods available.
Another method for assaying hypertrophy involves measuring for atrial natriuretic peptide (ANP) release by means of an assay that determines the competition for binding of 125I-rat ANP for a rat ANP receptor A-IgG fusion protein. The method suitable for use is similar to that used for determining gp120 using a CD4-IgG fusion protein described by Chamow et al., Biochemistry. 2: 9885-9891 (1990).
The basis for the isolation and characterization of the novel hypertrophy factor, CT-1, is the miniaturized high through-put hypertrophy assay system, which was developed in a 96 well format, in which hypertrophy is scored on individual myocardial cells following crystal-violet staining of neonatal rat cardiac myocytes. This assay was used in combinatio with an in vitro model of embryonic stem cell cardiogenesis (Miller-Hance et al., Journal of Biological Chemistry, 268:25244-25252 (1993)). These totipotent stem cells 20 can differentiate into multi-cellular cystic embryoid bodies (EBs) when cultured in the absence of a fibroblast feeder layer, or without LIF. Since these embryoid bodies spontaneously beat and display cardiac specific markers, it has been suggested that they may serve as a vital source of novel factors that can induce a hypertrophic response in vitro )Miller-Hance et al., Journal of Biological Chemistry, 268:25244-25252 (1993); Chien, Science, 260:916-917 (1993)). By dual immunofluorescence staining of cultured myocardial cells incubated with EB conditioned medium, it was observed that embryoid bodies elaborate a factor that can induce an in vitro hypertrophic response in the cultured assay system. This response includes an increase in myocyte size, induction of the expression of ANF, and the assembly of sarcomeric proteins (MLC-2v) into organized contractile units. The hypertrophy assay system was then used to expression clone this factor, which proved to be the novel cytokine, CT-I. These studies document the utility of using expression cloning approaches to identify novel growth factors and cytokines from this in vitro model of embryonic stem cell differentiation. This assay system will be of interest in the isolation of other novel cytokines derived from precursors of other differentiated cell types found in EBs, neurogenic, skeletal myogenic, and hematopoietic precursors.
K. Neurotrophic Assay The assay used for ciliary ganglion neurotrophic activity described in Leung, 8Neuro. 1045-1053 (1992) is suitable herein. Briefly, ciliary ganglia are dissected from E7-E8 chick embryos and dissociated in trypsin-EDTA (Gibco 15400-013) diluted ten fold in phosphate-buffered saline for 15 minutes at 37 0 C. The ganglia are washed free of trypsin with three washes of growth medium (high glucose D-MEM supplemented with 10% fetal bovine serum, 1.5 mM glutamine, 100 gg/mL penicillin, and 100 pg/mL strepomycin), and then gently triturated in 1 mL of growth medium into a single-cell suspension. Neurons are enriched by plating this cell mixture in 5 mL of growth media onto a 100-mm tissue culture dish for 4 hours at 37* C in a tissue culture incubator. During this time the non-neuronal cells preferentially stick to the dish and neurons can be gently washed free at the end of the incubation. The enriched neurons are then plated into a 96-well plate previously coated with collagen. In each well, 1000 to 2000 cells are plated, in a final volume of 100 to 250 uL, with dilutions of the CT-1 to be tested. Following a 2-4-day incubation at 37* C, the number of live cells is assessed by staining live cells using the vital dye metallothionine (MTT). One-fifth of the volume of 5 mg/mL MTT (Sigma M2128) is added to the wells. After a 2-4-hour incubation at 37 C, live cells (filled with a dense purple precipitate) are counted by phase microscopy at 100X magnification.
3. Uses and Therapeutic Compositions and Administration of CT-1 As disclosed herein, CT-1 activates downstream cellular responses via the heterodimerization of gp 130 and LIFRp. The expression pattern of CT-I and pleiotropic activities suggest that it may have important functions, not only in the cardiac context, but in extra-cardiac tissues as well. CT-1 acts to maintain normal embryonic growth and morphogenesis, as well as physiological homeostasis in the adult.
CT-1 is believed to find use as a drug for treatment of mammals animals or humans) in vivo having heart failure, arrhythmic or inotropic disorders, and/or peripheral neuropathies and other neurological disorders involving motor neurons or other neurons in which CNTF is active. CT-1 has additional uses as shown herein.
For example, CT-1 may be useful in treating congestive heart failure in cases where ACE inhibitors .cannot be employed or are not as effective. CT-1 optionally is combined with or administered in concert with *other agents for treating congestive heart failure, including ACE inhibitors.
S* 20 The effective amount of ACE inhibitor to be administered, if employed, will be at the physician's or veterinarian's discretion. Dosage administration and adjustment is done to achieve optimal management of congestive heart failure and ideally takes into account use of diuretics or digitalis, and conditions such as hypotension and renal impairment. The dose will additionally depend on such factors as the type of inhibitor used and the specific patient being treated. Typically the amount employed will be the same dose as that used 25 if the ACE inhibitor were to be administered without CT-1.
Thus, for example, a test dose of enalapril is 5 mg, which is then ramped up to 10-20 mg per day, once a day, as the patient tolerates it. As another example, captopril is initially administered orally to human patients in a test dose of 6.25 mg and the dose is then escalated, as the patient tolerates it, to 25 mg twice per day (BID) or three times per day (TID) and may be titrated to 50 mg BID or TID. Tolerance level is estimated by determining whether decrease in blood pressure is accompanied by signs ofhypotension. If indicated, the dose may be increased up to 100 mg BID or TID. Captopril is produced for administration as the active ingredient, in combination with hydrochlorothiazide, and as a pH stabilized core having an enteric or delayed release coating which protects captopril until it reaches the colon. Captopril is available for administration in tablet or capsule form. A discussion of the dosage, administration, indications and contraindications associated with captopril and other ACE inhibitors can be found in the Physicians Desk Reference, Medical Economics Data Production Co., Montvale, NJ. 2314-2320 (1994).
CT-I is also potentially useful in the generation, maturation, and survival of oligodendrocytes in vitro for protection of oligodendrocytes against natural and tumor necrosis factor-induced death, in the survival and differentiation of astrocytes and the induction of type-2 astrocyte development, and in the stimulation of the -46recombinant production of low-affinity nerve growth factor receptor and CD-4 by rat central nervous system (CNS) microglia.
CT-I is also potentially useful in having atrophic effect on denervated skeletal muscle. In addition, it is expected to have the proliferative responses and binding properties of hematopoietic cells transfected with low-affinity receptors for leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor, to regulate fibrinogen gene expression in hepatocytes by binding to the interleukin-6 receptor, to have trophic actions on murine embryonic carcinoma cells, to be an endogenous pyrogen, and to have a mitogenic effect on human IMR 32 neuroblastoma cells.
In addition, CT-1 is expected to enhance the response to nerve growth factor of cultured rat sympathetic neurons, to maintain motoneurons and their target muscles in developing rats, to induce motor neuron sprouting in vivo, to promote the survival of neonatal rat corticospinal neurons in vitro, to prevent degeneration of adult rat substantia nigra dopaminergic neurons in vivo, to alter the threshold of hippocampal pyramidal neuron sensitivity to excitotoxin damage, to prevent neuronal degeneration and promote low-affinity NGF receptor production in the adult rat CNS, and to enhance neuronal survival in embryonic rat hippocampal cultures.
CT-1 induces a phenotypic switch in sympathetic neurons and it promotes the survival of dopaminergic neurons from the central nervous system and ciliary neurons from the periphery These activities translate into the treatment of all neurodegenerative diseases by CT-1, including peripheral neuropathies (motor and sensory), ALS, Alzheimer's disease, Parkinson's disease, stroke, Huntington's disease, and ophthalmologic diseases, for example, those involving the retina.
20 As shown herein CT-I shares at least some of the growth inhibitory activities of the IL-6 family cytokines. CT-I has the potential for use as a therapeutic non-proliferative agent for suppressing some forms of myeloid leukaemia as well as a reagent for modifying macrophage function and other responses to infections.
CT-1 was 6 fold more potent than LIF in inhibiting the uptake of 3H-thymidine by M cells and thus the growth of the myeloid leukemia cell line. CT-1 inhibits the growth of the mouse myeloid leukemia cell line, M and 25 induces its differentiation into a macrophage-like phenotype. CT-I does not mimic the activity of IL-6 in promoting B cell expansion. Unlike IL-6, CT- has the advantage of not stimulating the growth of several B cell lymphomas, myelomas, and plasmacytomas. Thus, CT-I will find use in treating lymphomas and leukemias, preferably B-cell and myeloid leukemias and patients with certain infections. Since CT-I is useful the treatment of patients with some forms of myeloid leukaemia and patients with certain infections, the present invention also extends to pharmaceutical compositions comprising CT-1, particularly human CT-I, either completely or in part, produced for example using cloned CT-I-encoding DNA sequences or by chemical synthesis, and to pharmaceutical compositions of analogues of CT-1, for example produced by chemical synthesis or derived by mutagenesis of aforesaid cloned CT-1-encoding DNA sequences. The pharmaceutical compositions may also contain at least one other biological regulator of blood cells, such as G-CSF or GM-CSF. Furthermore, the invention also extends to diagnostic reagents for use in detecting genetic rearrangements, alterations or lesions associated with the human CT-I gene in diseases of blood cell formation, including leukaemia and congenital diseases associated with susceptibility to infection. CT-I can be used in the treatment of a wide variety of neoplastic conditions, such as carcinomas, sarcomas, melanomas, lymphomas, leukemias, which may affect a wide variety of organs, including the blood, lungs, mammary organ, prostate, intestine, liver, heart, skin, -47pancreas, and brain. CT-I can be used in vitro to eliminate malignant cells from marrow for autologous marrow transplants or to inhibit proliferation or eliminate malignant cells in other tissue, e.g. blood, prior to reinfusion.
CT-I can also be used as a treatment in disorders of the hematopoietic system, especially as a means of stimulating hematopoiesis in patients with suppressed bone marrow function, for example, patients suffering from aplastic anemia, inherited or acquired immune deficiency, or patients undergoing radiotherapy or chemotherapy.
Antagonists to CT-I can also be used for treating a wide variety of wounds including substantially all cutaneous wounds, corneal wounds, and injuries to the epithelial-lined hollow organs of the body and those involving myocytes and neurons. Wounds suitable for treatment include those resulting from trauma such as bums, abrasions, cuts, and the like as well as from surgical procedures such as surgical incisions and skin grafting. Other conditions suitable for treatment with the CT-i antagonists include chronic conditions, such as chronic ulcers, diabetic'ulcers, and other non-healing (trophic) conditions. Preferably, a CT-I antagonist is incorporated in physiologically-acceptable carriers for local or site-specific application to the affected area. The nature of the carriers may vary widely and will depend on the intended location of application. If desired, it will be possible to incorporate CT-I antagonist compositions in bandages and other wound dressings to provide for continuous exposure of the wound to the peptide. Aerosol applications also find use. The antagonist will be .present in an amount effective to suppress CT-I inhibition of epithelial cell proliferation. The cofmpositions will be applied topically to the affected area, typically as eye drops to the eye or as creams, ointments or lotions to the skin. In the case of eyes, frequent treatment is desirable, usually being applied at intervals of 4 hours or less.
20 On the skin, it is desirable to continually maintain the treatment composition on the affected area during healing, with applications of the treatment composition from two to four times a day or more frequently.
"CT-I maintains the undifferentiated phenotype of embryonic stem cells. CT-1 can promote cell survival and acts as an anti-apoptotic factor during mouse embryogenesis. Thus CT-1 will find use in techniques in which undifferentiated ES cells are useful as well as techniques in which control of their differentiation is useful For 25 example, CT-I will find use to maintain the undifferentiated state of embryonic stem cells during recombinant DNA transformation and their synchronized differentiation in methods such as gene cloning and creating transgenic animals. CT-1 also find use in artificial insemination techniques. Thus, in one preferred embodiment, CT-I is used in the enhancement of development and maintenance of animal or mammalian embryos and to enhance impregnation.
A major difficulty associated with present in vitro fertilization (IVF) and embryo transfer (ET) programs, particularly in humans, is the success rate "achieved" on implantation of fertilized embryos. Currently, in human IVF programs, the implantation rate may be as low as 10%, leading to the present practice of using up to four fertilized embryos in each treatment which, in turn, leads occasionally to multiple births. Accordingly, there is a need to improve the implantation rate in human IVF programs. Similarly, in IVF and ET treatments in domestic animals such as sheep, cattle, pigs and goats, it is highly desirable for economic reasons to have as high an implantation rate as possible so as to reduce the numbers of fertilized embryos lost and unsuccessful treatment procedures performed. Furthermore, as with human IVF procedures, the practice of transferring more than one embryo to the recipient animal to ensure pregnancy can result in unwanted multiple births. One major constraint with embryo transfer is the need to hold embryos in culture media for either relatively short periods -48of time, perhaps only a few hours prior to transfer or for longer periods of some days, after micromanipulation.
In the development of a mammalian embryo, the fertilized egg passes through a number of stages including the morula and the blastocyst stages. In the blastocyst stage, the cells form an outer cell layer known as the trophectoderm (which is the precursor of the placenta) as well as an inner cell mass (from which the whole of the embryo proper is derived). The blastocyst is surrounded by the zona pellucida, which is subsequently lost when the blastocyst "hatches". The cells of the trophectoderm are then able to come into close contact with the wall of the uterus in the implantation stage. Prior to formation of the embryo proper by the inner cell mass by gastrulation, the whole cell mass may be referred to as "pre-embryo." Embryo mortality has been attributed to incomplete hatching of the blastocyst from the zona pellucida and/or unsuccessful implantation of the embryo to the uterine wall, possibly due to spontaneous differentiation of the embryonic stem cells (ES) during their period in culture prior to transplantation. CT-I can be included in an in vitro embryo culture niedium to enhance the hatching process leading to an increased number of embryos completing the development stage by undergoing developmental changes associated with implantation. Thus, CT-I is an embryo protective agent. As a result, the implantation rates for IVF and ET programs can be significantly improved by the use of CT-I in the in vitro embryo culture medium. Furthermore, media containing CT-I is suitable for use in early manipulative "procedures on the oocyte/embryo such as in vitro fertilization, embryo splitting and nuclear transfer where survival rates of embryos are low. CT-I also has important applications in the growth oftotipotent stem cell lines for cloning for inclusion into the media used for the transport of cooled or frozen embryos/semen. Thus a method for enhancing the impregnation rate in an animal with one or more embryos is provided which comprises 20 the steps of maintaining and/or developing the embryos in a medium containing an effective amount of CT-I for sufficient time and under appropriate conditions and then implanting the embryos into the animal. By "impregnation" means the rate of successful implantations and subsequent development of a fertilized embryo.
oo* Also provided is a method for maintaining embryos or pre-embryos in culture while retaining viability for use in embryo transfer and/or genetic manipulation which method includes culturing the embryos in a medium 25 containing an effective amount of CT-1 for sufficient time and under appropriate conditions. This method of maintaining the viability of embryos in culture has potential for allowing genetic manipulation of the whole embryo. Such successful genetic manipulation is restricted at the present time due to the limited amount of time available to perform experiments on viable embryos. The method also may be advantageous in maintaining S viability of embryos under transport conditions and may also be beneficial in the storage of embryos when compared to techniques currently employed. Another aspect of the present invention relates to a method for enhancing the in vitro development of a mammalian embryo to the implantation stage, which method comprises the step of culturing the embryo in vitro in a culture medium containing an effective amount of mammalian CT-I.
As is demonstrated below the inclusion of CT-I in the culture medium prior to the formation of the blastocyst, or both prior to and following blastocyst formation, also increases the number of pre-embryos completing the developmental stage by undergoing development changes associated with implantation. The addition of CT-I also reduces the number of pre-embryos degenerating while in culture. As a result, the implantation rate for IVF and ET programs can be significantly improved by use of CT-I in the in vitro culture medium. The present invention, also extends to a method for in vitro fertilization and subsequent implantation of a mammalian embryo which is characterized in that the embryo is cultured in vitro in a culture medium containing an effective amount -49of mammalian CT-1 prior to transfer into animal or mammalian host, where "host" is defined as a suitably receptive female animal or mammal. A further aspect of the present invention relates to a non-human animal and in particular a chimeric non-human animal or transgenic progeny of said animal generated by known techniques using ES cells which have been maintained in vitro in CT-I-containing culture medium. In accordance with this aspect of the present invention, ES cells are derived from animal embryos passaged in a culture medium containing CT-I wherein said ES cells have additional genetic material inserted therein. The transgenic animals contemplated include nonhuman mammals such as livestock and ruminant animals and domestic animals. The present invention is also directed to composition comprising an effective amount of CT-i in combination with an animal mammalian) embryo maintaining medium. The present invention also provides a composition having embryotrophic and/or embryo protective properties comprising CT-I. The amount of CT-i used in accordance with the present invention is that required to maintain and/or develop embryos and/or enhance impregnation. Generally it is in the range of 0.1 ng/ml to 10,000 ng/ml, preferably I ng/ml to 1000 ng/ml.
CT-I also finds use to produce a mammalian pluripotential embryonic stem cell composition which can be maintained on feeder layers and give rise to embryoid bodies and multiple differentiated cell phenotypes ir monolayer culture. Provided is a method of making a pluripotential embryonic stem cell by administering a growth enhancing amount of basic fibroblast growth factor, CT-i, membrane associated steel factor, and soluble steel factor to primordial germ cells under cell growth conditions, thereby making a pluripotential embryonic stem cell. A "pluripotential embryonic stem cell" as used herein means a cell which can give rise to many differentiated cell types in an embryo or adult, including the germ cells (sperm and eggs). This cell type is also 20 referred to as an "ES cell." Only those mammals which can be induced to form ES cells by the described methods are within the scope of the invention. Although not a requirement for application of this embodiment of the invention, the ES cells may be capable of indefinite maintenance, typically at least 15 days. Once the ES cells are established, they can be genetically manipulated to produce a desired characteristic. For example, the ES cells can be mutated to render a gene non-functional, e.g. the gene-associated with cystic fibrosis or an 25 oncogene. Alternatively, functional genes can be inserted to allow for the production of that gene product in an 9 animal, e.g. growth hormones or valuable proteins. The invention also provides a composition comprising pluripotential ES cells and/or primordial germ cells and/or embryonic ectoderm cells and CT-i, an FGF, membrane associated SF, and soluble SF wherein the factors are present in amounts to enhance the growth of and allow the continued proliferation of the cell. Growth and proliferation enhancing amounts can vary.
Generally, 0.5 to 500 ng factor/ml of culture solution is adequate. Preferably, the amount is between 10 to ng/ml. Alternatively, CT-I can be used to maintain ES cells. In this case, the amounts of CT-i, FGF, and SF necessary to maintain ES cells can be much less than that required to enhance growth or proliferation to become ES cells. In addition, CT-1, FGF, or SF may not be required for maintenance of ES cells. The invention also provides a method of making a pluripotential ES cell comprising administering a growth enhancing amount of CT-I, basic FGF, membrane associated SF, and soluble SF to primordial germ cells and/or embryonic ectoderm cells under cell growth conditions, thereby making a pluripotential ES cell. This method can be practiced utilizing any animal cell, especially mammal cells including mice, rats, rabbits, guinea pigs, goats, cows, pigs, humans, etc. The ES cell produced by this method is also contemplated. "Cell growth conditions" are set forth in the Examples. However, many alterations to these conditions can be made and are routine in-the art. Since the invention provides ES cells generated for virtually any animal, the invention provides a method of using the ES cells to contribute to chimeras in vivo comprising injecting the cell into a blastocyst and growing the blastocyst in a foster mother. Alternatively, aggregating the cell with a morula stage embryo and growing the embryo in a foster mother can be used to produce a chimera. The ES cells can be manipulated to produce a desired effect in the chimeric animal. Alternatively, the ES cells can be used to derive cells for therapy to treat an abnormal condition. For example, derivatives of human ES cells could be placed in the brain to treat a neurodegenerative disease.
CT-1 will stimulate the proliferation of satellite cells and the subsequent development of myoblasts.
Accordingly, provided are methods of stimulating the proliferation and/or differentiation of mammalian satellite cells into myoblasts which includes the steps of contacting said cells with a stimulation-effective amount of CT-1 for a time and under conditions sufficient for said satellite cells to proliferate and/or differentiate into myoblasts.
The stimulation-effective amount of CT-l can be administered simultaneously or in sequential combination with one or more other cytokines, for a time and under conditions sufficient for said satellite cells to proliferate and/or differentiate into myoblasts. Also provided are methods ofmyoblast transfer therapy which include the steps of contacting mammalian satellite cells with a proliferation- and/or differentiation-effective amount of CT-1 for a time and under conditions sufficient for said satellite cells to proliferate and/or differentiate into myoblasts and then administering said myoblasts at multiple sites into muscles. In an alternative to this embodiment, CT-1 is used in simultaneous or sequential combination with one or more other cytokines. Accordingly, a cell activating composition comprising CT-1 in combination with one or more other cytokines, and one or more physiologically 20 acceptable carriers and/or diluents is provided. And there is provided a pharmaceutical composition for stimulating the proliferation and/or differentiation of satellite cells which includes CT-1 and one or more other go"* cytokines and one or more pharmaceutically acceptable carriers and/or diluents. In one preferred embodiment, the cytokines in optional combination with CT-1 include IL-6 and/or TGF alpha and/or FGF. The methods and compositions find use especially in relation to primary, genetically determined, muscle myopathies, the most 25 severe and the most common of which is Duchenne muscular dystrophy (DMD). Because of the size and complexity of the DMD gene, it is unlikely that genetic manipulation will be possible in the near future.
However, an effective approach involves the growing ofmyoblasts in culture derived from normal mammals and 2 injecting them, at multiple sites, into muscles of the patient to result in the muscles containing dystrophin whereas previously there was little or none. Thus human myoblasts, grown in culture, are injected at multiple sites into muscles of DMD. This approach is applicable to all primary myopathies, not only DMD. At present, techniques of culturing myoblasts utilize medium to long term culture with varying concentrations of the expensive reagent fetal calf serum. Thus, accelerating myoblast differentiation and growth should be significant advance toward reducing the cost of myoblast production and facilitate therapy. CT-1 alone, or in combination with other cytokines such as IL-6 and/or TGF alpha and/or FGF, will provide this acceleration. Accordingly, provided herein is a method (and compositions for same) of stimulating the proliferation and/or differentiation of mammalian satellite cells into myoblasts which includes the steps of contacting said satellite cells with a stimulation-effective amount of CT-1, alone or in combination with other cytokines such as IL-6 and/or TGF alpha and/or FGF, for a time and under conditions sufficient to stimulate the satellite cells. In these methods the satellite cells are most preferably from the same mammal to be treated, less preferably from the same species -51of mammal, and least preferably from different mammals. The mammal can be human, mouse, a livestock or a pet animal. Most preferably CT-I and the satellite cells are from the same species of mammal. CT-I can be provided at a concentration of from about 0.1 to about 1000 ng/ml, and more preferably from a concentration of from about 1 to 100 ng/ml.
CT-1 can be involved in the repair of injured muscle and the maintenance of cellular homeostasis. For example, the prominent expression of CT-I in skeletal muscle indicates that CT-1 will serve to promote the survival of skeletal muscle cells during periods of muscle injury. This is consistent with the finding that in skeletal muscle, LIF and CNTF were found to be involved in the repair of injured muscle (Barnard et al:, J Neurol Sci., 123:108-113 (1994); Helgren et al., Cell, 76:493-504 (1994)). This function of CT-1 is consistent with the enlarging role of the gp130 dependent cytokines in promoting cell survival. In addition, the level of CT- 1 expression in the mature heart and other tissues is consistent with its supportive role to maintain tissue survival in these tissues. In this regard, previous studies have demonstrated that LIF and CNTF can promote neuronal cell survival in vitro (Oppenheim et al., Science, 251:1616-1618 (1991); Martinou et al., Neuron, 8:737-744 (1992)). In addition, analysis of LIF deficient mice suggests that LIF may be required for the microenvironment to maintain the survival of hematopoietic cells (Escary et al., Nature, 363:361-364 (1993)). Although the members of the IL-6 family share a great degree of functional redundancy, individual family members may have their own specific target tissues and divergent functions, based upon the localized distribution and density of the cytokines and their receptors. CT-1 can block viral induced apoptosis of neonatal cardiac muscle cells following infection with cardiomyopathic viruses.
20 As shown herein, CT-1 is a multi-functional cytokine which shares several biological activities with other members of the IL-6 cytokine family. CT-1 and LIF have similar activities in the in vitro assay systems examined thus far. Accordingly, CT-1 is expected to find use in the medical treatment uses known for LIF.
Figure 21 is a schematic that summarizes the diverse bioactivities of CT-1 in a wide variety of cell types. These activities include the ability of CT-1 to inhibit embryonic stem cell differentiation and aortic endothelial cell proliferation, thus CT-1 will function in regulating development. Like other IL-6 family members, CT-I induces acute phase proteins in hepatocytes and thus will modulate local inflammatory processes, and play a role as an acute phase mediator in vivo (see also Peters et al., FEBS Letters, 372:177-180 (1995)). CT-1 or its antagonists will be useful in the treatment of arthritis and inflammatory pathologies. During the inflammatory reaction, substantial modifications occur in the synthesis of a group of plasma proteins called acute-phase proteins. Some of these proteins-including fibrinogen, reactive protein C, haptoglobin are increased during the acute-phase reaction, whereas others such as albumin and transferrin are reduced. The alteration of these proteins, in particular fibrinogen, is responsible for the modifications in the plasma viscosity and for the increase in the speed of sedimentation which are observed in the inflammation. Because of their correlation with clinical parameters during the development and the therapeutic remissions observed in rheumatoid arthritis, some of these acute-phase proteins have been used as a criterion for evaluating the disease (Mallya et al., J. Rheumatol. 9:224-8 (1982); Thompson et al., Arthritis Rheum. 30:618-23 (1987)). Accordingly, a method is provided for treating a mammal afflicted with arthritis or an inflammatory disease, including those related to autoimmune diseases.
The method includes the step of administering to the mammal an amount of compound which is effective for alleviation of the condition. Inflammatory states in mammals include, but are not limited to, allergic and -52asthmatic manifestations, dermatological diseases, inflammatory diseases, collagen diseases, reperfusion injury and stroke, infections, and lupus erythematosus. Treatment of both acute and chronic diseases are possible.
Preferred diseases for treatment are arthritis, asthma, allergic rhinitis, inflammatory bowel disease (IBD), psoriasis, reperfusion injury and stroke. Other disorders involving acute phase proteins are acute lymphoblastic leukemia (ALL), acute graft versus host disease (aGvHD), chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL), type 1 diabetes, aplastic anemia Crohn's Disease, and scleroderma. Additional inflammatory conditions include patients with severe burns, kidney transplants, acute infections of the central nervous system and septic shock.
Furthermore, CT-1 like LIF, inhibits the proliferation and induces the differentiation of a mouse myeloid leukemia cell line. Similar to the activity seen for LIF and CNTF, CT-1 has neuronal function, in that it promotes the survival of cultured dopaminergic neurons and ciliary ganglion neurons and induces 'a switch in the transmitter phenotype of sympathetic neurons. Thus, while CT-1 was initially isolated on the basis of its actions on cardiac muscle cells, it may also have pleiotropic functions in other organ systems that overlap to a significant extent with the activities other IL-6 family cytokines, preferably those of LIF and OSM, and more preferably those of LIF.
As shown herein, CT-1 signals through and induces tyrosine phosphorylation of the gpl 30/LIFR3heterodimer in cardiac myocytes and other cell types. This does not exclude the possibility that CT-1 may use an alternative signaling pathway via an additional private receptor in some cell types. Members of the IL-6 cytokine family including, IL-11, LIF, CNTF, and OSM trigger downstream signaling pathways in multiple cell 20 types through the homodimerization of gpl30 or through the heterodimerization of gpl30 and a related transmembrane signal transducer, the LIF receptor subunit LIFRp (Figure 15B; Gearing et al., Science, 255:1434-1437 (1992); Ip et al., Cell, 69:1121-1132 (1992); Murakami et al., Science, 260:1808-1810 (1993); Davis et al., Science, 260:1805-1808 (1993). An anti-gpl30 monoclonal antibody was used to determine its effect on CT-1 binding to Ml cells. This neutralizing antibody inhibited CT-1 binding to Ml cells indicating 25 that gpl30 is a component of the CT-I receptor complex. CT-1 and LIF also cross-compete for binding to rat cardiac myocytes and mouse M1 cells indicating that these two ligands act on these cells via the LIF receptor.
In addition, c-fos induction by CT-1 and LIF in cardiac myocytes was antagonized by the anti-gpl30 monoclonal antibody as well as by a mutated human LIF protein, acting as a LIFRP-antagonist. A direct demonstration that CT-I interacts with LIFRp and gpl30 has been shown by the binding of CT-I to purified soluble gpl30 and LIFRp. Accordingly, CT-1 will find use in disorders, diseases or condition relating to cells expressing the LIFRP and to its signaling pathways.
As demonstrated by immunoprecipitation with a polyclonal anti-gpl30 cytoplasmic peptide antibody and subsequent anti-phosphotyrosine immunoblotting, stimulation of cardiomyocytes with CT-1, LIF, and a combination of IL-6 and soluble IL-6 receptor (sIL-6R) resulted in the rapid tyrosine phosphorylation of gp 130.
These data indicate that tyrosine phosphorylation of the receptor component gpl30 is an early step in CT-1 signaling, as has previously been shown for the other members of the IL-6 cytokine family (Ip et al., Cell, 69:1121-1132 (1992); Yin et al., Journal of Immunology, 151:2555-2561 (1993); Taga et al., Proc. Natl Acad. Sci. USA, 89:10998-11001 (1992)). As determined by immunoblotting with an anti-phosphotyrosine antibody, LIF induced the tyrosine phosphorylation of an additional -200 kDa protein, which was not -53phosphorylated upon stimulation with the IL-6/sIL-6R complex. Based on previous results, this protein most likely corresponds to the LIF receptor subunit LIFR3 (Ip et al., Cell, 69:1121-1132 (1992); Davis et al., Science, 260:1805-1808 (1993); Boulton et al., Journal of Biological Chemistry, 269:11648-11655 (1994)).
As shown herein, stimulation of cardiac cells with CT-1 also resulted in the tyrosine phosphorylation of a protein, indistinguishable in size from the LIFR3. And an LIFRP antagonist blocked the action of CT-1 in cardiomyocytes. Accordingly, CT-I, like LIF, induces the tyrosine phosphorylation of LIFRp.
Since CT-1 and LIF appear to have functional redundancy in these assay systems, the possibility exists that CT-1 compensated for the complete loss of LIF during embryonic development and adulthood in these LIF deficient embryos. Alternatively, since LIF is not expressed at very high levels in the embryo, CT-I may be the endogenous ligand which normally performs this function during mouse embryonic development. If the latter is the case, one might expect severe embryonic defects in CT-1 deficient embryos, analogous to either the LIFRp deficient or gpl30 deficient phenotypes. CT-1 will be involved in the maintenance of normal cardiac growth, morphogenesis, and hypertrophy, which can be analyzed in the basal state and in response to the imposition of a mechanical stimulus for hypertrophy via miniaturized physiological technology (Rockman et al., Proc. Natl Acad Sci. USA, 88:8277-8281 (1991)). This system will allow screening and identification ofCT-I agonists and antagonists. Interestingly, a large disparity between the phenotypes seen in mice lacking the CNTF receptor and mice lacking CNTF have been reported (DeChiara et al., Cell, 83:313-322 (1995)). While animals which completely lack the CNTF receptor display prominent motor neuron deficits at birth, mice that lack CNTF appear to be relatively unaffected (DeChiara et al., Cell, 83:313-322 (1995)), and do not display any notable 20 abnormalities in the developing nervous system. In addition, LIFRp deficient neonates also display similar profound motor neuron deficits (Li et al, Nature, 378:724-727 (1995)). These studies strongly suggest the possibility that there may be an alternative ligand to CNTF that binds to the CNTF receptor and LIFRp that is required to maintain normal nervous system development. While the CNTF receptor is not required for CT-1 binding to the gpl30/ LIFRp complex and interaction of CT-1 with the CNTF receptor has not been 25 demonstrated, CT-1 may be this alternative ligand.
CT-1 may also be useful as an adjunct treatment of neurological disorders together with such neurotrophic factors as, CNTF, NGF, BDNF, NT-3, NT-4, and The nucleic acid encoding the CT-1 may be used as a diagnostic for tissue-specific typing. For example, such procedures as in situ hybridization, northern and Southern blotting, and PCR analysis may be used to determine whether DNA and/or RNA encoding CT-1 is present in the cell type(s) being evaluated.
Isolated CT-1 polypeptide may also be used in quantitative diagnostic assays as a standard or control against which samples containing unknown quantities of CT-1 may be prepared.
Therapeutic formulations of CT-1 for treating heart failure, neurological disorders, and other disorders are prepared for storage by mixing CT-1 having the desired degree of purity with optional physiologically acceptable carriers, excipients, or stabilizers (Remington's Pharmaceutical Sciences, supra), in the form of lyophilized cake or aqueous solutions. Acceptable carriers, excipients, or stabilizers are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as -54polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween, Pluronics, or polyethylene glycol (PEG).
CT-I to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution. CT-I ordinarily will be stored in lyophilized form or in solution.
Therapeutic CT-1 compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
The route of CT-l or CT-I antibody administration is in accord with known methods, injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial, or intralesional routes, or by sustained-release systems as noted below. CT-1 is administered continuously by infusion or by bolus injection. CT-I antibody is administered in the same fashion, or by administration into the blood stream or lymph. Most preferably, CT-I or its antagonist is administered locally or site-specifically to better obtain a local or site-specific effect. Such suitable delivery methods are known in the art including implants, pumps, patches, direct injection, and transmucosal delivery. Site-specific delivery can be obtained by gene delivery vectors and viruses and by transplantation of cells expressing CT-I or an antagonist.
Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the protein, which matrices are in the form of shaped articles, films, or 20, microcapsules. Examples of sustained-release matrices include polyesters, hydrogels poly(2-hydroxyethylmethacrylate) as described by Langer et al., J. Biomed. Mater. Res.. 15: 167-277 (1981) and Langer, Chem.
Tgch.. 12: 98-105 (1982) or poly(vinylalcohol)), polylactides Patent No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman et al., Biopolvmers, 22: 547-556 (1983)), non-degradable ethylene-vinyl acetate (Langer et al., supra), degradable lactic acid-glycolic acid copolymers 25 such as the Lupron DepotTM (injectable microspheres composed of lactic acid-glycolic acid copolymer and .leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid (EP 133,988).
While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated proteins remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37* C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for protein stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.
Sustained-release CT-1 compositions also include liposomally entrapped CT-I. Liposomes containing CT-1 are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. USA, 82: 3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA, 2: 4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese patent application 83-118008; U.S. Patent Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. cholesterol, the selected proportion being adjusted for the optimal CT-I therapy.
An effective amount of CT-I to be employed therapeutically will depend, for example, upon the therapeutic objectives, the route of administration, and the condition of the patient. Accordingly, it will be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect. A typical daily dosage might range from about 1 pg/kg to up to 100 mg/kg of patient body weight or more per day, depending on the factors mentioned above, preferably about 10 pg/kg/day to mg/kg/day. Typically, the clinician will administer CT-I until a dosage is reached that achieves the desired effect for treatment of the heart, neural, or other dysfunction. For example, the amount would be one which increases ventricular contractility and decreases peripheral vascular resistance or ameliorates or treats conditions of similar importance in congestive heart failure patients. The progress of these therapies is easily monitored by conventional assays.
4. CT-I Antibody Preparation Starting Materials and Methods Immunoglobulins (Ig) and certain variants thereof are known and many have been prepared in recombinant cell culture. For example, see U.S. Patent No. 4,745,055; EP 256,654; EP 120,694; EP 125,023; EP 255,694; EP 266,663; WO 88/03559; Faulkner et al., Nature, 298: 286 (1982); Morrison, J. Immun., 123: 793 (1979); Koehler et al., Proc. Natl. Acad. Sci. USA, 72: 2197 (1980); Raso et al., Cancer Res., 41: 2073 (1981); Morrison etal., Ann. Rev. Immunol., 2:239 (1984); Morrison, Science, 222: 1202 (1985); and Morrison 20 et al., Proc. Natl. Acad. Sci. USA, 81: 6851 (1984). Reassorted immunoglobulin chains are also known. See, for example, U.S. Patent No. 4,444,878; WO 88/03565; and EP 68,763 and references cited therein. The i immunoglobulin moiety in the chimeras of the present invention may be obtained from IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA, IgE, IgD, or IgM, but preferably from IgG-1 or IgG-3.
(ii) Polyclonal antibodies 25 Polyclonal antibodies to CT-I polypeptides or CT-1 fragments are generally raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of CT-I or CT-I fragment and an adjuvant. It may be useful to conjugate CT-1 or a fragment containing the target amino acid sequence to a protein that is immunogenic in the species to be immunized, keyhole limpet hemocyanin, serum albumin, bovine i thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride, SOCI 2 or RIN=C=NR, where R and R 1 are different alkyl groups.
Animals are immunized against the CT-1 polypeptide or CT-I fragment, immunogenic conjugates, or derivatives by combining 1 mg or 1 pg of the peptide or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later the animals are boosted with 1/5 to 1/10 the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later the animals are bled and the serum is assayed for CT-1 or CT-I fragment antibody titer. Animals are boosted until the titer plateaus. Preferably, the animal is boosted with the conjugate of the same CT-I or CT-I fragment, but conjugated to a different protein -56and/or through a different cross-linking reagent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are suitably used to enhance the immune response.
(iii) Monoclonal antibodies Monoclonal antibodies are obtained from a population of substantially homogeneous antibodies, i.e., S the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Thus, the modifier "monoclonal" indicates the character of the antibody as not being a mixture of discrete antibodies.
For example, the CT-1 monoclonal antibodies of the invention may be made using the hybridoma method first described by Kohler and Milstein, Nature, 256: 495 (1975), or may be made by recombinant DNA methods (Cabilly et al., supra).
In the hybridoma method, a mouse or other appropriate host animal, such as a hamster, is immunized as hereinabove described to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the CSF or CSF fragment used for immunization. Alternatively, lymphocytes may be immunized in vitro. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp.59- 103 [Academic Press, 1986)).
The hybridoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphorib,osyl transferase .i 20 (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.
Preferred myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. Among these, preferred myeloma cell lines are murine myeloma lines, such as those derived from MOPC-21 and MPC-11 25 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego, California USA, and SP-2 cells available from the American Type Culture Collection, Rockville, Maryland USA.
Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against CT-I. Preferably, the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).
The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107: 220 (1980).
After hybridoma cells are identified that produce antibodies of the desired specificity, affinity, and/or activity, the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, supra). Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium. In addition, the hybridoma cells may be grown in vivo as ascites tumors in an animal.
The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxyapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
-57- DNA encoding the monoclonal antibodies of the invention is readily isolated and sequenced using conventional procedures by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. Review articles on recombinant expression in bacteria of DNA encoding the antibody include Skerra et al., Curr. Opinion in Immunol., 5: 256-262 (1993) and Pltckthun, Immunol. Revs., 13: 151-188 (1992).
The DNA also may be modified, for example, by substituting the coding sequence for human heavyand light-chain constant domains in place of the homologous murine sequences (Morrison; et al., Proc. Nat.
Acad. Sci., 8: 6851 (1984)), or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. In that manner, "chimeric" or "hybrid" antibodies are prepared that have the binding specificity of an anti-CT-1 monoclonal antibody herein.
Typically such non-immunoglobulin polypeptides are substituted for the constant domains of an antibody of the invention, or they are substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for a CT-I and another antigen-combining site having specificity for a different antigen.
S* Chimeric or hybrid antibodies also may be prepared in vitro using known methods in synthetic protein 20 chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disulfide-exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate.
For diagnostic applications, the antibodies of the invention typically will be labeled with a detectable moiety. The detectable moiety can be any one which is capable of producing, either directly or indirectly, a 25 detectable signal. For example, the detectable moiety may be a radioisotope, such as 3H, 14C, 32 p, 3 5 S, or 1251; a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin; radioactive isotopic labels, such as, 1251, 3 2 p, 14 C, or 3 H; or an enzyme, such as alkaline phosphatase, beta-galactosidase, or horseradish peroxidase.
Any method known in the art for separately conjugating the antibody to the detectable moiety may be employed, including those methods described by Hunter et al., Nature, 14: 945 (1962); David et al., Biochemistry. 1: 1014 (1974); Pain et al., J. Immunol. Meth.. 40:219 (1981); and Nygren, J. Histochem. and Cvtochem.. 30: 407 (1982).
The antibodies of the present invention may be employed in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays. Zola, Monoclonal Antibodies: A Manual of Techniques. pp. 147-158 (CRC Press, Inc., 1987).
Competitive binding assays rely on the ability of a labeled standard (which may be a CT-1 or an immunologically reactive portion thereof) to compete with the test sample analyte (CT-I) for binding with a limited amount of antibody. The amount of CT-I in the test sample is inversely proportional to the amount of standard that becomes bound to the antibodies. To facilitate determining the amount of standard that becomes -58bound, the antibodies generally are insolubilized before or after the competition, so that the standard and analyte that are bound to the antibodies may conveniently be separated from the standard and analyte which remain unbound.
Sandwich assays involve the use of two antibodies, each capable of binding to a different immunogenic portion, or epitope, of the protein (CT-1) to be detected. In a sandwich assay, the test sample analyte is bound by a first antibody which is immobilized on a solid support, and thereafter a second antibody binds to the analyte, thus forming an insoluble three-part complex. David and Greene, U.S. Patent No. 4,376,110. The second antibody may itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using an anti-immunoglobulin antibody that is labeled with a detectable moiety (indirect sandwich assay). For example, e* one type of sandwich assay is an ELISA assay, in which case the detectable moietyis an enzyme horseradish peroxidase).
(iv) Humanized antibodies Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These nonhuman amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers (Jones et al., Nature 32j, 522-525 (1986); Riechmann et al., Nature 32, 323-327 (1988); V'erhoeyen et al., o Science 229, 1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (Cabilly et o. 20 al., supra), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
The choice of human variable domains, both light and heavy, to be used in making the humanized 25 antibodies is very important to reduce antigenicity. According to the so-called "best-fit" method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variabledomain sequences. The human sequence which is closest to that of the rodent is then accepted as the human framework (FR) for the humanized antibody (Sims et al., J. Immunol.. 11: 2296 (1993); Chothia and Lesk, L Mol, Biol., 196: 901 (1987)). Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies (Carter et al., Proc. Natl. Acad. Sci. USA, 8: 4285 (1992); Presta et al., J.Immnol., 151: 2623 (1993)).
It is further important that antibodies be humanized with retention of high affinity for the antigen and other favorable biological properties. To achieve this goal, according to a preferred method, humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the -59residues in the functioning of the candidate immunoglobulin sequence, the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the consensus and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved. In general, the CDR residues are directly and most substantially involved in influencing antigen binding.
Human antibodies Human monoclonal antibodies can be made by the hybridoma method. Human myeloma and mousehuman heteromyeloma cell lines for the production of human monoclonal antibodies have been described, for example, by Kozbor, J. Immunol. 1. 3001 (1984); Brodeur, et al., Monoclonal Antibody Production Techniques and Applications, pp.
5 1-63 (Marcel Dekker, Inc., New York, 1987); and Boemer et al., J. Immunol., 147: 86-95 (1991).
It is now possible to produce transgenic animals mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production. For example, it has been described that the homozygous deletion of the antibody heavy-chain joining region (JH) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production.
Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge. See, Jakobovits et al., Proc. Natl. Acad. Sci. USA, 2551 (1993); Jakobovits etal., Nature, 362: 255-258 (1993); Bruggermann et al., Year in Immuno., 2: 33 (1993).
20 Alternatively, the phage display technology (McCafferty et al., Nature, 348: 552-553 (1990)) can be used to produce human antibodies and antibody fragments in vitro, from immunoglobulin variable domain gene repertoires from unimmunized donors. According to this technique, antibody V domain genes are cloned *in-frame into either a major or minor coat protein gene of a filamentous bacteriophage, such as M 13 or fd, and displayed as functional antibody fragments on the surface of the phage particle. Because the filamentous particle 25 contains a single-stranded DNA copy of the phage genome, selections based on the functional properties of the antibody also result in selection of the gene encoding the antibody exhibiting those properties. Thus, the phage mimicks some of the properties of the B-cell. Phage display can be performed in a variety of formats; for their review see, Johnson, Kevin S. and Chiswell, David Current Opinion in Structural Biology, 3: 564-571 (1993). Several sources of V-gene segments can be used for phage display. Clackson et al., Nature, 352: 624- 628 (1991) isolated a diverse array of anti-oxazolone antibodies from a small random combinatorial library of V genes derived from the spleens of immunized mice. A repertoire of V genes from unimmunized human donors can be constructed and antibodies to a diverse array of antigens (including self-antigens) can be isolated essentially following the techniques described by Marks et al., J. Mol. Biol., 222: 581-597 (1991), or Griffith et al., EMBO J. 12: 725-734 (1993).
In a natural immune response, antibody genes accumulate mutations at a high rate (somatic hypermutation). Some of the changes introduced will confer higher affinity, and B cells displaying high-affinity surface immunoglobulin are preferentially replicated and differentiated during subsequent antigen challenge.
This natural process can be mimicked by employing the technique known as "chain shuffling" (Marks et al., Bio/Technol., 1Q: 779-783 (1992)). In this method, the affinity of"primary" human antibodies obtained by phage display can be improved by sequentially replacing the heavy and light chain V region genes with repertoires of naturally occurring variants (repertoires) of V domain genes obtained from unimmunized donors.
This technique allows the production of antibodies and antibody fragments with affinities in the nM range. A strategy for making very large phage antibody repertoires has been described by Waterhouse et al., Nucl. Acids Res., 21: 2265-2266 (1993).
Gene shuffling can also be used to derive human antibodies from rodent antibodies, where the human antibody has similar affinities and specificities to the starting rodent antibody. According to this method, which is also referred to as "epitope imprinting", the heavy or light chain V domain gene of rodent antibodies obtained by phage display technique is replaced with a repertoire of human V domain genes, creating rodent-human chimeras. Selection on antigen results in isolation of human variable capable of restoring a functional antigenbinding site, i.e. the epitope governs (imprints) the choice of partner. When the process is repeated in order to replace the remaining rodent V domain, a human antibody is obtained (see PCT WO 93/06213, published 1 April 1993). Unlike traditional humanization of rodent antibodies by CDR grafting, this technique provides completely human antibodies, which have no framework or CDR residues of rodent origin.
(vi) Bispecific antibodies Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding Sospecificities for at least two different antigens. In the present case, one of the binding specificities is for a CT-1, the other one is for any other antigen, and preferably for another ligand that binds to a GH/cytokine receptor family member. For example, bispecific antibodies specifically binding a CT-I and neurotrophic factor, or two 20 different types of CT-1 polypeptides are within the scope of the present invention.
Methods for making bispecific antibodies are known in the art.
Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy chain-light chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, Nature, 305: 537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of 10 different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and the product yields are low. Similar procedures are disclosed in WO 93/08829 published 13 May 1993, and in Traunecker et al., EMBO 10: 3655-3659 (1991).
30 According to a different and more preferred approach, antibody-variable domains with the desired binding specificities (antibody-antigen combining sites) are fused to immunoglobulin constant-domain sequences.
The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CHI), containing the site necessary for light-chain binding, present in at least one of the fusions. DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. This provides for great flexibility in adjusting the mutual proportions of the three polypeptide fragments in embodiments when unequal ratios of the three polypeptide chains used in the construction provide the optimum yields. It is, however, possible to insert the coding sequences for two or all three polypeptide chains in one expression vector when the production of at -61least two polypeptide chains in equal ratios results in high yields or when the ratios are of no particular significance. In a preferred embodiment of this approach, the bispecific antibodies are composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. It was found that this asymmetric structure facilitates the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations, as the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides for a facile way of separation. For further details of generating bispecific antibodies, see, for example, Suresh et Methods in Enzymology, 121: 210 (1986).
(vii) Heteroconjugate antibodies Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalentlyjoined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/00373; and EP 03089). Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in U.S. Pate-.
No. 4,676,980, along with a number of cross-linking techniques.
5. Uses ofCT-1 Antibodies CT-1 antibodies are useful in diagnostic assays for CT-1, its production in specific cells, tissues, or serum. The antibodies are labeled in the same fashion as CT-1 described above and/or are immobilized on an insoluble matrix. In one embodiment of a receptor-binding assay, an antibody compositionthat binds to all 20 or a selected plurality of CT-Is is immobilized on an insoluble matrix, the test sample is contacted with the immobilized antibody composition to adsorb all CT-is, and then the immobilized CT-Is are contacted with a plurality of antibodies specific for each CT-1, each of the antibodies being individually identifiable as specific for a predetermined CT-1, as by unique labels such as discrete fluorophores or the like. By determining the presence and/or amount of each unique label, the relative proportion and amount of each CT-1 can be determined.
The antibodies of this invention are also useful in passively immunizing patients.
CT-I antibodies also are useful for the affinity purification of CT-I from recombinant cell culture or natural sources. CT-I antibodies that do not detectably cross-react with the rat CT-1 can purify CT-1 free from such protein.
Suitable diagnostic assays for CT-I and its antibodies are well known per se. In addition to the bioassays described in the examples below wherein the candidate CT-I is tested to see if it has hypertrophic, antiarrhythmic, inotropic, or neurotrophic activity, competitive, sandwich and steric inhibition immunoassay techniques are useful. The competitive and sandwich methods employ a phase-separation step as an integral part of the method, while steric inhibition assays are conducted in a single reaction mixture. Fundamentally, the same procedures are used for the assay of CT-1 and for substances that bind CT-1, although certain methods will be favored depending upon the molecular weight of the substance being assayed. Therefore, the substance to be tested is referred to herein as an analyte, irrespective of its status otherwise as an antigen or antibody, and proteins that bind to the analyte are denominated binding partners, whether they be antibodies, cell-surface receptors, or antigens.
-62- Analytical methods for CT-1 or its antibodies all use one or more of the following reagents: labeled analyte analogue, immobilized analyte analogue, labeled binding partner, immobilized binding partner, and steric conjugates. The labeled reagents also are known as "tracers." The label used (and this is also useful to label CT-I nucleic acid for use as a probe) is any detectable functionality that does not interfere with the binding of analyte and its binding partner. Numerous labels are known for use in immunoassay, examples including moieties that may be detected directly, such as fluorochrome, chemiluminscent, and radioactive labels, as well as moieties, such as enzymes, that must be reacted or derivatized to be detected. Examples of such labels include the radioisotopes 32 p, 14C, 125, 3 H, and 1311; fluorophores such as rare earth chelates or fluorescein and its derivatives; rhodamine and its derivatives; dansyl; umbelliferone; luciferases, firefly luciferase and bacterial luciferase Patent No: 4,737,456); luciferin; 2,3-dihydrophthalazinediones; malate dehydrogenase; urease; peroxidase such as horseradish peroxidase (HRP); alkaline phosphatase; P-galactosidase; glucoamylase; lysozyme; saccharide oxidases, glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase; heterocyclic oxidases such as uricase and xanthine oxidase, coupled with an enzyme that employs hydrogen peroxide to oxidize a dye precursor such as HRP, lactoperoxidase, or microperoxidase; biotin/avidin; spin labels; bacteriophage labels; stable free radicals; and the like.
Those of ordinary skill in the art will know of other suitable labels that may be employed in accordance with the present invention. The binding of these labels to CT-1, antibodies, or fragments thereof can be accomplished using standard techniques commonly known to those of ordinary skill in the art. For instance, 20 coupling agents such as dialdehydes, carbodiimides, dimaleimides, bis-imidates, bis-diazotized benzidine, and the like may be used to tag the polypeptide with the above-described fluorescent, chemiluminescent, and enzyme labels. See, for example, U.S. Patent Nos. 3,940,475 (fluorimetry) and 3,645,090 (enzymes); Hunter et al., Nature, 144: 945 (1962); David et al., Biochemistry, 1014-1021 (1974); Pain etal., J. Immunol. Methods, 40: 219-230 (1981); Nygren, J. Histochem. and Cvtochem., 2: 407-412 (1982); O'Sullivan et al., "Methods for the Preparation of Enzyme-antibody Conjugates for Use in Enzyme Immunoassay," in Methods in Enzvmology, ed. J.J. Langone and H. Van Vunakis, Vol. 73 (Academic Press, New York, New York, 1981), pp. 147-166; Kennedy et al., Clin. Chim. Acta, 70: 1-31 (1976); and Schurs et al., Clin. Chim. Acta, 81: 1-40 (1977).
Coupling techniques mentioned in the lattermost reference are the glutaraldehyde method, the periodate method, the dimaleimide method, and the m-maleimidobenzyl-N-hydroxysuccinimide ester method.
30 In the practice of the present invention, enzyme labels are a preferred embodiment. No single enzyme is ideal for use as a label in every conceivable assay. Instead, one must determine which enzyme is suitable for a particular assay system. Criteria important for the choice of enzymes are tumover number of the pure enzyme (the number of substrate molecules converted to product per enzyme site per unit of time), purity of the enzyme preparation, sensitivity of detection of its product, ease and speed of detection of the enzyme reaction, absence of interfering factors or of enzyme-like activity in the test fluid, stability of the enzyme and its conjugate, availability and cost of the enzyme and its conjugate, and the like. Included among the enzymes used as preferred labels in the assays of the present invention are alkaline phosphatase, HRP, beta-galactosidase, urease, glucose oxidase, glucoamylase, malate dehydrogenase, and glucose-6-phosphate dehydrogenase. Urease is -63among the more preferred enzyme labels, particularly because of chromogenic pH indicators that make its activity readily visible to the naked eye.
Immobilization of reagents is required for certain assay methods. Immobilization entails separating the binding partner from any analyte that remains free in solution. This conventionally is accomplished by either insolubilizing the binding partner or analyte analogue before the assay procedure, as by adsorption to a waterinsoluble matrix or surface (Bennich et al., U.S. Patent No. 3,720,760), by covalent coupling (for example, using glutaraldehyde cross-linking), or by insolubilizing the partner or analogue afterward, by immunoprecipitation.
Other assay methods, known as competitive or sandwich assays, are well established and widely used in the commercial diagnostics industry.
Competitive assays rely on the ability of a tracer analogue to compete with the test sample analyte for a limited number of binding sites on a common binding partner. The binding partner generally is insolubilized before or after the competition and then the tracer and analyte bound to the binding partner are separated from the unbound tracer and analyte. This separation is accomplished by decanting (where the binding partner was preinsolubilized) or by centrifuging (where the binding partner was precipitated after the competitive reaction).
The amount of test sample analyte is inversely proportional to the amount of bound tracer as measured by the amount of marker substance. Dose-response curves with known amounts of analyte are prepared and compared with the test results to quantitatively determine the amount of analyte present in the test sample. These assays are called ELISA systems when enzymes are used as the detectable markers.
20 Another species of competitive assay, called a "homogeneous" assay, does not require a phase separation. Here, a conjugate of an enzyme with the analyte is prepared and used such that when anti-analyte binds to the analyte, the presence of the anti-analyte modifies the enzyme activity. In this case, CT-1 or its immunologically active fragments are conjugated with a bifunctional organic bridge to an enzyme such as peroxidase. Conjugates are selected for use with anti-CT-I so that binding of the anti-CT-I inhibits or 25 potentiates the enzyme activity of the label. This method per se is widely practiced under the name of EMIT.
Steric conjugates are used in steric hindrance methods for homogeneous assay. These conjugates are synthesized by covalently linking a low-molecular-weight hapten to a small analyte so that antibody to hapten 99,9 substantially is unable to bind the conjugate at the same time as anti-analyte. Under this assay procedure the *9 analyte present in the test sample will bind anti-analyte, thereby allowing anti-hapten to bind the conjugate, resulting in a change in the character of the conjugate hapten, a change in fluorescence when the hapten is a fluorophore.
Sandwich assays particularly are useful for the determination of CT-1 or CT-I antibodies. In sequential sandwich assays an immobilized binding partner is used to adsorb test sample analyte, the test sample is removed as by washing, the bound analyte is used to adsorb labeled binding partner, and bound material is then separated from residual tracer. The amount of bound tracer is directly proportional to test sample analyte. In "simultaneous" sandwich assays the test sample is not separated before adding the labeled binding partner. A sequential sandwich assay using an anti-CT-1 monoclonal antibody as one antibody and a polyclonal anti-CT-1 antibody as the other is useful in testing samples for CT-1 activity.
-64- The foregoing are merely exemplary diagnostic assays for CT-I and antibodies. Other methods now or hereafter developed for the determination of these analytes are included within the scope hereof, including Sthe bioassays described above.
The following examples are offered by way of illustration and not by way of limitation. The disclosures of all citations in the specification are expressly incorporated herein by reference.
EXAMPLE I Identification and In Vitro Activity of a CT-I A. Assay for Expression-Cloned Material The assay used for hypertrophy is an in vitro neonatal rat heart hypertrophy assay described in general as follows: 1. Preparation of the Mvocvte Cell Suspension The preparation of the myocyte cell suspension is based on methods outlined in Chien et al., J. Clin.
Invest., 75: 1770-1780 (1985) and Iwaki et al., supra. Ventricles from the hearts of 1-2 day Sprague-Dawley rat pups were removed and trisected. The minced ventricles were digested with a series of sequential collagenase treatments. Purification of the resulting single-cell suspension on a discontinuous Percoll gradient resulted in a suspension of 95% pure myocytes.
2. Plating and Culture of the Mvocvtes Two published methods for plating and culturing the myocytes are as follows: Long et al., supra, preplated the cell suspension for 30 min. in MEM/5% calf serum. The unattached myocytes were then plated 20 in serum-free MEM supplemented with insulin, transferrin, BrdU, and bovine serum albumin in 35-mm tissueculture dishes at a density of 7.5 x 104 cells per mL. Iwaki et al., supra, plated the cell suspension in D- MEM/199/5% horse serum/5% fetal calf serum in 10-cm tissue-culture dishes at 3 x 105 cells per mL. After 24 hr in culture the cells were washed and incubated in serum-free D-MEM/199.
A different protocol has been developed in accordance with this invention for plating and culturing these 25 cells to increase testing capacity with a miniaturized assay. The wells of 96-well tissue-culture plates are precoated with D-MEM/F12/4% fetal calf serum for 8 hr at 37C. This medium is removed and the cell suspension is plated in the inner 60 wells at 7.5 x 104 cells per mL in D-MEM/F-12 supplemented with insulin, transferrin, and aprotinin. The medium typically also contains an antibiotic such as penicillin/streptomycin and glutamine. This medium allows these cells to survive at this low plating density without serum. Test substances are added directly into the wells after the cells have been in culture for 24 hours.
3. Readout of Hypertrophy After stimulation with alpha adrenergic agonists or endothelin, neonatal rat myocardial cells in culture display several features of the in vivo cardiac muscle cell hypertrophy seen in congestive heart failure, including an increase in cell size and an increase in the assembly of an individual contractile protein into organized contractile units. Chien et al., FASEB supra. These changes can be viewed with an inverted phase microscope and the degree of hypertrophy scored with an arbitrary scale of 7 to 0, with 7 being fully hypertrophied cells and 3 being non-stimulated cells. The 3 and 7 states may be seen in Simpson et al., Circulation Research, 51: 787-801 (1982), Figure 2, A and B, respectively. To facilitate the microscopic readout of the 96-well cultures and to generate a permanent record, the myocytes are fixed and stained after the appropriate testing period with crystal violet stain in methanol. Crystal violet is a commonly used protein stain for cultured cells.
Additionally, an aliquot can be taken from the 96-well plates and monitored for the expression of protein markers of the response such as release of ANF or ANP.
B. Expression Cloning Poly(A) RNA was isolated (Aviv and Leder, Proc. Natl. Acad. Sci. USA, 69: 1408-1412 (1972); Cathala et al., DNA, 2: 329-335 (1983)) from day 7 mouse embryoid bodies. Embryoid bodies were generated by the differentiation of pluripotent embryonic stem (ES) cells (Doetschman et al., J. Embrvol. Exp. Morphol., 87: 27-45 (1985)). The embryonic stem cell line ES-D3 (ATCC No. CRL 1934) was maintained in an undifferentiated state in a medium containing LIF (Williams et al., Nature, 336: 684-687 (1988)). This medium contained D-MEM (high glucose), 1% glutamine, 0.1 mM 2-mercaptoethanol, penicillin-streptomycin, 15% heatinactivated fetal bovine serum, and 15 ng/mL mouse LIF. When these cells were put into suspension culture in the same medium without LIF and containing 20% heat-inactivated fetal bovine serum (day they aggregated and differentiated into multicellular structures called embryoid bodies. By day 8 of culture, beating primordial heart-like structures formed on a fraction of the bodies. The embryoid bodies were evaluated for the production of CT-I activity by changing the differentiating ES cells to serum-free medium (D-MEM/F-12, 1% glutamine, penicillin-streptomycin, containing 0.03% bovine serum albumin) for a 24-hour accumulation. Prior to assay, the conditioned medium was concentrated 10 fold with a 3-K ultrafiltration membrane (Amicon), and dialyzed against assay medium. Medium conditioned for 24 hours starting at day 3 gave a hypertrophy score of 4.5-5.5, and starting at day 6 a score of 5.5-7.5.
A cDNA library in the plasmid expression vector, pRK5B (Holmes et al., Science, 25: 1278-1280 (1991)), was prepared following a vector priming strategy (Strathdee et al., Nature, 356: 763-767 (1992)). The vector, pRK5B, was linearized at the NotI site, treated with alkaline phosphatase, and ligated to the singlestranded oligonucleotide, ocdl. 1.3, having the sequence: 25 5'-GCGGCCGCGAGCTCGAATTCTrI 1 I111 11 1 I I 11 I T1 11 III IIIIT (SEQ ID NO: The ligated product was then cut with BstXI, and the 4700-bp vector fragment was isolated by agarose gel electrophoresis. The vector was further purified by oligo dA chromatography.
The expression library was constructed using 1 pg of the poly (A) RNA, 5 pg of vector primer, and reagents from Amersham. Following first- and second-strand synthesis and T4 DNA polymerase fill-in reactions, the material was sized for inserts of greater than 500 bp by gel electrophoresis and circularized by blunt-end ligation without the addition of linkers. The ligations were used to transform E. coli strain DH5a by electroporation. From 1 pg of poly(A) RNA, 499 ng of double-stranded cDNA were generated. Seventeen nanograms of cDNA were ligated, and 3.3 ng were transformed to yield 780,000 clones, 83% of which had inserts with an average size of 1470 bp.
DNA was isolated from pools of 75-15,000 clones and transfected into human embryonic kidney 293 cells by Lipofectamine transfection (Gibco BRL). Two micrograms of DNA were used to transfect -200,000 cells in 6-well dishes. The cells were incubated in 2 mL of serum-free assay medium for four days. This medium consisted of 100 mL D-MEM/F-12, 100 pL transferrin (10 mg/mL), 20 pL insulin (5 mg/mL), 50 pL aprotinin (2 mg/mL), I mL pen/strep (JRH Biosciences No. 59602-77P), and 1 mL L-glutamine (200 mM). Transfection -66and expression efficiency was monitored by the inclusion of 0.2 pg of DNA for a plasmid expressing a secreted form of alkaline phosphatase (Tate et al., FASEB 4: 227-231 (1990)).
One hundred microliters of conditioned culture medium from each transfected pool was assayed for hypertrophy in a final volume of 200 pL. For some pools the conditioned medium was concentrated 4-5 fold before assay with Centricon 3TM microconcentrators (Amicon). Ninety pools of 10,000-15,000 clones, 359 pools of 1000-5800 clones, and 723 pools of 75-700 clones were transfected and assayed for hypertrophy activity. Of these 1172 pools, two were found to be positive. Pool 437 (a pool of 187 clones) and pool 781 (a pool of 700 clones) gave scores of 4. A pure clone (designated pchf.437.48) from pool 437 was isolated by retransfection of positive pools containing fewer and fewer numbers of clones until a single clone was obtained. A pure clone from pool 781 (designated pchf.781) was isolated by colony hybridization to the insert from clone pchf.437.48.
The sequence for the insert of clone pchf.781 is provided in Figure 1 (SEQ ID NOS: 2, and 3 for the two nucleotide strands and amino acid sequence, respectively). The sequence of the insert of clone pchf.437.48 matches clone 781 starting at base 27 (underlined).
The first open reading frame of clone pchf.781 (see translation, Fig. 1) encodes a protein of 203 amino acids (translated MW 21.5 kDa). This protein contains one cysteine residue, one potential N-linked glycosylation site, and no hydrophobic N-terminal secretion signal sequence. The 3' untranslated region of clone pchf.781 contains a common mouse repeat known as bl (bp -895-1015). Hybridization of 7-day embryoid body poly(A) RNA with a probe from clone pchf.781 shows a single band of -1.4 kb, which is about the same size S2 as the insert from the cDNA clones.
The encoded sequence is not highly similar 35% amino acid identity) to any known protein sequences in the Dayhoff database. It does, however, show a low degree of similarity to a family of distantly related proteins including CNTF, interleukin-6 interleukin-11 (IL-11), LIF, and oncostatin M (OSM) (Bazan, SNeuron, 197-208 (1991)). Mouse CT-1 has 24% amino acid identity with mouse LIF (Rose and Todaro, WO 93/05169) and 21% amino acid identity with human CNTF (McDonald et al., Biochim. Biophvs. Acta, 1090: 25 70-80(1991)). See Figure 2 for an alignment of mouse CT-I and human CNTF sequences. CNTF, IL-6, IL-11, LIF, and OSM use related receptor signaling proteins including gpl30 that are members of the GH/cytokine receptor family (Kishimoto et al., Cell, 76: 253-262 (1994)). CNTF, like CT-1, lacks an N-terminal secretion signal sequence.
C. Identity and Activity of Clone To demonstrate that clone pchf.781 encodes a CT-I, expression studies were performed both by transfection of 293 cells and by utilizing a coupled in vitro SP6 transcription/translation system. 3 5 S-methionine and cysteine labeling of the proteins produced by pchf.78 1-transfected 293 cells (in comparison with vectortransfected cells) showed that the conditioned medium contained a labeled protein of about 21.8 kDa, and that the cell extract showed a protein of 22.5 kDa. Conditioned media from these transfections gave a morphology score of 6 when assayed for cardiac hypertrophy at a dilution of 1:4 using the assay described above.
Conditioned media from unlabeled transfections gave a morphology score of 5.5-6.5 at a dilution of 1:1.
These assays were also positive for a second measure of cardiac hypertrophy-ANP release. See Figure 3. This assay was performed by determination of the competition for the binding of 12 5 -rat ANP for a rat ANP receptor A-IgG fusion protein. This method is similar to that used for the determination ofgpl20 using a CD4- -67- IgG fusion protein (Chamow et al., Biochemistry, 2: 9885-9891 (1990)). Briefly, microtiter wells were coated with 100 pL of rat anti-human IgG antibody (2 pg/mL) overnight at 4* C. After washing with phosphate-buffered saline containing 0.5% bovine serum albumin, the wells were incubated with 100 pL of 3 ng/mL rat ANP receptor A-IgG (produced and purified in a manner analogous to the human ANP receptor A-IgG (Bennett et al., J. Biol. Chem., 266: 23060-23067 (1991)) for one hour at 24* C. The wells were washed and incubated with pL of rat ANP standard or sample for one hour at 240 C. Then 50 pL of 12 5 I-rat ANP (Amersham) was added for an additional one-hour incubation. The wells were washed and counted to determine the extent of binding competition. ANP concentrations in the samples were determined by comparison to a rat ANP standard curve.
3 5 S-methionine labeling of the proteins made by SP6-coupled in vitro transcription/translation (materials from Promega) of clone pchf.781 showed a labeled protein of 22.4 kDa. The labeled translation product was active when assayed for cardiac hypertrophy at a dilution of 1:200 (morphology score To verify that the 22.4-kDa-labeled band was responsible for the hypertrophy activity, the labeled translation product was applied to a reverse-phase C4 column (Synchropak RO-4-4000) equilibrated in 10% acetonitrile, 0.1% TFA.
and eluted with an acetonitrile gradient. Coincident peaks of labeled protein and hypertrophy activity eluted from this column at -55% acetonitrile.
A cardiac myocyte hypertrophy activity has been reported and partially purified from rat cardiac fibroblasts. Long et al., supra. To investigate further the identity of the CT-1 herein, rat cardiac fibroblasts were S.cultured. Conditioned medium from these primary cultures does have cardiac hypertrophy in the in vitro neonatal rat heart hypertrophy assay herein. Blot hybridization of rat fibroblast mRNA isolated from these cultures shows a clear band of 1.4 kb when probed with a coding region fragment of clone pchf.781.
(Hybridization was performed in 5 x SSC, 20% formamide at 42* C with a final wash in 0.2 x SSC at 50* C.) D. Purification of Factor The culture medium conditioned by cells transfected with clone pchf.781 or a human clone is adjusted to 1.5 M NaCI and applied to a ToyopearlTM Butyl-650M column. The column is washed with 10 mM TRIS- HC1, pH 7.5, 1 M NaCI, and the activity eluted with 10 mM TRIS-HCI, pH 7.5, 10 mM ZwittergentTM 3-10. The peak of activity is adjusted to 150 mM NaCI, pH 8.0, and applied to a MONO-Q Fast Flow column. The column is washed with 10 mM TRIS-HCI, pH 8.0, 150 mM NaCI, 0.1% octyl glucoside and activity is found in the flowthrough fraction. The active material is then applied to a reverse phase C4 column in 0.1% TFA, acetonitrile, and eluted with a gradient of 0.1% TFA up to 80%. The activity fractionates at about 15-30 kDa on gel-filtration columns. It is expected that a chaotrope such as guanidine-HCI is required for resolution and recovery.
EXAMPLE II Testing for in vivo Hypertrophy Activity A. Normal Rats The purified CT-1 from Example I is tested in normal rats to observe its effect on cardiovascular parameters such as blood pressure, heart rate, systemic vascular resistance, contractility, force of heart beat, concentric or dilated hypertrophy, left ventricular systolic pressure, left ventricular mean pressure, left ventricular end-diastolic pressure, cardiac output, stroke index, histological parameters, ventricular size, wall thickness, etc.
-68- B. Pressure-Overload Mouse Model The purified CT-1 is also tested in the pressure-overload mouse model wherein the pulmonary artery is constricted, resulting in right ventricular failure.
C. RV Murine Dysfunctional Model A retroviral murine model of ventricular dysfunction can be used to test the purified CT-1, and the dP/dt, ejection fraction, and volumes can be assayed with the hypertrophy assay described above. In this model, the pulmonary artery of the mouse is constricted so as to generate pulmonary hypertrophy and failure.
D. Transgenic Mouse Model Transgenic mice that harbor a muscle actin promoter-IGF-I fusion gene display cardiac and skeletal muscle hypertrophy, without evidence of myopathy or heart failure. Further, IGF-I- gene-targeted mice display defects in cardiac myogenesis (as well as skeletal) including markedly decreased expression of ventricular muscle contractile protein genes. The purified CT-1 is tested in these two models.
Additional genetic-based models of dilated cardiomyopathy and cardiac dysfunction, without necrosis, can be developed in transgenic and gene-targeted mice (MLC-ras mice; aortic banding of heterozygous IGF-Ideficient mice).
SE. Post-Myocardial Infarction Rat Model The purified CT-1 is also tested in a post-myocardial infarction rat model, which is predictive of human congestive heart failure in producing natriuretic peptide. Specifically, male Sprague-Dawley rats (Charles River S2 Breeding Laboratories, Inc., eight weeks of age) are acclimated to the facility for at least one week before surgery. Rats are fed a pelleted rat chow and water ad libitum and housed in a light- and temperature-controlled room.
1. Coronary Arterial Ligation ~Myocardial infarction is produced by left coronary arterial ligation as described by Greenen et al., J.
Appl. Phvsiol., 21: 92-96 (1987) and Buttrick et al., Am. J. Phvsiol., 260: 11473-11479 (1991). The rats.are 25 anesthetized with sodium pentobarbital (60 mg/kg, intraperitoneally), intubated via tracheotomy, and ventilated by a respirator (Harvard Apparatus Model 683). After a left-sided thoracotomy, the left coronary artery is ligated approximately 2 mm from its origin with a 7-0 silk suture. Sham animals undergo the same procedure except that the suture is passed under the coronary artery and then removed. All rats are handled according to the "Position of the American Heart Association on Research Animal Use" adopted 11 November 1984 by the American Heart Association. Four to six weeks after ligation, myocardial infarction could develop into heart failure in rats.
In clinical patients, myocardial infarction or coronary artery disease is the most common cause of heart failure. Congestive heart failure in this model reasonably mimics congestive heart failure in most human patients.
2. Electrocardiograms One week after surgery, electrocardiograms are obtained under light metofane anesthesia to document the development of infarcts. The ligated rats of this study are subgrouped according to the depth and persistence of pathological Q waves across the precordial leads. Buttrick et al., supra; Kloner et al., Am. Heart 51: 1009- 1013 (1983). This provides a gross estimate of infarct size and assures that large and small infarcts are not -69differently distributed in the ligated rats treated with CT-1 or CT-1 antagonist and vehicle. Confirmation is made by precise infarct size measurement.
3. CT-1 or CT-I Antagonist Administration Four weeks after surgery, CT-i or CT-I antagonist (10 pg/kg to 10 mg/kg twice a day for 15 days) or saline vehicle is injected subcutaneously in both ligated rats and sham controls. Body weight is measured twice a week during the treatment. CT-I or CT-1 antagonist is administered in saline or water as a vehicle.
4. Catheterization After 13-day treatment with CT-1, CT-I antagonist, or vehicle, rats are anesthetized with pentobarbital sodium (50 mg/kg, intraperitoneally). A catheter (PE 10 fused with PE 50) filled with heparin-saline solution (50/U/mL) is implanted into the abdominal aorta through the right femoral artery for measurement of arterial pressure and heart rate. A second catheter (PE 50) is implanted into the right atrium through the right jugular vein for measurement of right atrial pressure and for saline injection. For measurement of left ventricular pressures and contractility (dP/dt), a third catheter (PE 50) is implanted into the left ventricle through the right carotid artery. For the measurement of cardiac output by a thermodilution method, a thermistor catheter (Lyons 15 Medical Instrument Co., Sylmar, CA) is inserted into the aortic arch. The catheters are exteriorized at the back of the neck with the aid of a stainless-steel wire tunneled subcutaneously and then fixed. Following catheter implantation, all rats are housed individually.
5. Hemodvnamic Measurements One day after catherization, the thermistor catheter is processed in a microcomputer system (Lyons Medical Instrument Co.) for cardiac output determination, and the other three catheters are connected to a Model pressure transducer (Century Technology Company, Inglewood, CA) coupled to a Grass Model 7 polygraph (Grass Instruments, Quincy, MA). Mean arterial pressure (MAP), systolic arterial pressure (SAP), heart rate right atrial pressure (RAP), left ventricular systolic pressure (LVSP), left ventricular mean pressure (LVMP), left ventricular end-diastolic pressure (LVEDP), and left ventricular maximum (dP/dt) are 25 measured in conscious, unrestrained rats.
For measurement of cardiac output, 0.1 mL of isotonic saline at room temperature is injected as a bolus via the jugular vein catheter. The thermodilution curve is monitored by VR-16 simultrace recorders (Honeywell
S.
Co., NY) and cardiac output (CO) is digitally obtained by the microcomputer. Stroke volume (SV)=CO/HR; Cardiac index (CI)=CO/BW; Systemic vascular resistance (SVR)=MAP/CI.
After measurement of these hemodynamic parameters, I mL of blood is collected through the arterial catheter. Serum is separated and stored at -70 C for measurement of CT-I levels or various biochemical parameters if desired.
At the conclusion of the experiments, the rats are anesthetized with pentobarbital sodium (60 mg/kg) and the heart is arrested in diastole with intra-atrial injection of KCI (1 The heart is removed, and the atria and great vessels are trimmed from the ventricle. The ventricle is weighed and fixed in 10% buffered formalin.
All experimental procedures are approved by the Institutional Animal Care and Use Committee of Genentech, Inc. before initiation of the study.
6. Infarct Size Measurements The right ventricular free wall is dissected from the left ventricle. The left ventricle is cut in four transverse slices from apex to base. Five micrometer sections are cut and stained with Massons' trichrome stain and mounted. The endocardial and epicardial circumferences of the infarcted and non-infarcted left ventricle are determined with a planimeter Digital Image Analyzer. The infarcted circumference and the left ventricular circumference of all four slices are summed separately for each of the epicardial and endocardial surfaces and the sums are expressed as a ratio of infarcted circumference to left ventricular circumference for each surface.
These two ratios are then averaged and expressed as a percentage for infarct size.
7. Statistical Analysis Results are expressed as mean SEM. Two-way and one-way analysis of variance (ANOVA) is performed to assess differences in parameters among groups. Significant differences are then-subjected to post hoc analysis using the Newman-Keuls method.
p 0.05 is considered significant.
8. Results The mean body weight before and after treatment with CT-I or CT-I antagonist or vehicle is not expected to be different among the experimental groups. Infarct size in ligated rats is not expected to differ between the vehicle-treated group and the CT-1- or CT-1- antagonist-treated group.
It is expected that administration of CT-1 or CT-1 antagonist to the ligated rats in the doses set forth .above would result in improved cardiac hypertrophy by increasing ventricular contractility and decreasing peripheral vascular resistance over that observed with the vehicle-treated sham and ligated rat controls. This expected result would demonstrate that administration of CT-I or CT-1 antagonist improves cardiac function in congestive heart failure. In sham rats, however, CT-I or CT-1 antagonist administration at this dose is not expected to alter significantly cardiac function except possibly slightly lowering arterial pressure and peripheral vascular resistance.
25 It would be reasonably expected that the rat data herein may be extrapolated to horses, cows, humans, and other mammals, correcting for the body weight of the mammal in accordance with recognized veterinary and clinical procedures. Using standard protocols and procedures, the veterinarian or clinician will be able to adjust the doses, scheduling, and mode of administration of CT-1 or a CT-1 antagonist to achieve maximal effects in the desired mammal being treated. Humans are believed to respond in this manner as well.
EXAMPLE III Proposed Clinical Treatment of Dilated Cardiomvopathv A. Intervention Patient self-administration of CT-I or CT-1 antagonist at an initial dose of 10-150 pg/kg/day is proposed. The dose would be adjusted downward for adverse effects. If no beneficial effects and no limiting adverse effects are determined at the time of re-evaluation, the dose would be adjusted upward. Concurrent medication doses captopril as an ACE inhibitor and diuretics) would be adjusted at the discretion of the study physician. After the maximum dose is administered for 8 weeks, the CT-I or CT-1 antagonist administration is stopped, and re-evaluation is performed after a similar time period off treatment (or a placebo).
-71- B. Inclusion Criteria Patients would be considered for the study if they meet the following criteria: -Dilated cardiomyopathy (DCM). Idiopathic DCM, or ischemic DCM without discrete areas of akinesis/dyskinesis of the left ventricle (LV) on contrast ventriculography or 2D echocardiography. Evidence for impaired systolic function to include either LV end-diastolic dimension (EDD) 3.2 cm/m 2 BSA or EDV 82 mL/m 2 on 2D echocardiography, LV fractional shortening 28% on echocardiography, or ejection fraction (by contrast ventriculography or radionuclide angiography) 0.49.
-Symptoms. New York Heart Association class III or peak exercise V0 2 16 mL/kg/min. (adjusted for age), stable for at least one month on digoxin, diuretics, and vasodilators (ACE inhibitors).
-Concurrent ACE inhibitor therapy.
-Adequate echocardiographic "windows" to permit assessment of left ventricular vplume and mass.
-Ability to self-administer CT-1 or CT-I antagonist according to the dosage schedule, and to return reliably for follow-up assessments.
-Consent of patient and patient's primary physician to participate.
-Absence of exclusion criteria.
C. Exclusion Criteria Patients would be excluded from consideration for any of the following reasons: -Dilated cardiomyopathy resulting from valvular heart disease (operable or not), specific treatable etiologies (including alcohol, if abstinence has not been attempted), or operable coronary artery disease.
-Exercise limited by chest pain or obstructive peripheral vascular disease.
-Chronic obstructive lung disease.
-Diabetes mellitus or impaired glucose tolerance.
-History of carpal tunnel syndrome, or evidence for positive Tinel's sign on examination.
-History of kidney stones.
-Symptomatic osteoarthritis.
-Inability to consent for or participate in serial bicycle ergometry with invasive hemodynamic monitoring (as described below).
S* -Active malignancy.
D. Patient Assessment 1) Major Assessment Points: baseline; after peak stable CT-I or CT-I antagonist dose maintained for 8 weeks; after equal period after drug discontinuation.
-It is anticipated that patients would remain in the hospital for two to three days at the onset of active treatment, with daily weights and laboratory data including electrolytes, phosphorus, BUN, creatinine, and glucose. Following this, they would be monitored on the Clinical Research Center floor daily for an additional two to three days.
i. Physical examination.
ii. Symptom Point Score (Kelly et al., Amer. Heart 119: 1111 (1990)).
-72iii. Laboratory data: CBC; electrolytes (including Mg 2 and Ca BUN; creatinine; phosphorus; fasting glucose and lipid profile (total cholesterol, HDL-C, LDL-C, triglycerides); liver function tests (AST, ALT, alkaline phosphatase, total bilirubin); total protein; albumin; uric acid; and CT-I.
iv. 2D, M-mode, and doppler echocardiography, including: diastolic and systolic dimensions at the papillary muscle level; ejection fraction estimate by area planimetry from apical 2-chamber and 4-chamber views, estimated systolic and diastolic volumes by Simpson's rule method, and estimated left ventricular mass; doppler assessment of mitral valve inflow profile (IVRT, peak E, peak A, deceleration time, A wave duration), and pulmonary vein flow profile (systolic flow area, diastolic flow area, A reversal duration, and velocity).
v. Rest and exercise hemodynamics and measured oxygen consumption, using bicycle ergometry with percutaneously inserted pulmonary artery and arterial catheters. Perceived exertion level would be scored on the Borg scale, and measurements of pulmonary artery systolic, diastolic, and mean pressures, as well as arterial pressures and pulmonary capillary wedge pressure would be measured at each increment of workload, along with arterial and mixed venous oxygen content for calculating cardiac output.
vi. Assessment of body fat and lean body mass, as well as skeletal muscle strength and endurance.
2) Interim Assessment Points: weekly i. Physical examination.
ii. Symptom Point Score.
iii. Laboratory data: electrolytes, BUN, creatinine, phosphorus, fasting glucose, somatomedin- C, and CT-1.
Potential Benefits 1) Improved sense of well-being.
2) Increased exercise tolerance.
3) Increased muscle strength and lean body mass.
25 4) Decreased systemic vascular resistance.
Enhanced cardiac performance.
6) Enhanced compensatory myocardial hypertrophy.
EXAMPLE IV Testing for in vitro Neurotrophic Activity An assay used for ciliary ganglion neurotrophic activity was performed as described in Leung, Neuron, 1045-1053 (1992). Briefly, ciliary ganglia were dissected from E7-E8 chick embryos and dissociated in trypsin-EDTA (Gibco 15400-013) diluted ten fold in phosphate-buffered saline for 15 minutes at 37*C. The ganglia were washed free of trypsin with three washes of growth medium (high glucose D-MEM supplemented with 10% fetal bovine serum, 1.5 mM glutamine, 100 pg/mL penicillin, and 100 pg/mL strepomycin), and then gently triturated in 1 mL of growth medium into a single-cell suspension. Neurons were enriched by plating this cell mixture in 5 mL of growth media onto a 100-mm tissue culture dish for 4 hours at 37*C in a tissue culture incubator. During this time the non-neuronal cells preferentially stuck to the dish and neurons were gently washed free at the end of the incubation.
-73- The enriched neurons were then plated into a 96-well plate previously coated with collagen. In each well, 1000 to 2000 cells were plated, in a final volume of 100 to 250 pL, with dilutions of the conditioned medium from the pchf.781-transfected 293 cells of Example I. The cells were also plated with the transfected 293 conditioned medium as a control, and with a CNTF standard as a comparison. Following a 2-4-day incubation at 37 C, the number of live cells was assessed by staining live cells using the vital dye metallothionine (MTT). One-fifth of the volume of 5 mg/mL MTT (Sigma M2128) was added to the wells. After a 2-4-hour incubation at 37 C, live cells (filled with a dense purple precipitate) were counted by phase microscopy at 100X magnification.
The results of the assay are shown in Figure 4. It can be seen that the pchf.781 transfection (triangles) increased survival of the live neurons (measured by cell count) as the fraction of assay volume of transfected 293 conditioned medium increased. This is similar to the pattern for the CNTF standard (circles), and is in contrast to the control transfection (squares), which showed no increase in survival as a function of increased fraction of assay volume of conditioned medium. This indicates that CT-1 is useful as a neurotrophic agent, having a similar effect to that observed with CNTF.
S 15 EXAMPLE V A source of mRNA encoding human CT-1 (also known as human cardiotrophin-1 was identified 1 by screening poly(A)+RNA from several adult tissues with a probe from the mouse CT-I cDNA clones. Heart, skeletal muscle, colon, ovary, and prostate showed a 1.8 kb band upon blot hybridization with a 180-bp mouse CT-I probe (extending from 19 bp 5' of the initiating ATG through amino acid 50) in 20% formamide, 5 X SSC at 42*C with a final wash at 0.25 X SSC at 52° C. Clones encoding human CT-1 were isolated by screening a human heart cDNA library (Clontech) with the same probe and conditions (final wash at 55 C).
o Eleven clones were isolated from 1 million screened. The EcoRI inserts of several of the clones were subcloned into plasmid vectors and their DNA sequences determined.
The DNA sequence from clone h5 (SEQ ID NOS: 6 and 7 for the sense and anti-sense strands, respectively) is shown in Figure 5 and includes the whole coding region. Clone h5 (pBSSK+.hu.CTI.h5) was deposited on July 26, 1994 in the American Type Culture Collection as ATCC No. 75,841. The DNA sequence of another clone, designated h6, matches that of clone h5 in the region of overlap. Clone h6 begins at base 47 of clone h5 and extends 3' of clone h5 for an additinal 521 bases. The encoded protein sequence of human CT-1 (SEQ ID NO: 8) is 79% identical with the mouse CT-1 sequence (SEQ ID NO: as evident from Figure 6, wherein the former is designated "humctl" and the latter is designated "chf.781." To show that human CT-I encoded by clone h5 is biologically active, the EcoRI fragment was cloned into the mammalian expression vector pRK5 (EP 307,247) at the unique EcoRI site to give the plasmid pRKS.hu.CT1. This plasmid was transfected into human 293 cells, and the cells were maintained in serum-free medium for 3-4 days. This medium was then assayed for cardiac myocyte hypertrophy as described above for mouse CT-I. The transfected 293 conditioned medium was clearly active in this assay (hypertrophy score of at a dilution of 1:20; Table Other cytokines were also tested for hypertrophy activity (Table 3).
-74- Table 3 Hypertrophy assay of CT-i-related cytokines Conc., nM Cytokine Hypertrophy Score* None CT-1 fusion Mouse LIF Human IL-l Human OSM Mouse IL-6 Rat CNTF 0 0.05 0.1 0.25 0.05 0.25 0.1 0.2 1.0 2.0 6.25 12.5 50 50 100 25 100 3 6 6 7 4 6 6 4 4
C
0 tm C. @6 S m m mm S Come
C
CC m
C
C
cm C C
SC
*A score of 3 is no hypertrophy; 7 is maximal hypertrophy (see Materials and Methods).
The mouse and human CT-1 encoded by these clones have 80% amino acid identity and are about 200 amino acids in length corresponding to a calculated molecular mass of 21.5 kDA. Both human and mouse CT-1 lack a conventional hydrophobic amino terminal secretion sequence, however, they are found in the medium of transfected mammalian cells. The coding regions of human and mouse CT-I are contained on three separate exons that span 6-7 kbp of genomic DNA. The human CT-1 gene was localized by fluorescent in situ hybridization and bysomatic cell hybridization to chromosome 16pl 1.1 p 1.2. The expression pattern of mouse CT-I was determined by Northern blot analysis. CT-1 mRNA is widely (but not universally) expressed in adult mouse tissues including heart, kidney, skeletal muscle, and liver. A single 1.4 kb CT-1 mRNA species was detected in the adult mouse heart, skeletal muscle, liver, lung, and kidney. Lower amounts of mRNA were seen in testis and brain, while no expression was observed in the spleen. The CT-1 transcript was also detected in seven-day embryoid body mRNA, which was the RNA used to prepare the cDNA expression library. In a survey of human adult tissues (Figure 20), high levels of CT-1 mRNA (1.7 kb mRNA) were seen in heart, skeletal muscle, prostate and ovary. Lower levels were observed in lung, kidney, pancreas, thymus, testis and small intestine. Little or no expression was seen in the brain, placenta, liver spleen, colon or peripheral blood leukocytes. High levels of expression were also seen in human fetal heart, lung, and kidney, suggesting that CT-I might be involved in embryonic development of these organs. In situ analysis of CT-1 expression during mouse embryogenesis reveals widespread expression in a variety of noncardiac systems. The high level of expression in these other adult tissues suggests the possibility of functional roles for CT-1 in a wide variety of adult organ systems, outside of the cardiovascular s'ystem. The pattern in humans and mouse are similar with the exception of expression in the liver, which is weakly positive in human samples.
Like CNTF, CT-I lacks a conventional amino-terminal secretion signal sequence; it is, however, found in the medium of transfected mammalian cells.
The predicted tertiary structure of CT-1 is consistent with its containing four amphipathic helices that are features of a large number of cytokines and other proteins including growth hormone. (For reference see 15 Abdel-Meguid et al., Proc. NatlAcad. Sci. USA, 84:6434-6437 (1987) and Bazan, Neuron, 7:197-208 (1991)).
Although these cytokines share biological activities and receptor subunits, alignment of the amino acid sequence of human CT-1 and other members of the IL-6 cytokine family, reveals that they are only distantly related in primary sequence (15%-25% identity) Figure 16. There is little conservation of the cysteine residues and only a partial maintenance of the exon-intron boundaries. Based on the sequence identity comparison determined herein, studies analyzing the crystal structure and biological function of mouse LIF and their relevance to receptor binding (Robinson et al., Cell, 77:1101-1116 (1994)) suggest useful subunit regions of CT-I. As determined by X-ray crystallography at a 2.0 A resolution, the main chain fold of mouse LIF conforms to the four ca-helix bundle topography that has been noted for other members of the IL-6 cytokine family. Alignment of the 0. sequences for functionally-related molecules, such as oncostatin M and CNTF, and consequent mapping to the LIF structure, indicated regions of conserved surface character. A series of human and mouse LIF chimeras have identified the fourth helix and the preceding loop as potentially important sites for interaction with the LIF receptor (Robinson et al., Cell, 77:1101-1116 (1994)). Although LIF and CT-I display a high degree of divergence in primary sequence within these regions, the similar domains within CT-I are likely important in maintaining the interactions of CT-1 with the LIF receptor. Peptides derived from these regions will find use as CT-I agonists (see Figure 16 for example). Similar approaches to generate mouse LIF/CT-1 chimeras will be of value.
Human CT-I binds to the mouse LIF receptor. As discussed herein, human CT-I was expressed by subcloning the coding region from plasmid pBSSK+.hu.CT .h5, which contained all of the cDNA protein coding -76region, to give plasmid pRKS.hu.CTI. Clarified conditioned medium was obtained from human 293 cells transfected with this plasmid and maintained in serum-free medium for four days. Binding to MI cells (ATCC TIB 192), Hela cells and WI-26 VA4 (ATCC CCL-95.1) cells was performed for 2 hours a 4 degrees C and analyzed as described herein. For the Hela cell binding, CM was concentrated 10 fold and added at a 3-fold dilution to the binding assays. For the WI-26 binding the conditioned medium was used without concentration.
This conditioned medium competed for labeled human LIF (iodinated with IODO-BEAD from Pierce or lactoperoxidase methods to a specific activity of 1000-1500 Ci/mmol as described herein) as did purified mouse and human LIF and mouse CT-1. CM from vector transformed cells failed to compete.(Figure 17A). While booth mouse and human LIF bind and activate the mouse LIF receptor, mouse LIF fails to bind the human LIF receptor. As shown herein, human LIF competes for the binding of labeled human LIF to Hela cells while mouse LIF does not (Figure 17B). Mouse CT-i and conditioned medium form 293 cells transfected with the human CT-I expression vector compete for this binding as well. (Figure 17B). However, the binding of labeled mouse CT-I is completely competed by unlabeled human LIF. Thus, both human and mouse CT-I bind to human LIF receptor, and CT-1 lacks the species specificity of binding found for LIF. The affinity of mouse CT-I for human 15 LIF receptor was determined (Figure 18). A single binding component was observed with an affinity (Kd approx. 0.75 nM), about equal to that for the mouse LIF receptor as shown herein.
Human CT-1 does not bind the specific OSM Receptor. Although oncostatin M binds and functions via the LIF receptor (Gearing et al. (1992) New Biologist 4:61-65), but as shown herein CT-1 is not a ligand for the OSM specific receptor, the oncostatin M receptor, which has been identified in and cloned from the human lung cell line WI-26 VA4. Both purified mouse CT-1 and the CM from 293 cells transfected with human CT-I cDNA failed to compete for labeled OSM binding (Figure 19).
CT-1 induces a distinct form ofmyocardial cell hypertrophy characterized by sarcomeric assembly in series. The CT-1 induced hypertrophic phenotype is distinct from the hypertrophic phenotype observed following G-protein dependent stimulation with a-adrenergic agonists (Knowlton et al. (Journal of Biological 25 Chemistry, 266:7759-7768 (1991); Knowlton et al., Journal of Biological Chemistry, 268:15374-15380 (1993), endothelin-1, Shubeita et al., Journal of Biological Chemistry, 265:20555-20562 (1990), and angiotensin II (Sadoshima et al., Circ. Res., 73:413-423 (1993)). On a single cell level, heterotrimeric G-protein dependent pathways induce a form of hypertrophy with a relatively uniform increase in myocyte size and the addition of new myofibrils in parallel (Knowlton et al., Journal of Biological Chemistry, 268:15374-15380 (1993); Shubeita et al., Journal ofBiological Chemistry, 265:20555-20562 (1990); Iwaki et al., Journal of Biological Chemistry, 265, 13809-13817 (1990)). In contrast, CT-I induces an increase in myocyte size characterized by a marked increase in cell length, but little or no change in cell width. Consistent with the results presented herein for CT-I, LIF is also capable of activating a similar pattern of hypertrophy in the cultured myocardial cell assay -77system, while IL-6 and CNTF had little effect, presumably because of the lack of expression of the private receptor in cultured myocardial cells. LIF signals through the gpl30/LIFRP complex, through which CT-I also functions as shown herein.
To characterize the effects ofgpl30/LIFRP-dependent stimulation on the myofibrillar cytoarchitecture, cardiomyocytes were dual-stained for thick (pMHC) and thin (F-actin) myofilaments, and viewed by confocal laser microscopy (Messerli et al., Histochemistry, 100:193-202 (1993)). Cardiomyocytes stimulated with CT-I and LIF displayed a high degree of myofibrillar organization: myofibrils were organized in a strictly sarcomeric pattern, oriented along the longitudinal cell axis, and extended to the cell periphery. Importantly, the increase in cell size and length was not accompanied by a change in the average sarcomere length, strongly suggesting that the cell elongation in response to gpl30/LIFRp-stimulation results from an addition of new sarcomeric units in series. The morphologic changes induced by gpl30/LIFRP dependent stimulation in vitro are reminiscent of the changes observed in cardiac myocytes isolated from hearts subjected to chronic volume overload (Anversa et al., Circ Res., 52:57-64 (1983); Gerdes et al., Lab Invest., 59:857-861 (1988)). By contrast, the pattern of cardiomyocyte hypertrophy induced by a-adrenergic stimulation more closely resembles a pressure overload-like 15 phenotype (Morkin, Science, 167:1499-1501 (1970); Anversa et al., J.Am. Coll. Cardiol., 7:1140-1149 (1986)).
On a molecular level, gpl30 dependent stimulation and a-adrenergic stimulation result in distinct patterns of embryonic gene, MLC-2v, and immediate early gene expression. The reactivation of an embryonic pattern of gene expression is a central feature of cardiomyocyte hypertrophy (Chien et al., FasebJ, 5:5037-3046 (1991)). Members of the embryonic gene program, such as ANF and skeletal a-actin are abundantly expressed in the ventricular myocardium during embryonic development, but their expression is down-regulated shortly after birth. Stimulation of cardiomyocytes with CT-1 or LIF induced prepro-ANF mRNA expression, and perinuclear accumulation and secretion of immunoreactive ANF. However, in contrast to c-adrenergic stimulation, CT-1 and LIF did not induce skeletal a-actin expression. Growth factors, signaling through Gprotein coupled receptors, including a-adrenergic agonists, endothelin-l, and angiotensin II, induce ANF and 25 skeletal a-actin in a coordinate fashion (Knowltoh et al., Journal of Biological Chemistry, 266:7759-7768 (1991); Bishopric et al., Journal of Clinical Investigation, 80:1194-1199 (1987); Sadoshima et al., Circ. Res., 73:413-423 (1993)). A recent study compared the expression pattern of distinct members of the embryonic gene program in pressure overload versus volume overload hypertrophy in vivo in the rat myocardium (Calderone et al., Circulation, 92:2385-2390 (1995)). As shown previously (Izumo et al., Proc. NatlAcad Sci. USA, 85:339- 343 (1988)) pressure overload resulted in the coordinate induction of ANF and skeletal a-actin. However, volume overload hypertrophy was associated with a selective increase in ANF expression, and no induction of skeletal a-actin, suggesting that the regulation of distinct embryonic genes in vivo is related to the hypertrophic stimulus (Calderone et al., Circulation, 92:2385-2390 (1995)). The pattern of embryonic gene expression -78induced by CT-I and LIF in cardiomyocyte culture therefore resembles the pattern observed in volume overload hypertrophy in vivo.
Deposit of Material The following plasmid has been deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD, USA (ATCC): Plasmid ATCC Dep. No. Deposit Date 75,841 July 26, 1994 This deposit was made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable culture of the deposit for 30 years from the date of deposit. The deposit will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures permanent and unrestricted availability of the progeny of the •culture of the deposit to the public upon issuance of the pertinent U.S. patent or upon laying open to the public 15 of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 USC §122 and the Commissioner's rules pursuant thereto (including 37 CFR §1.14 with particular reference to 886 OG 638).
The assignee of the present application has agreed that if a culture of the plasmid on deposit should die 20 or be lost or destroyed when cultivated under suitable conditions, the plasmid will be promptly replaced on notification with another of the same plasmid. Availability of the deposited plasmid is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.
In respect of those designations in which a European patent is sought, a sample of the deposited 25 microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC) EXAMPLE VI MATERIALS AND METHODS.
Human IL-6 was from Genzyme, mouse LIF was from R D Systems and Genentech manufacturing, and rat CNTF and GDNF, Poulsen et al., Neuron, 13:1245-1252 (1994) were produced by Genentech. Mouse CT-I was expressed and purified as a fusion protein as described. This protein results in a 34 amino acid Nterminal extension that encodes a portion of the herpes simplex virus glycoprotein D and a factor Xa cleavage -79site. In some cases an alternative fusion protein was used that substitutes a different site for the Factor Xa cleavage site giving the amino acid sequence DQLLEGGAAHY followed by the CT-I sequence MSQREGSL... CT -1 and LIF were iodinated by the iodo-bead (Pierce) and lactoperoxidase (Gladek et al., Arch. Immunol. Ther. Exp., 31:541-553 (1983)) methods to specific activities of 900-1100 Ci/mmol.
Hematopoietic. neuronal. and developmental assays. Proliferation of the mouse hybridoma cell line, B9 (Aarden et al., Eur. J. Immunol., 17:1411-1416 (1987)) was assayed by 3H-thymidine incorporation 84 h after the addition of cytokine as described (Nordan et al., Science, 233:566-569 (1986)). Inhibition of the proliferation of the mouse myeloblast cell line, MI was assayed by 3H-thymidine incorporation 72 h after the addition of cytokine as described (Lowe et al., DNA, 8:351-359 (1989)). The data were fit to the four parameter equation, where the parameter c is the ECo.
For the assay of the transmitter phenotype, newborn rat sympathetic neurons were prepared as described (Hawrot el al., Meth. Enzymol., 58:574-583 (1979)). Superior cervical ganglia were dissociated with trypsin and plated in serum free F-12 medium containing nerve growth factor and additives as described (Davies et al., Neuron, 11:565-574 (1993)). Neurons were plated at 30,000 per well in 24 well plates precoated with •15 poly-omithine and ECL cell attachment matrix (Promega) and allowed to grow for ten days in the presence of indicated factors. Tyrosine hydroxylase and choline acetyltransferase activities were assayed as described •(Reinhard etal., Life Sci., 39:2185-2189 (1986); Fonnum, Biochem. 115:465-472 (1969)).
The survival of rat dopaminergic neurons was assayed as described (Poulsen et al., Neuron, 13:1245- .1252 (1994)). Ciliary neuron survival assays were performed with neurons isolated from E8 chick embryos as 20 described (Manthorpe et al., (Rush, eds.) Vol. pp. 31-56, John Wiley Sons (1989)). Survival was assessed by counting live neurons after staining with the vital dye MTT (Mosmann, J. Immunol. Meth., 65:55-63 (1983)).
The data were fit to the four parameter equation described above.
For the assay of embryonic stem cell differentiation, passage 15 embryonic stem cells, ES.D3 (Gossler et al., Proc. Natl. Acad. Sci. USA, 83:9065-9069 (1986)) were maintained in DMEM (GIBCO, high glucose, 25 no sodium pyruvate), containing 23.83 g/l HEPES, 500 mg/1 penicillin, 500 mg/1 streptomycin, 4 g/1 L-glutamine, 1 g/1 gentamicin sulfate, 1 mM 2-mercaptoethanol, 15% fetal bovine serum, and 1.2 Munits/l mouse LIF (GIBCO). Cells were trypsinized, plated in duplicate at 1000 cells per well in 24-well tissueculture plates in the above culture medium with or without LIF or CT-1, and scored 9 days later. No change in colony numbers was observed except in the no addition group where the cells had flattened and differentiated.
Cell binding and cross-linking. Binding was performed in RPMI-1640 containing 0.1 bovine serum albumin with 7.5-10 million MI cells (TIB 192, ATCC) in a volume of 250 pI for 2 h on ice with shaking.
Reactions were layered on 250 pl of RPMI containing 0.1 albumin and 20 sucrose, centrifuged at 4000 rpm for 1 min at 4* C, and the cell pellet counted. The data were fit to a one-site binding model as described (Munson et al., Anal. Biochem., 107:220-239 (1980)). Lines shown in the figures are from the curve fits.
antibody inhibition experiments were performed with a rat anti-mouse gpl30 monoclonal antibody (RX435) 2 or a rat anti-gpl20 control antibody (Genentech 6D8.1E9) in a volume of 150 pl. Reactions were incubated on ice 2 h, centrifuged at 12,500 rpm, and washed with I ml of cold phosphate buffered saline containing 0.1 albumin. The data were fit to the four parameter equation described above.
Binding to neonatal rat cardiac myocytes was performed as for Ml cells, but cells isolated as described herein and plated for 16 h. Assays were performed with 1 million cells in a volume of-100 pl.
Cross-linking was performed with 10 million Ml cells in phosphate buffered saline containing 0.1% albumin, 7.2 nM 2 sI-mouse CT-1 or 2.2 nM 2 I-mouse LIF, with or without a 100 fold molar excess of the unlabeled ligands in a volume of 250 pl. After 1 h at room temperature, 10 mM 1-ethyl-3-(3dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 5 mM N-hydroxysulfosuccinimide (sulfo-NHS) (Pierce) were added and the incubation continued for 30 min at room temperature. The samples were then processed as described (Greenlund et al., J. Biol. Chem., 268:18103-18110 (1983)).
15 DNA binding activity. Two hundred thousand Ml cells were incubated in 1 ml of RPMI-1640 in 12well dishes with ligand for 30 min at 37 C. After stimulation, the cells were collected by centrifugation, suspended in 200 ul of homogenization butter (10 mM HEPES (pH 10 mM KCI, 0.1 mM EDTA, 0.1 mM EGTA, ImM DTT, 1 mM phenylmethylsulfonylfluoride, 10 ug/ml leupeptin, 10 ug/ml aprotinin), and incubated *at 0 C for 15 min. Cells were lysed by the addition of NP-40 to and cell extracts prepared by incubation at 0 C for 15 min, centrifugation at 100 x g for 5 min, and retention of the supernatant. DNA binding activity in the cell extracts was assayed by electrophoretic mobility shift assay as described (Greenlund et al., EMBO J., 13:1591-1600 (1994)). Briefly, binding reactions contained 10 mM Tris-HCI buffer (pH 100 mM KCI, mM MgClz, 1 mM DTT, 6.7 glycerol, 0.067 gl/ poly(dIdC)(dIdC), 0.5 ng (25,000 cpm) P-SIE DNA CTAGAGTCGACATTTCCCGTAAATCT and 5'-CTAGAGATTTACGGGAAATGTCGACT, high affinity m67 (Sadowski et al., Science, 261:1739-1744 (1993); Wagner et al., EMBO 9:4477-4484 (1990)), and 3 ul of cell extract in a final volume of 15 ul. Some reactions included 100 ng of unlabeled SIE DNA. The reactions were incubated 30 min at 22 C and analyzed by polyacrylamide gel electrophoresis and autoradiography.
Binding to soluble LIF receptor and soluble gpl30. DNA encoding the extracellular domain of the mouse LIF receptor (amino acids 1-826) and mouse gpl30 (1-617) was generated by PCR of Ml cell (above) mRNA and of a mouse lung cDNA library (Clontech). These sequences were cloned with a C-terminal tag encoding 6 histidine residues in the mammalian expression vector, pRKS (Suva et al., Science, 237:893-896 (1987)) to give the plasmids, pRK5.mu.slifr and pRKS.mu.sgpl30. DNA sequencing of the coding regions confirmed that these plasmids encode proteins that match the published amino acid sequence (Tomida et al., J.
-81- Biochem., 115:557-562 (1994); Saito et al., J. Immunol., 148:4066-4071 (1992)), with the exception of the substitution of lysine for arginine at amino acid 326 of gpl30, a change that was found for three fragments from both sources. The plasmids were transfected into human 293 cells, and the proteins isolated from 4-day conditioned medium by Ni"-NTA-agarose (Qiagen) affinity purification. Briefly, the conditioned medium was concentrated 18 fold (Centriprep 10, Amicon), and the tagged protein purified by binding to the Ni" resin for 2 h at room temperature. Following two washes with phosphate buffer saline containing 5 mM imidazole, the proteins were eluted with phosphate buffer saline containing 200 mM imidazole and quantitated by colorimetric assay (BioRad). Analysis of the proteins by SDS-polyacrylamide gel electrophoresis showed single bands of 120 kDa for the soluble LIF receptor and 85 kDa for soluble gpl30. Amino acid sequencing gave the expected amino terminal sequence for the soluble LIF receptor beginning at amino acid 44 (Tomida et al., J. Biochem., 115:557-562 (1994); von Heijne, Nucl. Acids Res., 14:4683-4690 (1986)); the amino terminus of gpl30 is expected to be blocked (Saito et al., J. Immunol, 148:4066-4071 (1992); von Heijne, Nucl. Acids Res., 14:46S3- 4690 (1986)) and amino terminal protein sequencing gave no sequence for soluble Binding to the soluble LIF receptor and soluble gpl30 was performed in a manner similar to that 15 previously described (Layton et al., J. Biol. Chem., 269:17048-17055 (1994)). Briefly, assays were performed S. in 96-well Multiscreen-HV filtration plates with 0.45 pm PVDF membranes (Millipore) in phosphate buffered saline containing 0.1% bovine serum albumin and including 25 pl of phosphate buffer saline-washed Ni'-NTA- Agarose (Qiagen) in a final volume of 175 pl. Plates were incubated at room temperature overnight with "agitation. Following vacuum filtration and one wash with 200 pl of cold phosphate buffer saline, the individual assay wells were cut from the plate and counted. The data were analyzed as described above for M binding.
RESULTS
As shown herein some members of the IL-6 cytokine family (LIF, OSM, and IL- 11) induce cardiac myocyte hypertrophy in vitro like CT-1. The previously known members of this family have a wide range of hematopoietic, neuronal, and developmental activities (Kishimoto et al., Science, 258:593-597 (1992)). CT-1 was assayed for its activity in these biological systems.
Hematopoietic assays. IL-6 promotes the proliferation and differentiation of B cells into antibody producing cells following antigen stimulation (Akira et al., Adv. Immunol., 54:1-78 (1993)). In the order to determine whether CT-1 could also mediate these effects, CT-1 was tested on the mouse hybridoma cell line, B9 (Aarden et al., Eur. J. Immunol., 17:1411-1416 (1987)). While IL-6 stimulates the proliferation of B9 cells as indicated by an increase in 3H-thymidine incorporation, CT-I and LIF were inactive (Figure 7A), even at concentrations as high as 2 uM (data not shown). Thus, CT-1 does not mimic the activity of IL-6 in promoting B cell expansion.
-82- While IL-6 stimulates the growth of several B cell lymphomas, myelomas, and plasmacytomas, it also has growth inhibitory effects on certain B lymphoma and myeloid leukemia cells (Akira et al., Adv. Immunol., 54:1-78 (1993)). IL-6 (as well as LIF and OSM) inhibits the growth of the mouse myeloid leukemia cell line, M1, and induces its differentiation into a macrophage-like phenotype (Akira et al., Adv. Immunol., 54:1-78 (1993);Roseetal., Proc. Natl. Acad Sci. USA, 88:8641-8645 (1991)). CT-1 was 6 fold more potent than LIF in inhibiting the uptake of 3H-thymidine by MI cells (Fig. 7B). Thus, CT-I does share at least some of the growth inhibitory activities of the IL-6 family cytokines.
Neuronal assays. Members of the IL-6 cytokine family modulate the phenotype and promote the survival of neuronal cells (Patterson, Proc. Natl. Acad. Sci. USA, 91:7833-7835 (1994)). LIF and CNTF can induce a switch in the transmitter phenotype of sympathetic neurons from noradrenergic to cholinergic, a change that is accompanied by the induction of several neuropeptides including substance P, somatostatin, and vasoactive intestinal polypeptide (Rao, J. Neurobiol., 24:215-232 (1992)). The ability of CT-1 to induce this switch in the transmitter phenotype was determined with cultured rat sympathetic neurons. CT-1 inhibited the tyrosine hydroxylase activity (a noradrenergic marker) and stimulated somewhat the choline acetyltransferase 15 activity (a cholinergic marker) of these cells, effects that paralleled the actions of LIF (Fig. 8A). Thus, CT-1 is active in modulating the phenotype of sympathetic neurons.
Parkinson's disease is caused by the degeneration of dopaminergic neurons of the midbrain (Hirsch et al., Nature, 334:345-348 (1988)). While proteins of the neurotrophin family (brain-derived neurotrophic factor and neurotrophin-4/5) as well as of the TGF-P family (GDNF, TGF-P2 and TGF-33) promote the survival of 20 cultured dopaminergic neurons (Poulsen et al., Neuron, 13:1245-1252 (1994)) many other growth factors and cytokines, including CNTF, do not. Unlike CNTF, CT-1 was found to promote the survival of rat dopaminergic 9 neurons, although it was not as potent as GDNF (Fig. 8B).
While inactive on dopaminergic neurons, CNTF does promotes the survival of ciliary neurons (Ip et al., Prog. Growth Factor Res., 4:139-155 (1992)). CT-I was tested for its activity in promoting the survival of 0. 25 chick ciliary neurons (Fig. 8C). While at maximal concentrations, CT-1 was as active as CNTF, the potency of CT-1 in promoting ciliary neuron survival was about 1000 fold less than that of CNTF (Fig. 8C). Thus, CT-I shares some neuronal activities with the IL-6 family cytokines such as CNTF.
Embryonic development assay. The presence or absence of soluble factors plays a key role during embryonic and fetal development. For example, embryonic stem cells require the continuous presence of soluble factors secreted by fibroblasts to maintain their undifferentiated, pluripotent phenotype. LIF (Williams et al., Nature, 336:688-690 (1988); Smith et al., Nature, 336:688-690 (1988)), CNTF (Conover et al., Development, 119:559-565 (1993)), and OSM (Rose et al., Cytokine, 6:48-54 (1994))--but not IL-6 without the soluble IL-6 receptor (Yoshida et al., Mech. Dev., 45:163-171 (1994))--can replace these fibroblast-derived factors in -83maintaining the pluripotent phenotype of embryonic stem cells in culture. CT-I was also found to inhibit the differentiation of mouse embryonic stem cells (Fig. it was as effective as LIF at the concentrations tested.
Thus, the data from seven in vitro biological assays indicate that CT-1 is active in assays where LIF is active and vice versa. Accordingly, these assays systems (and others in which CT-1 has a demonstrated activity as shown herein) can be used to screen for and identify CT-I agonists and antagonists useful for treating disorders dependent upon or resultinf from the biological activity (or loss, reduction or overproducction of the activity) demonstrated in these assays. These data also show that CT-I is active in assays where CNTF is active, but that the converse is not always the case, and that CT-I is inactive in IL-6 specific assays, assays in which LIF is also inactive. Since the activity profiles of members of this cytokine family are determined by the receptors expressed on target cell populations, these data are consistent with the hypothesis that CT-1 binds and transduces its biological effects via the LIF receptor.
CT-I binding to MI cells. In order to show directly that CT-I functions via the LIF receptor, binding was performed on MI cells, where LIF binding has been previously characterized (Hilton et al., Proc. Natl.
Acad. Sci. USA, 85:5971-5975 (1988)). Both CT-1 and LIF inhibit the growth of this cell line (see above).
15 Labeled CT-1 was specifically bound to Ml cells (Fig. 10A), and this binding was completely competed by unlabeled LIF (Fig. 10B). Similarly, labeled LIF binding was competed by both unlabeled LIF and CT-1 (Fig.
S, 10C and 10D). These data suggest that CT-I and LIF bind to the same receptor on MI cells. Scatchard analysis yields a single class of binding sites in all cases; the binding parameters are similar regardless of the labeled ligand--KI (CT-I] 0.7 nM, Kd [LIF] 0.2 nM, and 1500 sites per cell.
20 Cross-linking of CT-I on MI cells. To analyze the protein(s) that bind CT-1 on the cell surface, labeled CT-I and LIF were bound to MI cells, chemically cross-linked, and the solubilized proteins analyzed by SDS gel electrophoresis (Fig. 11). Both ligands gave one specific band with a mobility of- 200 kDa, and in both cases this cross-linked band was competed by either unlabeled ligand. Thus, CT-I and LIF interact with a protein of the same size on the surface of M cells; this protein has a mobility expected for the LIF receptor 25 (Davis et Science, 260:1805-1808 (1993); Gearing et al., EMBOJ., 10:2839-2848 (1991)).
Inhibition of CT-1 binding to Ml cells by an anti-gpl30 monoclonal antibody. In order to show that the common signaling subunit shared by all receptors for ligands of the IL-6 cytokine family, is a part of the receptor binding complex for CT-1, the effect of an anti-gpl30 monoclonal antibody on CT-1 binding was determined (Fig. 12A). This neutralizing antibody inhibited over 80 of the specific CT-1 binding to MI cells; no inhibition was found with comparable concentrations of a control antibody. These data indicate that gp130 is a component of the CT-I receptor complex.
CT-I induction of DNA binding activity in Ml cells. To show that CT-1 induces intracellular signaling events like those found for other cytokines that signal via gpl30 (Yin et al., Exp. Hematol., 22:467-472 (1994); -84- Narazaki et aL, Proc. Natl. Acad USA, 91:2285-2289 (1994); Zhong et al., Science, 264:95-98 (1994); Akira et al., Cell, 77:63-71 (1994)) DNA mobility shift assays wee performed with cell extracts from M cells (Fig.
i 12B). CT-1, like LIF, induced a shift in the mobility of the DNA element, SIE. Addition of the unlabeled element showed that the shifted band was specific. Thus, CT-1 induces the activation of a DNA binding activity like that expected for signaling via gpl30 and activation of the Jak/STAT pathway.
CT-I binding to cardiac myocvtes. The binding of labeled CT-I and LIF was also determined for rat cardiac myocytes, the cells used for the original assay and isolation of CT-1. Both ligands specifically bound and cross-competed for binding to these cells (Fig. 13A and 13B), as was the case for.Ml cells. These data suggest that CT-1 and LIF bind and induce cardiac myocyte hypertrophy via the LIF receptor.
CT-1 binding to the soluble LIF receptor. In order to clarify whether CT-1 can bind directly to the LIF receptor or gpl30 without the need for an additional membrane-bound component (as is the case for CNTF), binding experiments were performed with purified, soluble forms of the mouse LIF receptor and gpl 30 expressed as their extracellular domains containing a C-terminal histidine tag. Such experiments have recently shown that OSM binds directly to soluble gp130 (Kd- 4 4 nM for the human proteins) (Saadat et al., J. Cell Biol., 108:1807- 15 1816 (1989)). On the other hand, LIF binds directly to the LIF binding protein, a naturally occurring soluble form of the LIF receptor (Kd 2 nM for the mouse proteins) (Layton et al., J. Biol. Chem., 269:17048-17055 (1994); Layton et al., Proc. Natl. Acad Sci. USA, 89:8616-8620 (1992)). The soluble mouse LIF receptor and were expressed in mammalian cells, purified by Ni' chelate chromatography, and judged to be at least "90 pure by SDS gel electrophoresis (data not shown). Binding experiments with labeled CT-I show that it specifically binds to the soluble LIF receptor (Fig. 14A), as does labeled LIF (data not shown). CT-1 failed to bind to soluble gpl30 at gpl30 concentrations as high as 350 nM (Fig. 14B). The binding of CT-I to the soluble LIF receptor was enhanced by the addition of soluble gpl30 (Fig. 14C), suggesting that CT-1, soluble LIF receptor, and soluble gpl30 form a tripartite complex as would be expected for the CT-I activation of the LIF receptor complex. Competition binding experiments show that CT-1 binds to the soluble LIF receptor with a 25 reasonable affinity, K 1.9 nM (Fig. 14D). This affinity is about the same as that found for the binding of LIF (Kd 1.5 nM, data not shown) and is the same as that found previously for LIF binding to the naturally occurring form of the soluble LIF receptor (KI 1-4 nM These data demonstrate that CT-1 interacts directly with the soluble LIF receptor without the need for an additional binding component. The results suggest that CT-1 (like LIF) binds first with a relatively low affinity to the LIF receptor on the cell membrane and then forms a heterotrimeric complex with a higher apparent affinity upon interaction with
DISCUSSION
In vitro hematopoietic, neuronal, and developmental assays have been used herein to show that CT-1 has a range of activities in addition to the induction of cardiac myocyte hypertrophy for which it was initially isolated. As disclosed herein, CT-I is more potent than LIF in inhibiting the growth of the myeloid leukemia cell line, Ml; it induces a phenotypic switch in sympathetic neutrons; it promotes the survival of dopaminergic neurons from the central nervous system and ciliary neurons from the periphery; and it maintains the undifferentiated phenotype of embryonic stem cells. CT-1 and LIF share a common activity profile--both inhibit the growth of MI cells, induce the switch in sympathetic neuron phenotype, inhibit the differentiation of embryonic stem cells, and induce cardiac myocyte hypertrophy. CT-1 is active in assays where CNTF is activeboth induce the switch in sympathetic neuron phenotype (Saadat et al., J. Cell Biol., 108:1807-1816 (1989)) promote the survival of ciliary neurons, and inhibit the differentiation of embryonic stem cells (Conover et al., Development, 119:559-565 (1993)). On the other hand, CT-I is active in several assays where CNTF is inactive- -inhibition of Ml cell growth (CNTF activity requires the inclusion of soluble CNTF receptor (Davis et al., Science, 259:1736-1739 (1993)), promotion of dopaminergic neuron survival, and induction of cardiac myocyte hypertrophy. CT-1 is inactive, as are LIF and CNTF (Davis et al., Science, 259:1736-1739 (1993); Kitamura et al., Trends Endo. Metabol., 5:87744-14 (1994)) in the stimulation B9 cell growth, an assay that is relatively specific for IL-6.
15 Alignments of the amino acid sequences of CT-I and other members of the IL-6 cytokine family show that while these cytokines share biological activities and receptor subunits, they are only distantly related in primary sequence (14-24% identity for the mammalian proteins, Fig. 15A). There is little conservation of the cysteine residues and only a partial maintenance of the exon-intron boundaries (Bruce et al., Prog. Growth
S
Factor Res., 4:157-170 (1992); Bazan, Neuron, 7:197-208 (1991)). More sophisticated analyses (including the crystal structure of LIF (Robinson et al., Cell, 77:1101-1116 (1994)) show that these proteins share a common o* structural architecture of four alpha helices (for reference see Bazan, Neuron, 7:197-208 (1991)). The individual family members are more related across species. The human and mouse sequences for CT-1, LIF, CNTF, or IL- 11 are 79-88 identical (Fig. 15A); the IL-6 homologues are 41 identical. Some uncertainty remains as to whether the chick protein, identified as GPA, is the avian homologue of CNTF or another family member for which no mammalian homologue has yet been identified (Leunget al., Neuron, 8:1045-1053 (1992); Richardson, Pharmacol. Ther., 63:187-198 (1994)). CT-1 does not appear to be the mammalian homologue of GPA, as chicken GPA is more similar in amino sequence to mouse CNTF than to mouse CT-1 (46 verses 26 identity, Fig. 15A). On the other hand, there are similarities among CT-1, CNTF, and GPA-all lack a conventional amino terminal, secretion signal sequence. Interestingly, CT-I and GPA appear to be secreted from cells while CNTF is not (Leung et al., Neuron, 8:1045-1053 (1992); Stockli et al., Nature, 342:920-923 (1989); Lin et al., Science, 246:1023-1025 (1989)).
As is shown diagrammatically in Fig. 15B, the receptors for cytokines of the IL-6 family are composed of related subunits some of which are cytokine specific and some of which are shared (Davis et al., Curr. Opin.
-86- Cell Biol., 5:281-285 (1993); Stahl et al., Cell, 74:587-590 (1993); Kishimoto et al., Cell, 76:253-262 (1994); Hilton et al., EMBO 13:4765-4775 (1994)). All the receptors in this family have in common the transmembrane signaling subunit, gpl30. The binding ofIL-6 to the 80 kDa IL-6 receptor a subunit leads to the dimerization of gpl30 as the first step in signal transduction. Similarly, the binding of IL-11 to the IL-I 1 receptor also leads to gpl30 dimerization. LIF, OSM, and CNTF induce the heterodimeriztion of gpl30 and with another signaling subunit, the LIF receptor. LIF and OSM bind directly to the LIF receptor or gpl30 and induce dimerization without a ligand-specific a subunit, while CNTF binds first to the GPI-linked CNTF receptor. While the formation of receptor complexes containing homo- or heterodimers of gp 130 is believed to be an essential signaling event, the exact stoichiometry of the subunits in the complex is not known in most cases.
For the IL-6 receptor, a recent report concludes that the signaling complex is a hexamer containing two 20 kDa ligands, two 80 kDa IL-6 receptors, and two 130 kDa gpl30 molecules (Ward et al., J. Biol. Chem., 269:23286- 23289 (1994)). The ligand-induced dimerization of gpl30 or gpl30 and LIF receptor leads to the tyrosine phosphorylation and activation of associated tyrosine kinases of the Jak family (Jakl, Jak2, and Tyk2) followed by the activation of transcription factors of the STAT family (STATI and STAT3) (Lottickeri et al., Science, 15 263:89-92 (1994); Stahl et al., Science, 263:92-95 (1994); Yin et al., Exp. Hematol., 22:467-472 (1994); Narazaki et al., Proc. Natl. Acad. USA, 91:2285-2289 (1994); Zhong et al., Science, 264:95-98 (1994); Akira Set al., Cell, 77:63-71 (1994)). Although not meant to be limiting, it is proposed that the activation of the Jak- STAT pathway is probably one of the key steps in the signal transduction mechanism for most if not all the actions of the IL-6 family cytokines, including CT-1.
The presence or absence of the different subunits of the IL-6 family receptors dictates the responsiveness of various cells to the different cytokines (Taga et al., FASEB J, 6:3387-3396 (1992); Kishimoto et al., Cell, 76:253-262 (1994)). Thus, all responsive cells are believed to express gpl30, B9 cells fail to respond to LIF and CNTF because they lack LIF receptor, IL-6 is inactive on embryonic stem cells because these cells lack the IL-6 receptor a subunit, LIF is active on M1 cells because both gp130 and LIF receptor are present, while CNTF is inactive due to a lack of CNTF receptor a, etc. Based on the profile of CT-1 activities reported here, CT-I functions via the LIF receptor. This is established directly herein as follows. First, as shown herein, CT-I and LIF completely cross-compete for binding to MI cells, a cell line where LIF binding has been previously well characterized, KI [LIF] 0.1-0.2 nM (Hilton et al., Proc. Natl. Acad. Sci. USA, 85:5971-5975 (1988); Gearing et al., New Biologist, 4:61-65 (1992)). Regardless of which ligand is used as the label or competitor, an affinity for CT-I, IK 0.7 nM which is 3-4 fold less than that found for LIF, K 0.2 nM is found. Secondly, cross-linking data show that CT-1 and LIF specifically interact with a protein of- 200 kDa, a protein about the size expected for the LIF receptor (Davis et al., Science, 260:1805-1808 (1993); Gearing et al., EMBO 10:2839-2848 (1991)). Third, as shown herein, an anti-gpl30 monoclonal antibody specifically -87inhibits the binding of labeled CT-1 to MI cells, showing that gpl30 is a component of the CT-1 receptor complex. Fourth, CT-I induces the activation of a DNA binding activity, an intracellular signaling event induced by LIF and other members of the IL-6 cytokine family in the course of activation of the Jak/STAT pathway (Ltltticken et al., Science, 263:89-92 (1994); Yin et al., Exp. Hematol., 22:467-472 (1994); Zhong et al., Science, 264:95-98 (1994); Akira et al., Cell, 77:63-71 (1994)). These data demonstrate that CT-I can bind to and activate the LIF receptor complex. This finding does not exclude the possibility that some cells have an additional CT-1 specific receptor or receptor subunit that forms a heterodimer with gp130, as has been reported for OSM (Mosley et al., Cytokine, 6:554 (1994)).
As shown herein, CT-I and LIF also cross-compete for binding to rat cardiac myocytes. This finding is consistent with the hypothesis that these two ligands act on these cells via the LIF receptor, as established herein for Ml cells.
While LIF and OSM induce the heterodimerization of the same receptor subunits, LIF receptor and gpl30, the affinity of these two ligands for the individual receptor components differs. LIF binds to the LIF receptor (Kd 2 nM (Gearing et al., EMBOJ., 10:2839-2848 (1991)) but does not interact with gpl30 in the absence of the LIF receptor. Conversely, OSM binds to gpl30 (Kd 1 nM (Liu et al., J Biol. Chem., 267:16763-16766 (1992)) but does not bind to the LIF receptor alone (Gearing et al., EMBO 10:2839-2848 (1991)). Soluble forms of these two receptor subunits, consisting of their extracellular domains, are found in the circulation (Layton et al., Proc. Nail. Acad. Sci. USA, 89:8616-8620 (1992); Narazaki et al., Blood, 82:1120- S* 1126 (1993)). The soluble LIF binding protein binds LIF with a Kd 2 nM (for the mouse proteins) (Layton et al., J. Biol. Chem., 269:17048-17055 (1994)), while a recombinant form of soluble gpl30 binds OSM with a Kd 44 nM (for the human proteins) (Sporeno et al., J. Biol. Chem., 269:10991-10995 (1994)). As shown herein, CT-1 binds to the soluble LIF receptor with about the same affinity as LIF (Kd 2 nM, for the mouse proteins) and in the absence of other proteins. CT-1 does not bind to soluble mouse gpl30 even at high concentrations.
The addition of soluble gpl30 does increase the binding of CT-1 to the soluble LIF receptor, however, presumably by the formation of a heterotrimeric complex. The concentration of soluble gpl30 required for this effect 100 nM), while high by solution binding standards, is readily attainable on the surface of a cell. For example, 500 molecules of gpl30 expressed on the surface of a cell of 10 pm diameter would have an effective concentration of- 300 nM in a 100 A shell surrounding the cell, see (Ward et al., J. Biol. Chem., 269:23286- 23289 (1994)). Thus, these results indicate that CT-I binds to the LIF receptor in the same manner as LIF, by first binding with low affinity to the LIF receptor subunit, an interaction that does not require additional components, and second by recruiting gpl30 to form a high affinity signaling complex. Although CT-1 was isolated based on its ability to induce cardiac myocyte hypertrophy, it clearly has a much wider range of activities, as is found for the other cytokines of the IL-6 family (Kishimoto et al., Science, 258:593-597 (1992); -88- Kishimoto et al., Cell, 76:253-262 (1994)). The receptor data presented here predict that CT-1 will mimic the many effects of LIF in vitro and in vivo. Some of the functions of LIF, and thus targets for CT-I and its antagonists or agonists, are obtained from the targeted deletion of the LIF gene in mice, which leads to animals that are outwardly normal although they do exhibit a reduced growth rate, a decrease in hematopoietic cells, and a failure of proper embryo implantation (Escary et al., Nature, 263:361-364 (1993)). These studies are consistent with the in vitro data presented herein and the uses of CT-1 and its antagonists and agonists.
The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the construct deposited, since the deposited embodiment is intended as a single illustration of certain aspects of the invention and any constructs that are functionally equivalent are within the scope of this invention. The deposit of material herein does not constitute an admission that the written description herein contained is inadequate to enable the practice of any aspect of the invention, including the best mode thereof, nor is it to be construed as limiting the scope of the claims to the specific illustrations that it represents. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the description herein 15 and fall within the scope of the appended claims.
o o *o I.: -89- SEQUENCE LISTING GENERAL INFORMATION: APPLICANT: Genentech, Inc.
The Regents of the University of California (ii) TITLE OF INVENTION: Cardiotrophin and Uses Therefor (iii) NUMBER OF SEQUENCES: 8 (iv) CORRESPONDENCE ADDRESS: ADDRESSEE: Genentech, Inc.
STREET: 460 Point San Bruno Blvd CITY: South San Francisco STATE: California COUNTRY: USA ZIP: 94080 COMPUTER READABLE FORM: 15 MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk COMPUTER: IBM PC compatible S(C) OPERATING SYSTEM: PC-DOS/MS-DOS SOFTWARE: WinPatin (Genentech) CURRENT APPLICATION DATA: APPLICATION NUMBER: FILING DATE:
CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION: NAME: Torchia, PhD., Timothy E.
25 REGISTRATION NUMBER: 36,700 REFERENCE/DOCKET NUMBER: P0994PCT (ix) TELECOMMUNICATION INFORMATION: TELEPHONE: 415/225-8674 TELEFAX: 415/952-9881 TELEX: 910/371-7168 INFORMATION FOR SEQ ID NO:1: SEQUENCE CHARACTERISTICS: LENGTH: 1352 base pairs TYPE: Nucleic Acid STRANDEDNESS: Single TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: GGATAAGCCT GGGGCCAGCA ACCAGACTGA CTCCTCAATC CGCCAGACAC ACAACCTTGC TCTGGAGGAA TACGTGCAGC TCTCACCACC GCGGCTGCCG CATGCAGGGC TACCGGTGTC GAGTGTGCTG CCCGCGCTGT TGAACCCGCG CGCCCCGCGC CAGGTTCGGG CCCTGGGCGC CGCTGCAGCC CGCGGGCCCG TCACGGCCAA CAGCACTGCA CACGTGTGCG GCCTCTATGG GGGCCAGCTG GTGCCAGGGG TAAGCTCGCT CTGTCTCGCC CTGTGTCCTG TGTGTTCTTG TCTCTCTCTT CTGCTCTCCT TTCTCGTTTT GTCTCTCTCC TCTTTTTGTT TCCTTGTCTC GCTTGCTTGT TGTTGAGACA GAACTTGCTA TGTAGGCCAG CCTCCGACTC CCAATTTCCC GTGTAACCCT TACTTTGTCT TTCTTTGTTC TTTACTGACC AGGCCATTCA CCTTAGGACC
TGAGCCAGAG
TCATTCCTAC
CCGCCTCCTG
AACAGGGAGA
CTGGCCGGCC
CGAGCGGCTG
TGGATGCCGT
CTGCTGCGGA
CGCGGTGGAG
GGCCAGAGCC
GGCATCTTCT
CGAGTGGGTG
GCGTCGCCTG
TCTTTGGCTT
GGCTGTCCCT
CTCTGCAGGG
AGTCTTGAAC
TTGGTTCTTT
GGGTCTCACC
GCTGGCCTCC
CATCTGTCTC
CATGGAGGTG
AGAAAAGTGC
TTCCCACCAG
GGAGGGAAGT4
CCCATTTGGA
ACCAAATATG
GCCCTTTGGG
TGAGTGGCCC
CGGCAGGATG
CCGCCGCCGC
GCCTGGAGGA
ACAGTGCTGG
CGTCACCGTC
CAGCCAAGGT
AGCCGCACAG
AGAGTGAATA
CAAATTTTCT
ATCTTTCTGC
AGCTTCTTTT
ACTTTTGTCT
CTTTGCTTGC
ATATAGCTCT
AGCTCATAGA
CCTGTGATCC
ACAATTTTTC
CTACTTGTCC
TTCCTTTGTA
CTGGAAGACC GGCCAAGATC 100 CAGAACAACT 150 CTGCCGGGCT 200 GGCTCCGAGC 250 CAGCCGCCCT 300 CAGGCGGAGC 350 CGCAGCCCGC 400 CCGCGCTGGG 450 GCCACCCTCT 500 GCTGGGGTTC 550 AGGGCGACCT 600 CTTTTTCTTG 650 GTCTCTCCAT 700 ATTTGTGTGG 750 TTCCAACAGT 800 CCGAGAGGTC 850 TTGCTTGCTT 900 GGATGGCCTG 950 GATCCACTTG 1000 ATATGGGTAT 1050 TCCCTTCAGT 1100 CCTGGTGGCA 1150 GGCAAATCCC 1200 TCCCCCTTTG AGGTCCTTCC CTTTCATACC GCCCTAGGCT -91- GGTCAATGGA 1250 GAGAGAAAGG CAGAAAAACA. TCTTTAAAGA. GTTTTATTTG AGAATAAATT 1300 AATTTTTGTA AATAAAATGT TTAACAATAA AACTAAACTT TTATGAAAAA 1350 AA 1352 INFORMATION FOR SEQ ID NO:2: SEQUENCE CHARACTERISTICS: LENGTH: 1352 base pairs TYPE: Nucleic Acid STRAN~DEDNESS: Single TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: CCTATTCGGA CCCCGGTCGT ACTCGGTCTC CCTCCCTTCA GACCTTCTGG TGGTCTGACT GAGGAGTTAG GCGGTCTGTG TGTTGGAACG AGACCTCCTT ATGCACGTCG AGAGTGGTGG CGCCGACGGC GTACGTCCCG ATGGCCACAG CTCACACGAC GGGCGCGACA ACTTGGGCGC GCGGGGCGCG GTCCAAGCCC GGGACCCGCG 20 GCGACGTCGG GCGCCCGGGC AGTGCCGGTT GTCGTGACGT GTGCACACGC CGGAGATACC CCCGGTCGAC! CACGGTCCCC ATTCGAGCGA GACAGAGCGG GACACAGGAC ACACAAGAAC AGAGAGAGAA GACGAGAGGA AAGAGCAAAA CAGAGAGAGG
AGTAAGGATG
GGCGGAGGAC
TTGTCCCTCT
GACCGGCCGG
GCTCGCCGAC
ACCTACGGCA
GACGACGCCT
GCGCCACCTC
CCGGTCTCGG
CCGTAGAAGA
GCTCACCCAC
CGCAGCGGAC
AGAAACCGAA
CCGACAGGGA
GAGACGTCCC
TCAGAACTTG
GGGTAAACCT
TGGTTTATAC
CGGGAAACCC
ACTCACCGGG
GCCGTCCTAC
GGCGGCGGCG
CGGACCTCCT
TGTCACGACC
GCAGTGGCAG
GTCGGTTCCA.
TCGGCGTGTC
TCTCACTTAT
GTTTAAAAGA
TAGAAAGACG
TCGAAGAAAA
TGAAA.ACAGA
-92- CCGGTTCTAG 100 GTCTTGTTGA 150 GACGGCCCGA 200 CCGAGGCTCG 250 GTCGGCGGGA 300 GTCCGCCTCG 350 GCGTCGGGCG 400 GGCGCGACCC 450 CGGTGGGAGA 500 CGACCCCAAG 550 TCCCGCTGGA 600 GAA.AAAGAAC 650 CAGAGAGOTA 700 TAAACACACC 750 AAGGTTGTCA 800 GGCTCTCCAG 850 AGAAAAACAA AGGAACAGAG AACCAAGAAA CGAACGAACA ACAACTCTGT CCCAGAGTGG1 CTTGAACGAT ACATCCGGTC CGACCGGAGG I GGAGGCTGAG GGTTAAAGGG GTAGACAGAG C CACATTGGGA ATGAAACAGA GTACCTCCAC I AAGAAA.CAAG AAATGACTGG TCTTTTCACGC TCCGGTAAGT GGAATCCTGG AAGGGTGGTC AGGGGGAAAC TCCAGGAAGG GAAAGTATGG CTCTCTTTCC GTCTTTTTGT AGAAATTTCT 10 TTAAAAACAT TTATTTTACA AATTGTTATT TT 1352 INFORMATION FOR SEQ ID NO:3: SEQUENCE CHARACTERISTICS: LENGTH: 203 amino acids 15 TYPE: Amino Acid TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ I Met Ser Gin Arg Giu Gly Ser Leu G 1 5 20 Ser Ile Ser Phe Leu Pro His Leu G
,AAACGAJ
'ATATCG
CGAGTA!
;GACACT.
~GTTAAA
ATGAAC.
k.AGGAAA
:GGGATC
:AAAATA
rTGATTT ~CG AACGAACGAA 94 W.A CCTACCGGAC 9 1CT CTAGGTGAAC 1 AGG TATACCCATA 1 ~.AGGGAAGTCA 1 AGG GGACCACCGT 1 CAT CCGTTTAGGG 1 CGA CCAGTTACCT 1 ACTCTTATTTAA 1 'GAA AATACTTTTT 1 His Gin Thr Asp Lys Ilie Arg Gin Ala Giu Gin Leu Phe Giy Leu Pro Leu Ser Gly Pro Arg Leu Arg Gin 000 050 100 150 200 250 300 350 Ser Thr Leu Giy Ala Asp D NO: 3: iu Asp 10 iu Ala His Asn Leu Giu Giu Tyr Phe Ser Pro Pro Ser His Ala Arg Val Gin Pro Arg Ala Giy 25 Leu Leu Thr Lys Tyr 40 Gin Gin Giy Giu Pro 55 Leu Pro Leu Ala Gly 70 Leu Pro Vai Ser Giu 85 -93- Ala Ala Ala Leu Ser Val Leu Pro Ala Leu Leu Asp Ala Val Arg Arg Arg Gin Ala Ser Leu Giu Asp Val Glu Thr Val Gly Pro Glu Pro Giu 110 Ala 125 Leu 140 Val 155 Phe 170 Giu 185 Gly 200 Leu Asn Pro Arg Ala Arg Gln Val Ala Ala Leu Gly Thr Val Ala Thr Ser Ala Lys Val Trp Val Ser Arg Ala 115 Arg 130 Ala 145 Leu 160 Leu 175 Thr 190 Pro Arg Leu Leu Ala Leu Gly Ala Ala Ala Arg Gly Phe Thr Ala Asn 105 Arg 120 Ala 135 Pro 150 Ser 165 Cys 180 Gly 195 Thr Ala Gly Ile Gly Glu Phe His Val Gly Asp Leu Gly Leu Tyr Gly 15 Gin Leu Val Pro Gly Val Ala 203 INFORMATION FOR SEQ ID NO:4: SEQUENCE CHARACTERISTICS: LENGTH: 200 amino acids TYPE: Amino Acid TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ II Met Ala Phe Thr Giu His Ser Pro Li 1 5 Leu Cys Ser Arg Ser Ile Trp Leu A.
Leu Thr Ala Leu Lys Asn Ile Asn Thr Asp Gin Trp Glu Ser Tyr Asp Ser Ala Giu Leu Thr
V
A
G
D NO: 4: eu Thr Pro 10 la. Arg Lys 25 al. Lys His sp Gly Met lu Ala Giu His Arg Ile Arg Gin Gly Pro Val Arg Leu Arg Asp Ser Asp Leu Asn Ala Ser Gin Glu Asn Leu Gin Ala Tyr Arg Thr Phe His Val -94- Leu Leu Ala Arg Leu 85 Leu Glu Asp Gin Gin Val His Phe Thr Pro Thr Glu Gly Asp Phe 100 105 His Gin Ala Ile His Thr Leu Leu Leu Gin Val Ala Ala Phe Ala 110 115 120 Tyr Gin Ile Glu Glu Leu Met Ile Leu Leu Glu Tyr Lys Ile Pro 125 130 135 Arg Asn Glu Ala Asp Gly Met Pro Ile Asn Val Gly Asp Gly Gly 140 145 150 Leu Phe Glu Lys Lys Leu Trp Gly Leu Lys Val Leu Gin Glu Leu 155 160 165 Ser Gin Trp Thr Val Arg Ser Ile His Asp Leu Arg Phe Ile Ser 170 175 180 Ser His Gin Thr Gly Ile Pro Ala Arg Gly Ser His Tyr Ile Ala 15 185 190 195 Asn Asn Lys Lys Met 200 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 50 base pairs TYPE: Nucleic Acid STRANDEDNESS: Single TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID GCGGCCGCGA GCTCGAATTC TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT INFORMATION FOR SEQ ID NO:6: SEQUENCE CHARACTERISTICS: LENGTH: 1018 base pairs TYPE: Nucleic Acid STRANDEDNESS: Single TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: ot* 0 0 S.0 S0
GTGAAGGGAG
AGTCTGGAAG
GGAGGCCAAG
ACGCTGAGCA
GGGCTGCCCA
CCCGGCTCCG
ACGCGGCGGC
CGCCAGGCCG
GGACGCGGCG
TGGCCGCGCT
GCCACCGCCT
GGGGCTCCGC
GCGACCTGGG
AGCTCGCCCC
GTCTTTCTCT
ATTGCCTCGG
AGGGTCTCTG
AGCCTCAACC
AGCTGGGACT
CCGGGATCAG
ACCCCCAGAC
ATCCGTCAGA
GCTGCTCCAG
GCTTCTCGCC
AGCCACGCGG
GCTGGCCGCG
AGCTGAACCC
CGCCAGGCCC
GGGCGCCGCC
CAGCCGCCTC
GTTTGCGGCC
CCAGCTGCTG
GCCTCCTCCC
GCCGCTGTCG
CCTTCTTTGC
TCGCCCAGGC
TCCTGGGCTC
ACAGGCACGC
CCAGGGGCCA
TGATTCCTCA
CACACAGCCT
GAATATGTGC
GCCGCGGCTG
GGCTGCCAGT
CTGCCCCCGC
GCGCGCGCCG
GGGCCCTGGG
AACCGCGGGC
CGCCACCGGG
TCTACCGCGA
CCCGGGGGCT
GCTGGGTTCC
GTGTCTGTCT
TTTTTGTGGG
TGGGGTGCAG
AAGCCATCCT
GCCACCACAG
GCATGAGCCG
GTCTCACTTC
TGCGCACCTC
AGCTCCAGGG
CCGGTGGCCG
GCACGAGCGG
TGCTGGACGC
CGCCTGCTGC
CGCCGCCGTG
CCCGGGCCGA
GTCTTCCCCG
GTGGCTGAGC
CGGCCTGAGC
GTCTCTCCTT
GTCTGCTCTT
GGAGAGGGGA
TGGCGCGATC
TCCGCCTCAG
CCGGCTAATT
GAGGGAGGGA TTCCCCACTT 100 CTCACCAAAT 150 AGACCCCTTC 200 GCCTGAGCGC 250 CTGCGGCTGG 30'0 AGTGTGTCGC 350 GCCGCCTGGA 400 GAGGCCTTGC 450 GCCCCCCGCC 500 CCAAGGTGCT 550 CGCACCGAGG 600 GCCGCGGGGC 650 CCGCTTCTTT 700 AGCTGTCTCC 750 GGGGACGGGC 800 CCAGCACTGC 850 CTTCCCCAGC 900 TTTTATTTAA. 950 TTTTTTGTAG AGACGAGGTT TCGCCATGTT GCCCAGGCTG GTCTTGAACT 1000 CCGGGGCTCA AGCGATCC 1018 INFORMATION FOR SEQ ID NO:?: Wi SEQUENCE CHARACTERISTICS: LENGTH: 1018 base pairs TYPE: Nucleic Acid STRANDEDNESS: Single TOPOLOGY: Linear -96- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: CACTTCCCTC GGCCCTAGTC GGTCCCCGGT CGTACTCGGC TCAGACCTTC TGGGGGTCTG ACTAAGGAGT CAGAGTGAAG CCTCCGGTTC TAGGCAGTCT GTGTGTCGGA ACGCGTGGAG TGCGACTCGT CGACGAGGTC CTTATACACG TCGAGGTCCC CCCGACGGGT CGAAGAGCGG CGGCGCCGAC GGCCACCGGC! GGGCCGAGGC TCGGTGCGCC CCGACGGTCA CGTGCTCGCC! TGCGCCGCCG CGACCGGCGC GACGGGGGCG ACGACCTGCG GCGGTCCGGC TCGACTTGGG CGCGCGCGGC GCGGACGACG CCTGCGCCGC GCGGTCCGGG CCCGGGACCC GCGGCGGCAC ACCGGCGCGA CCCGCGGCGG TTGGCGCCCG GGGCCCGGCT CGGTGGCGGA GTCGGCGGAG GCGGTGGCCC CAGAAGGGGC CCCCGAGGCG CAAACGCCGG AGATGGCGCT CACCGACTCG CTCCCTCCCT 'AGGGGTGAA 100 GAGTGGTTTA 150 ICTGGGGAAG, 200 CGGACTCGCG 250 GACGCCGACC 300 TCACACAGCG 350 CGGCGGACCT 400 CTCCGGAAC!G 450 CGGGGGGCGG 500 GGTTCCACGA 550 GC!GTGGCTCC 600 CGGCGCCCCG 650 GGCGAAGAAA 700 TCGACAGAGG 750 CCCCTGCCCG, 800 GGTCGTGACG 850 GAAGGGGTCG 900 AAAATAAATT 950 CAGAACTTGA 1000
CGCTGGACCC
15 TCGAGCGGGG
CAGAAAGAGA.
TAACGGAGCC
TCCCAGAGAC
TCGGAGTTGG
TCGACCCTGA
AAAAAACATC
GGTCGACGAC
CGGAGGAGGG
CGGCGACAGC
GGAAGAAACG
AGCGGGTCCG
AGGACCCGAG
TGTCCGTGCG
TCTGCTCCAA
GGGCCCCCGA
CGACCCAAGG
CACAGACAGA
AA~AAACACCC
ACCCCACGTC
GCCGGACTCG
CAGAGAGGAA
CAGACGAGAA
CCTCTCCCCT
ACCGCGCTAG
TTCGGTAGGA AGGCGGAGTC CGGTGGTGTC GGCCGATTAA AGCGGTACAA CGGGTCCGAC GGCCCCGAGT TCGCTAGG 1018 INFORMATION FOR SEQ ID NO:B: Wi SEQUENCE CHARACTERISTICS: LENGTH: 201 amino acids TYPE: Amino Acid -97- TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: Met Ser Arg Arg Glu Gly Ser Leu Glu Asp Pro Gin Thr Asp Ser 1 Ser Val Ser Leu His Ser Leu Ala Gin Glu Tyr Val.
Phe Ser Pro Pro Pro Ser His Ala 15 Ala Ala Ala Leu Arg Arg Gin Ala Arg Leu Glu Asp 5 Leu Pro His Leu Glu His Leu Leu Thr Lys Gin Leu Gin Gly Asp Arg Leu Pro Val Ala Gly Leu Pro Val His Ala Ala Leu Pro Pro 95 Glu Leu Asn Pro Arg 110 Ala Ala Arg Gin Ala 125 Leu Ala Ala Leu Gly 140 Pro Ala Ala Thr Ala 155 Ala Lys Val Leu Gly 170 Leu Ser Arg Thr Glu 185 10 Ala 25 Tyr 40 Pro 55 Gly 70 Glu 85 Leu 100 Ala 115 Arg 130 Ala 145 Ser 160 Leu 175 Gly 190 Lys Ile Arg Gin Thr Ala Glu Gin Leu Leu Phe Gly Leu Pro Ser Leu Ser Ala Pro Ala Arg Leu Arg Leu Asp
I
Val Glu Ala Leu Arg Ala Glu Pro Leu Asp Ala Val Pro Arg Leu Leu Ala Leu Gly Ala Ala Asn Arg Gly Ala Ala Ser Ala Arg Val Cys Gly Asp Leu Gly Gin Cys 105 Arg 120 Ala 135 Pro 150 Thr 165 Leu 180 Leu 195 Gly Val Phe Pro Tyr Arg Glu Trp Leu Pro Gly Gly Ser Ala 200 201 -98-
Claims (26)
1. A method of enhancing the maintenance of pregnancy in a mammal into which an embryo has been introduced, the method comprising prior to said introducing, culturing at least one embryo in a medium containing an amount of CT-1 for sufficient time and under appropriate conditions so as to effect an enhancement of the maintenance of pregnancy in said mammal.
2. The method according to claim 1, wherein said mammal is selected from the group consisting of human, sheep, pig, cow, goat, donkey, horse, dog and cat. 15
3. The method according to claim 1, wherein CT-1 is of human or murine origin.
4. The method according to claim 1, wherein the medium for maintenance of the embryo is SOF or M2 medium.
A composition, comprising pluripotential embryonic stem cells an CT-i, a fibroblast growth factor, membrane associated steel factor, and soluble steel factor, the factors present in amounts to enhance the 25 growth of and allow the continued proliferation of the cells.
6. A composition, comprising primordial germ cells and CT-I, a fibroblast growth factor, membrane associated steel factor and soluble steel factor, the factors present in amounts to enhance the growth of and allow the continued proliferation of the cells.
7. A composition, comprising embryonic ectoderm cells and CT-I, fibroblast growth factor, membrane associated steel factor and soluble steel factor, the factors present in amounts to enhance the growth of and H:\WendyS\Keep\species\P41618 Gen&CA Uni DIV.doc 22/03/01 100 allow the continued proliferation of the cells.
8. A composition, comprising CT-1, fibroblast growth factor, membrane associated steel factor and soluble steel factor in amounts to enhance the growth of and allow the continued proliferation of- primordial germ cells.
9. A composition, comprising CT-1, fibroblast growth factor, membrane associated steel factor and soluble steel factor in amounts to promote the formation of pluripotent embryonic stem cells from primordial germ cells.
A method of making a mammalian pluripotential embryonic stem cell, comprising administering a growth enhancing amount of CT-1, a basic fibroblast growth factor, membrane associated steel factor, and soluble steel factor to primordial germ cells under cell growth conditions, thereby making a pluripotential embryonic stem cell.
11. A method of making a pluripotential embryonic stem cell comprising administering a growth enhancing amount of CT-1, a basic fibroblast growth factor, membrane associated steel factor, and soluble steel factor to 25 embryonic ectoderm cells under cell growth conditions, thereby making a pluripotential embryonic stem cell.
12. A method of stimulating the proliferation and differentiation of mammalian satellite cells into myoblasts, which method comprises contacting said cells with a stimulation-effective amount of CT-1 for a time and under conditions sufficient for said satellite cells to proliferate and differentiate into myoblasts.
13. The method according to claim 1 which further comprises the addition of one or more other cytokines in simultaneous or sequential combination with CT-1. H:\WendyS\Keep\species\P41618 Gen&CA Uni DIV.doc 22/03/01 101
14. A method of myoblast transfer, comprising contacting mammalian satellite cells with a proliferation and differentiation-effective amount of CT-1 for a time and under conditions sufficient for said satellite cells to proliferate and differentiate into myoblasts and then administering said myoblasts at multiple sites into muscles.
15. A method of treating a mammal afflicted with arthritis or an inflammatory disease, comprising administering to the mammal in need of such treatment an amount of CT-1 antagonist which is effective for alleviation of the condition.
16. A method of treating a neuron, other than a S. ciliary ganglion neuron, comprising providing the neuron with an amount of CT-1 effective to promote neuronal survival, growth, regeneration, sprouting or a change in 20 neuronal type.
17. The method of claim 16, wherein the neuron is a central nervous system neuron. 25
18. The method of claim 17 or claim 18 wherein the change in neuronal phenotype is in the transmitter phenotype of the neuron.
19. The method of any one of claims 16 to 18, wherein the neuron is in vivo. Use of an effective amount of CT-1 in the preparation of a medicament for the treatment of a neuron other than a ciliary ganglion neuron, to promote neuronal survival, growth, regeneration, sprouting or a change in neuronal type.
H:\WendyS\Keep\species\P41618 Gen&CA Uni DIV.doc 22/03/01 102 0
21. Use according to claim 20, wherein the neuron is a central nervous system neuron.
22. Use according to claim 20 or claim 21, wherein the change in neuronal phenotype is in the transmitter phenotype of the neuron.
23. Use according to any one of claims 20 to 22, wherein the neuron is in vivo.
24. A method according to any one of claims 10 to 14, and 16 substantially as herein described with reference to the examples and drawings.
25. A composition according to any one of claims 5 to 9, substantially as herein described with reference to the Sexamples and drawings.
26. Use according to claim 20, substantially as herein described with reference to the examples and drawings. Dated this 22nd day of March 2001 25 GENENTECH, INC. and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA By their Patent Attorneys GRIFFITH HACK Fellows Institute of Patent and Trade Mark Attorneys of Australia H:\WendyS\Keep\species\P41618 Gen&CA Uni DIV.dOC 22/03/01
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU29811/01A AU768995B2 (en) | 1996-02-14 | 2001-03-22 | Cardiotrophin and uses therefor |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/601395 | 1996-02-14 | ||
AU19654/97A AU733403B2 (en) | 1996-02-14 | 1997-02-11 | Cardiotrophin and uses therefor |
AU29811/01A AU768995B2 (en) | 1996-02-14 | 2001-03-22 | Cardiotrophin and uses therefor |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU19654/97A Division AU733403B2 (en) | 1996-02-14 | 1997-02-11 | Cardiotrophin and uses therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2981101A true AU2981101A (en) | 2001-06-07 |
AU768995B2 AU768995B2 (en) | 2004-01-15 |
Family
ID=30449843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU29811/01A Expired AU768995B2 (en) | 1996-02-14 | 2001-03-22 | Cardiotrophin and uses therefor |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU768995B2 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0755446B1 (en) * | 1994-04-25 | 2006-09-13 | Genentech, Inc. | Cardiotrophin and uses therefor |
-
2001
- 2001-03-22 AU AU29811/01A patent/AU768995B2/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
AU768995B2 (en) | 2004-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2188017C (en) | Cardiotrophin and uses therefor | |
US6117650A (en) | Assay for cardiac hypertrophy | |
US5763213A (en) | Sensory and motor neuron derived factor (SMDF) | |
US6399746B1 (en) | Structure, production and use of heregulin 2 ligands | |
US20030166020A1 (en) | Receptor polypeptides and their production and uses | |
HUT75657A (en) | Thrombopoietin | |
AU733403B2 (en) | Cardiotrophin and uses therefor | |
KR100627754B1 (en) | Method for Enhancing Proliferation of Inner Ear Hair Cells Using Ligands for HER2 and/or HER3 Receptors | |
US20040006018A1 (en) | Cardiotrophin and uses therefor | |
AU768995B2 (en) | Cardiotrophin and uses therefor | |
AU697165C (en) | Cardiotrophin and uses therefor | |
US20060275274A1 (en) | Use of saposin-related proteins for preventing and treating obesity, diabetes and/or metabolic syndrome | |
CA2245635A1 (en) | Cardiotrophin and uses therefor | |
US6660256B1 (en) | Porcine mpl ligand | |
US8192955B1 (en) | Nucleic acids encoding MPL ligand (thrombopoietin), variants, and fragments thereof | |
US8241900B1 (en) | mpl ligand | |
US8278099B1 (en) | Monoclonal antibody to human thrombopoietin | |
US8147844B1 (en) | Mpl ligand (thrombopoietin), nucleic acids encoding such, and methods of treatment using mpl ligand | |
WO1998029547A1 (en) | Modulators of radial glia-astrocyte differentiation and transformation, and diagnostic and therapeutic uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |